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Improving medication management for Aboriginal 
and Torres Islander people by investigating the use of 
Home Medicines Reviews 
Abstract 
 
Background 
The Australian Home Medicines Review (HMR) has been found to be an important tool to 
raise awareness of medication safety, reduce adverse events and improve medication 
adherence. The HMR program consists of pharmacists reviewing patients’ medicines at their 
homes and reporting findings to their general practitioners (GPs) to optimise medicine 
management. 
Under-use of medicines contributes to poorer control of chronic disease states, higher 
hospital admissions and increased morbidity and mortality for Aboriginal and Torres Strait 
Islander people. Aboriginal and Torres Strait Islander people are “under-serviced” by the 
HMR program and are the most likely of all Australians to miss out on HMRs despite their 
high burden of chronic disease and high rates of hospitalisation due to medication 
misadventure. 
The 2008 Campbell report commissioned by the Australian Government called for the urgent 
introduction of a more culturally appropriate model of HMRs and for expanded HMR 
services to Aboriginal Australians. To date these recommendation have not been 
implemented. 
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Very little research has been conducted in the area of medication management and cognitive 
pharmacy services for Aboriginal and Torres Strait Islander people or the role of pharmacists 
in Aboriginal health. 
Goal 
To ascertain the usefulness of medication review and inform medication review program 
design for Aboriginal and Torres Strait Islander people by understanding barriers and 
facilitators to utilisation of the HMR program from patient, pharmacist and Aboriginal Health 
Service provider perspectives. 
Methods 
This was a descriptive, qualitative study. Aboriginal Health Services of various sizes and 
locations were chosen as the sites for recruitment of patients and providers. 
Focus groups were conducted to collect patients’ views. Eighteen semi-structured focus 
groups with 102 Aboriginal and Torres Strait participants were conducted at 11 AHSs. 
Participants were Aboriginal and Torres Strait Islander patients, taking multiple medicines, 
who attended AHSs and who spoke English. 
Semi-structured interviews were used to explore perceptions of AHS health professional 
staff to the HMR program. Thirty-one semi-structured interviews were conducted with 
health professionals at 11 AHSs. Fourteen Aboriginal Health Workers (AHWs), five nurses, 
one manager and 11 GPs participated. 
 Focus groups and interviews were recorded, de-identified and transcribed. Transcripts were 
coded and analysed thematically. 
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A cross-sectional survey was used to gather demographic, qualitative and quantitative data 
from Australian pharmacists (n=187) accredited to undertake HMR. The survey consisted of 
39 items which included closed, open-ended and Likert scale questions. Data were extracted 
from the online survey tool and analysed. Descriptive statistics were used to explore the 
quantitative data, whilst qualitative data were thematically analysed and coded for 
emergent themes. 
Results 
Both patients and health professionals viewed a culturally appropriate medication review as 
a very useful tool. They stated that because the medication review engaged patients in 
discussions about their medications and empowered patients with knowledge and 
medication choices, they would be likely to improve medication adherence. 
 The interviews with AHS staff identified a number of barriers to provision of HMRs, specific 
to Aboriginal and Torres Strait Islander clients. These included paternalistic attitudes of some 
health professionals to their clients, protection by GPs of their GP-client relationships, lack 
of pharmacist relationships with AHS staff and the need for more culturally responsive 
pharmacists. 
Changes to the HMR model to make it more effective and culturally appropriate for 
Aboriginal and Torres Strait Islander people were recommended. These changes included 
the need for the HMR interview to be organised by the AHS and occur at a location of the 
patient’s choice, the inclusion of AHWs in HMR processes and the need for cultural training 
for pharmacists. 
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Aboriginal Health Service providers reported that improved relationships between GPs and 
pharmacists, between pharmacists and the AHS, and between pharmacists and Aboriginal 
and Torres Strait patients were required to enable effective communication and integrated 
care. 
The accredited pharmacists who participated in the survey were keen to deliver more 
services to AHSs. However, they needed assistance and training to broker relationships and 
overcome the barriers which were inhibiting them from working more closely with AHSs. 
Conclusion 
Current HMR rules impede rather than facilitate HMRs for Aboriginal and Torres Strait 
Islander people. Burdensome program rules and funding structures need to be revised. 
Many of the barriers to HMR delivery to Aboriginal and Torres Strait Islander people could 
be addressed by locating pharmacists within AHSs. The AHS pharmacist would be culturally 
mentored and would build strong relationships with AHS health professionals and clients, 
resulting in more effective communication and positive health outcomes. An AHS pharmacist 
would be able to provide the tiered, flexible and regular medication reviews needed to 
increase patients’ knowledge of medicines and empower patients to manage their 
medicines. The AHS pharmacist would integrate and manage medication management 
programs at a systems level and liaise closely with all care providers, including community 
pharmacists. 
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PhD thesis outline 
 
I present this PhD thesis for examination as a thesis containing published work. It contains 
four publications, as well as additional unpublished text. The thesis is structured as follows: 
Chapter 1: Introduction -  Unpublished text 
 literature review 
 situating the study 
 aims and objectives 
Chapter 2:  Methodology and methods-   Unpublished text 
  Rationale and overview of: 
 methodology 
 study design – 3 phases 
 setting & sample 
 data collection & analysis 
 
Chapter 3:  Aboriginal and Torres Strait Islander people’s experiences with medicines – 
patient data paper 
 Publication 1: Swain L, Barclay L. “They’ve given me that many tablets, 
I’m bushed. I don’t know where I’m going.” Australian Journal of Rural 
Health. 2013;21:216-9. 
http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajr.12053/abstract 
xiv 
 
The Australian Journal of Rural Health was chosen to maximise readership by 
multi-disciplinary practitioners working with Aboriginal and Torres Strait 
Islander people. Impact Factor 0.764 (Word limit = 2000) 
Chapter 4: Aboriginal and Torres Strait Islander perspectives of the Home Medicines 
Review program – patient data paper 
 Publication 2: Swain L, Barclay L. An exploration of Aboriginal and Torres 
Strait Islander perspectives of Home Medicines Review. Rural and Remote 
Health 15:3009 (Online) 2015. 
http://www.rrh.org.au/articles/showarticlenew.asp?ArticleID=3009 
Rural and Remote Health is an online journal with a targeted rural and remote 
researcher and practitioner audience. The larger word limit allowed a more 
detailed explanation of research methods. Impact Factor 0.783 (Word limit = 
5000) 
Chapter 5:  Perspectives of Aboriginal Health Service health professionals on Home 
Medicines Review – service provider data paper 
 Publication 4: Swain L, Barclay L. “Medication reviews are useful, but the 
model needs to be changed”: perspectives of Aboriginal Health Service health 
professionals on Home Medicines Review. BMC Health Services Research. 
2015;15:366. doi:10.1186/s12913-015-1029-3. 
http://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-015-
1029-3 
xv 
 
BMC Health Services Research is an open access, peer-reviewed journal that 
publishes articles on all aspects of health services research. The open access 
allows this publication to be highly visible to the wide range of global people who 
may find this article of interest. The unlimited word count allowed full 
exploration of all service provider issues. Impact factor 1.606 (Unlimited) 
Chapter 6: Pharmacists and Aboriginal Health – pharmacist data paper 
 Publication 3: Swain L, Griffits C, Pont L, Barclay L. Attitudes of 
pharmacists to provision of Home Medicines Review for Indigenous 
Australians. International Journal of Clinical Pharmacy. 2014;36:1260-7. 
The International Journal of Clinical Pharmacy includes research on 
medication management, pharmacy services and pharmaceutical care. The 
attitudes of pharmacists and the delivery of medication review to Indigenous 
people have relevance for all pharmacists who work with minority population 
groups and design medication management programs. Impact Factor 1.339 
(Word limit = 3000) 
Chapter 7:  Discussion and conclusions -  Unpublished text 
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Prologue 
 
In 2001, after 20 years as a community pharmacist and industry consultant in Sydney, I 
moved to Bathurst, a regional centre in the Central West of New South Wales (NSW). There 
in the pharmacy I was suddenly aware of a higher percentage of Aboriginal clients. Although 
I treated everyone with compassion and respect I was aware that my engagement with these 
clients should have been better. I had received no training and had little understanding. I 
found that there was not much literature related to Aboriginal people and medicines, but I 
started reading, asking and trying harder. 
Whilst in the Central West I also started working at the new pharmacy school at the 
University of Sydney’s Orange campus (now Charles Sturt University). My role in this new 
degree was to develop and run a unit of study called Rural Health and Pharmacy. As part of 
this unit of study and under the mentorship of Dr Susan Taylor, I invited Wiradjuri people 
from the local AHS to speak to the students. We took the students on a bus trip to the 
Condobolin AHS and the Murrin Bridge community, and so began some cultural 
understanding. 
We tasked the pharmacy students with designing resources which pharmacists could use 
with Aboriginal clients. The students presented their resources to the local Aboriginal 
people. The response was overwhelming. We heard stories about how many Aboriginal 
people found pharmacy environments uncomfortable, how they struggled to understand 
their medicines and how there was a great need for culturally appropriate resources. 
In 2008 I learned of a new Aboriginal pharmacy project, Quality Use of Medicines Maximised 
for Aboriginal and Torres Strait Islander People (QUMAX). I phoned the Pharmacy Guild and 
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asked to be employed as a QUMAX Support Pharmacist. In this role I assisted in 
implementation of the QUMAX program into eight AHSs across northern NSW. Part of the 
QUMAX Support Pharmacist’s role was to broker relationships between the AHSs and 
community pharmacies. The divide between Aboriginal Health Services and pharmacists in 
most cases was great, but the program began to build bridges. Some AHSs tried to 
implement HMR, with varying degrees of success. Unfortunately, funding for QUMAX 
Support Pharmacists was ceased in 2010. 
As my relationships with AHSs grew, a number of pharmacy researchers asked me to assist 
to organise the occasional focus group with Aboriginal people for their projects. I felt such 
small inclusions of Aboriginal opinion, whilst usually well-meaning, were really tokenistic. I 
was aware that every month my Aboriginal friends and colleagues attended multiple 
funerals for their family and community members. If we were going to conduct research it 
needed to make a difference – but how? 
As an accredited HMR pharmacist, when conducting HMR interviews I had experienced the 
empowerment of engaging one on one in a person’s home. I believed that these HMR 
interviews could truly assist with understanding of medicines and help to unravel the 
complexities of medicines, prescribing, patient self-management and the healthcare system, 
both for patients and GPs. I realised that HMRs might be useful for Aboriginal people but 
had not received any referrals for HMRs for Aboriginal people. Why? 
I commenced my PhD studies in 2009 in a quest to find a way to make HMRs useful and 
accessible for Aboriginal and Torres Strait Islander people. Initially, I called the study 
“Strategies for increasing HMR uptake in Aboriginal and Torres Strait Islander communities”. 
I soon realised that as well as being a cumbersome title, it was almost dictatorial. I realised I 
xx 
 
must first learn whether HMRs were considered useful by Aboriginal and Torres Strait 
Islander people, not just by me. No one had done a national study asking Aboriginal people 
their opinions of taking medicines. And so began my journey. Many times along the journey 
I have questioned who was benefiting more ‒ Aboriginal people or me? Only the hope that 
this work might be useful has kept me on track to finish it. 
On this journey not only have I learnt about research; I have learnt so much about the 
humour, resilience and generosity of Aboriginal people, and I have also learnt much about 
myself. Many people have supported and assisted me on my journey, and for this I will 
always be grateful. 
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Chapter 1 
Introduction 
1.1 Overview 
In this opening chapter I explain the rationale for this thesis. The study aims and research 
questions are stated. 
The health of Aboriginal and Torres Strait Islander people and Aboriginal and Torres Strait 
people’s experiences of primary healthcare services and pharmacies are outlined. In 
particular, patients’ challenges regarding medicines use are examined, as are the roles of 
health professionals in the delivery of medicines information. Literature about 
communication between health professionals and clients is reviewed, and concepts of 
cultural competency are explored (1). 
Medication management, the role of pharmacists and medication review are discussed to 
establish the usefulness of the Home Medicines Review (HMR) program in the Australian 
setting. The chapter explains the HMR model, and reviews the literature which addresses 
the benefits and challenges of HMR. 
This study explores whether medication review may improve Aboriginal and Torres Strait 
Islander people’s medication knowledge and medication management. As this study 
addresses medication management, rather than medicines supply and access, the literature 
on medicines supply is not explored. 
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The limited literature pertaining to pharmacists’ roles in assisting Aboriginal and Torres 
Strait Islander people has been used to situate the study. 
This chapter concludes with a summary of how this study was conducted and outlines the 
three phases of the study. 
1.2 Why conduct this study? 
Aboriginal and Torres Strait Islander people are often prescribed multiple medicines to 
manage their co-morbidities and, like all population groups trying to manage multiple 
medicines, are at high risk of medication misadventure and low medication adherence (2, 
3). 
There is extensive literature discussing Aboriginal and Torres Strait Islander health and the 
social, economic, emotional and physical determinants of Aboriginal and Torres Strait 
Islander health. However, very little research has been conducted into Aboriginal and 
Torres Strait Islander patients’ perceptions, experience and understanding of medicines. 
Similarly, little is known about the role of pharmacists in Aboriginal health. 
Whilst there has been some evaluation of medicine access programs for Aboriginal and 
Torres Strait Islander people, there is very little comprehensive research examining 
medication management for Aboriginal people. Dr Alex Brown, a remote practitioner and 
researcher, laments the lack of Aboriginal-specific research on quality use of medicines (4). 
Apart from Government-commissioned evaluations of specific Aboriginal medicine access 
schemes (5-8), there is only a handful of researchers and clinicians who have significantly 
contributed to the literature on medication usage by Aboriginal and Torres Strait Islander 
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people in Australia. Some of the main research groups discussed in this chapter are 
introduced here. De Crespigny, Kowanko, Emden and colleagues examined the medication 
experiences of Aboriginal clients in South Australia (9-11). Taylor and colleagues from the 
pharmacy school at the University of Sydney explored the role of Aboriginal Health Workers 
(AHWs) and pharmacists in assisting Aboriginal clients with medications and education in 
NSW (12, 13). Larkin, a pharmacist, and Murray, a GP, when both at the Kimberley 
Aboriginal medical service, wrote about their experiences in assisting remote Aboriginal 
clients with medications (14). Davidson, Abbott and colleagues, academics at the University 
of Western Sydney and medical practitioners at Western Sydney Aboriginal Health Service 
(AHS), used the literature to classify barriers to medication adherence for Aboriginal and 
Torres Strait Islander people (15). Dr Alex Brown, a former Northern Territory (NT) clinician, 
on behalf of the Heart Foundation Pharmaceutical Roundtable, undertook 42 interviews 
with individuals who deliver health services to Aboriginal people to write a report on the 
appropriate use of medicines among Indigenous Australians (4). Sanburg, a pharmacist 
within the Pika Wiya Aboriginal Service, evaluated her HMR practices within Pika Wiya AHS 
in South Australia (16). 
The Australian HMR is a professional pharmacy service managed by the Pharmacy Guild of 
Australia (17). It aims to achieve safe, effective and appropriate use of medicines and to 
improve the health outcomes and knowledge of medicines in participating patients. Studies 
show that HMRs can improve medication safety and reduce adverse events for high-risk 
patients (18-20). The HMRs can result in improved medication understanding by patients, 
identify untreated conditions and resolve issues related to medication under-use (18, 21, 
22). 
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The 2008 HMR program evaluation report (23), commissioned by the Department of Health, 
identified that Aboriginal and Torres Strait Islander people, despite their high burden of 
chronic disease, were the most likely of all Australians to miss out on an HMR and that the 
HMR current model was not appropriate for Aboriginal and Torres Strait Islander people. 
Whilst it has been reported that the current model was inappropriate for Aboriginal and 
Torres Strait Islander people (23, 24), it was not documented why the model was 
inappropriate, and little was understood about what an appropriate model should look like. 
This study was undertaken to inform the future design of medication review programs for 
Aboriginal and Torres Strait Islander people. The objective was to investigate how 
pharmacists can better assist Aboriginal and Torres Strait Islander people with their 
medication management and so improve health outcomes in this population. 
1.3 Aims 
 To ascertain the usefulness of medication review and inform medication review 
program design for Aboriginal and Torres Strait Islander people by understanding 
barriers and facilitators to utilisation of the HMR program from patient, pharmacist 
and AHS provider perspectives. 
 To investigate how medication management programs, such as HMR, could be 
better utilised to address the needs of Aboriginal and Torres Strait Islander people. 
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1.4 What this study adds 
This is the first study to analyse facilitators and barriers to uptake of the HMR program by 
Aboriginal and Torres Strait Islander people across multiple settings. This study was 
conducted in urban, rural and remote settings across 12 sites in four states and one 
territory.  
This study has analysed the perspectives of patients, health professionals and pharmacists. 
Findings from this study will be used to inform other projects, as described in the Epilogue 
of this thesis. 
1.5 Aboriginal and Torres Strait Islander health 
Despite a higher burden of acute infections and chronic diseases, under-use of medicines is 
evident in Australian Aboriginal populations (25, 26). In 2010-11 the Pharmaceutical 
Benefits Scheme (PBS) expenditure for Aboriginal people was about 80% of expenditure for 
non-Indigenous Australians, indicating increasing access, but continuing under-utilisation 
of medicines by Aboriginal and Torres Strait Islander people (25, 27, 28). Under-use of 
medicines is likely to contribute to poorer control of chronic disease states, higher hospital 
admissions and increased morbidity and mortality (29). 
Between July 2010 and June 2012, Aboriginal and Torres Strait Islander people were 
hospitalised for potentially preventable conditions nearly four times as often as non-
Indigenous Australians (28). Many of these hospital admissions for potentially preventable 
conditions might have been prevented through improved access to primary care and 
improved medication management (30). 
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The health of Aboriginal people in Australia has been described as “third world health in a 
first world nation” (31). Many Australian Aboriginal and Torres Strait Islander people have 
a higher mortality rate, higher burden of disease, more hospitalisations, higher levels of 
trauma and grief, and more social disadvantage than other Australians (32). The health 
inequalities between Aboriginal and Torres Strait Islander people and non-Indigenous 
Australians are particularly apparent in chronic diseases, communicable diseases, infant 
health, mental health and life expectancy (1). 
Compared with non-Indigenous Australians, Aboriginal and Torres Strait Islander people are 
three times more likely to die of cardiovascular disease, ten times more likely to die of 
diabetes and 30 times more likely to die from end-stage renal disease (33). Aboriginal and 
Torres Strait Islander people are also twice as likely to suffer asthma or other respiratory 
conditions and also report high or very high levels of psychological distress (28, 34, 35). 
Rates of mortality from cancer are markedly higher for Indigenous compared with non-
Indigenous Australians (35). Tropical and developing-country diseases such as tuberculosis, 
rheumatic fever, strongyloides, trachoma and hepatitis B and C are also more prevalent in 
Aboriginal and Torres Strait Islander people than in non-Indigenous Australians (33). Over 
two-thirds of adult Aboriginal and Torres Strait Islander people have at least one long-term 
condition (28). 
There is a clear relationship between the social disadvantages experienced by Aboriginal 
and Torres Strait Islander people and their current health status. These social disadvantages 
directly relate to dispossession, are characterised by poverty and powerlessness, and are 
reflected in education, employment, income and lack of empowerment to make health 
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choices (36). Racism and discrimination, both individual and organisational, are known to 
be directly associated with poorer health outcomes (37). 
Ill health for Aboriginal and Torres Strait Islander people is more than physical illness; it is a 
manifestation of spiritual and emotional alienation from land, family and culture (38). 
Aboriginal and Torres Strait Islander health is defined as not just the physical wellbeing of 
an individual, but the social, emotional and cultural wellbeing of the whole community (39). 
Pharmacists and other health professionals need to be cognisant that their own views of 
health may differ from that of their Aboriginal and Torres Strait Islander patients. 
A “wellbeing framework” for Aboriginal and Torres Strait Islander people living with chronic 
disease has been outlined by the Kanyini Vascular Collabration (40). It states that wellbeing 
is supported by upholding people’s identities in connection to culture, spirituality, families, 
community and country. Wellbeing is supported by culturally safe primary healthcare 
services which have appropriately skilled and culturally competent healthcare teams 
providing best practice holistic care (40). 
In the Australian healthcare system, there is often a power imbalance between health 
professionals and their patients. Factors such as language differences and patients’ lack of 
education and low socio-economic status may further contribute to this imbalance (41, 42). 
The power imbalance, together with the disempowerment that has resulted from 
colonisation, disconnection from land, racism and trans-generational trauma, negatively 
impacts health and how Aboriginal and Torres Strait Islander people access healthcare and 
participate in clinical decision-making, including medication usage (43). 
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King, a researcher in Canadian Indigenous health inequalities, argues that the means by 
which people are enabled to control their destinies is crucial to self-esteem and health (44). 
Similarly, the Whitehall studies in the United Kingdom (UK) showed that perceptions of lack 
of control of one’s life also resulted in poorer health outcomes (45). Fisher, a Northern 
Territory physician, found that better self-esteem, together with better communication by 
the health professional and better understanding by the patient, improved a patient’s 
compliance with treatment options and translated to better health outcomes (46). 
1.5.1 Primary care for Aboriginal and Torres Strait Islander people 
Aboriginal people’s rate of access to primary health services is increasing, but remains 
disproportional to Aboriginal people’s poorer health and higher burden of chronic disease 
(28). Whilst primary healthcare in Australia is changing to meet the challenges of an ageing 
population and the increasing prevalence of chronic disease, challenges remain for 
Aboriginal and Torres Strait Islander people in accessing healthcare and effective 
management of chronic disease (47). 
Factors which contribute to Aboriginal and Torres Strait Islander patients not accessing 
primary health services, including pharmacies, may include transport and distance to 
services, cost, language, racism, cultural barriers and family responsibilities (48). A number 
of psychosocial reasons, such as fear of death, fatalism, shame, communication difficulties, 
lack of Indigenous staff, preference for traditional healers, and spiritual issues, have also 
been identified as barriers to Aboriginal people’s accessing health services (35). 
Health systems and service providers can perpetuate Aboriginal healthcare disparities 
through their attitudes and practices. Many mainstream health services have not been 
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demonstrated to be culturally competent or culturally safe for Aboriginal people, and 
systems and services do not allow for long complex consultations and multi-disciplinary 
care (42, 49). 
Aboriginal Health Services have been established to address the need for more accessible 
and culturally safe primary care services for Aboriginal and Torres Strait Islander people. 
There are two main types of AHS: those that are government-operated and those that are 
community controlled. Aboriginal Community Controlled Health Organisations (ACCHOs) 
were established in the 1970s in response to experiences of racism in the health system 
and the significant financial, cultural and social barriers to healthcare access experienced 
by Aboriginal and Torres Strait Islander people (1, 50). 
Aboriginal Community Controlled Health Organisations are operated by local Aboriginal and 
Torres Strait Islander communities to deliver holistic, comprehensive and culturally 
appropriate healthcare to their communities. The community controls the service through 
a locally elected board of management (39.) The philosophy of community control and self-
determination are reflected in community-initiated, community-driven and community-
owned health services. Community empowerment is a vital contributor to health equality 
(37). Whilst there are now some 170 AHSs, they do not have the reach and capacity to meet 
the needs of all Aboriginal and Torres Strait Islander people. The balance of services is 
provided by mainstream health systems, such as hospitals and private general practice. 
Aboriginal Health Workers (AHWs) play a vital role in the primary health workforce and in 
assisting to deliver holistic care. The AHWs are pivotal members of AHS staff as they 
perform a broad range of clinical and social services whilst helping to ensure cultural safety 
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and effective communication between Aboriginal and Torres Strait Islander patients and 
healthcare professionals (9, 51). 
The duties performed by AHWs will depend on their qualifications and the AHS needs. 
Whilst many employed AHWs are not registered practitioners, they still play a vital role in 
the care of Aboriginal and Torres Strait Islander people. In this study the term, Aboriginal 
Health Worker, is inclusive of both qualified and non-qualified AHWs. 
The AHWs can assist people to navigate the healthcare system and they usually understand 
community needs and its complexities. Many AHWs play an important role in delivering and 
administering medicines, although some AHWs lack medication training (52) (9, 10). The 
extent to which AHWs and registered nurses have legal coverage for dispensing of 
medicines is dependent the setting, and on state and territory legislation (14). Brown, an 
Aboriginal doctor and researcher, commented that there was a need for improved systems 
of support for nursing and AHW staff within AHSs. He found the lack of Quality Use of 
Medicines (QUM) training in nurse and AHW courses, and the lack of access to pharmacists, 
particularly in remote settings, were contributors to sub-optimal medicines management 
within AHSs (4). 
Kowanko et al in their evaluation of chronic condition management at three AHSs in South 
Australia identified some of the system enablers to chronic condition management. These 
included access to culturally appropriate and affordable health services, effective clinical 
information management systems, co-ordination of team care arrangements, and 
facilitation of peer support (53). It was also identified that training staff in chronic disease 
management, making time for health staff to develop trust and rapport with clients, and 
11 
 
working closely with clients to set achievable goals, were all enablers for better 
management of chronic conditions (53). 
The Sentinel Site evaluation conducted by the Menzies School of Health Research for the 
Australian Government found that systems within GP practices and AHSs needed to be 
strengthened, simplified and integrated. Integrated systems enable increased 
implementation of Aboriginal chronic care initiatives, such as Indigenous adult health 
assessments and care plans (54). Complexity of patient conditions and time-poor clinicians 
have been cited as barriers to comprehensive management of chronic disease. To address 
these barriers, some Australian GP practices and AHSs are trialling new methods of care, 
such as group or shared medical appointments (SMAs) (55). 
Shared medical appointments were developed in the United States of America (USA) in 
1996 to improve access to care, utilise peer support, reduce costs and improve patient 
satisfaction in the management of chronic disease (56). Effective chronic disease 
management often requires extensive information to be repeated regularly by the health 
practitioner. This repetition of key points can occur in SMAs.  It is difficult for GPs to deliver 
all the information needed to complex patients with multiple co-morbidities in a time-
limited, one-on-one appointment, and often little or no discussion occurs about 
medications (57). It appears that SMAs or similar group gatherings may provide useful 
opportunities for discussions about health and medications. 
Evaluations of SMAs in USA, Canada and The Netherlands indicated that they are an 
effective adjunct to individual appointments in the health management of chronic disease 
(56). An SMA allows facilitated peer interaction and encourages patient self-management 
and empowerment (56). The SMAs have been found to be particularly beneficial for 
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patients with low health literacy (57). Whilst SMAs are fairly new to Australia, anecdotally 
they appear to be well-received by Aboriginal and Torres Strait Islander participants, and 
“yarning with others could help the healing process” (58).  
Complex health systems, together with poor communication from health providers, make 
it difficult for many patients to understand and manage their care. This can be exacerbated 
for Aboriginal patients if they have high levels of chronic disease and have to access services 
from a variety of providers including doctors, nurses, AHWs and pharmacists and especially 
if these providers are not culturally sensitive (59). 
Many Aboriginal patients have reported that they find community pharmacies culturally 
alienating and were embarrassed or ashamed to ask pharmacists for medication 
information in environments which lacked privacy (12, 15). Strategies for making the 
environment more welcoming and comfortable, such as displaying Aboriginal paintings or 
signage, and making available Aboriginal-specific information leaflets, have been utilised in 
some GP practices, and need to be adopted by community pharmacies (60, 61). Pharmacists 
also need to engage with local communities to communicate the benefits of the services 
they offer as many Aboriginal and Torres Strait Islander people have little understanding of 
the role of the pharmacist (62).  
Whilst Taylor and Hamrosi’s research found that community pharmacists were generally 
the first persons seen when seeking medical advice due to ease of access (61), this is 
contrary to the findings of de Crespigney et al who found that few of their study participants 
viewed the pharmacist as a legitimate first source of medication information. The majority 
of Aboriginal women in their study viewed their GPs as the primary and most legitimate 
source of medication information and advice (11). 
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Evidence has demonstrated that employment of Indigenous staff within a health service 
increases the access of the health service for other Indigenous people (1, 63). There are 
very few Aboriginal pharmacists or pharmacy assistants. The 2014 pharmacy workforce 
report indicated that only 0.2% of pharmacists, or 36 out of over 21,000, reported 
Aboriginal and Torres Strait Islander status in 2012 (64). Hamrosi’s research suggested 
employment of, or increased collaboration with, AHWs in community pharmacies to co-
ordinate health education programs, improve access, and educate the Aboriginal 
community about the role of the pharmacist (12). 
Culturally responsive pharmacists could play an important role in assisting Aboriginal and 
Torres Strait Islander patients to navigate the complex health system and primary care 
services, as well as the program requirements for the myriad of Aboriginal and Torres Strait 
Islander medicines programs (62). 
In addition to training more Aboriginal healthcare providers, recommendations to improve 
care for Aboriginal and Torres Strait Islander people include cross-cultural training for 
health professionals (41, 52, 65-67). 
1.6 Cultural competence and cultural safety 
Health providers are often unaware their behaviours are racist or exclusionary (68-71). The 
evaluations of the QUMAX program and the Sentinel sites reported that Aboriginal people 
found pharmacists were at times racist and culturally insensitive (8, 54). In Australia, 
cultural differences between services providers and Aboriginal and Torres Strait Islander 
people has been referred to as the “cultural chasm” (72). 
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 A reduction in racist attitudes and narrowing of the cultural chasm can sometimes be 
achieved by education and community immersion (73). For care of Aboriginal patients to 
become more effective, cultural safety in primary health services and pharmacies needs to 
be improved. Health professionals, including pharmacists, need to understand cultural 
difference and become culturally responsive health providers (68, 74). 
Cultural competency is a key strategy for improving healthcare access and the quality of 
care received (1). Developing and imbedding cultural competence in health services and 
pharmacies requires a sustained focus on knowledge, awareness, behaviour, skills and 
attitudes at all levels of the services (1). Beach et al showed that cultural awareness training 
for healthcare professionals improves their attitudes and skills, as well as impacting on 
patient satisfaction (75). The AHWs in Hamrosi’s study recommended that pharmacists and 
pharmacy staff undertake cultural awareness training (12). 
Cultural awareness training by itself is not usually enough to achieve culturally competent 
health professioanls, but is the entry level to achieve knowledge, as shown in Figure 1.1 
below (1). Cultural competency education is not a definitive solution, but should be used in 
conjunction with policies in which cultural competency principles are imbedded, and so 
may enhance understanding and the effectiveness of health professionals’ intercultural 
interactions (1). Pharmacists need to be taught to reflect on their values and beliefs and 
how they inform their practice (68). Cultural Immersion experiences for pharmacy students 
are recommended. Cultural immersion has been shown to encourage self-reflection on 
attitudes towards cultural differences and to provide opportunities to build relationships 
and work with community members (76). 
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Davidson et al’s research on improving medication uptake for Aboriginal patients also 
suggested cultural competence training for clinicians. Other recommendations included 
increasing the capacity for AHWs to engage in healthcare teams and empowering patients 
to interact with health professionals, in particular to increase engagement with community 
pharmacists (15). 
 
 
 
 
 
 
Kowanko et al found that a recurrent theme throughout their chronic condition 
management project was the importance of culturally safe health services (53). A culturally 
safe service is one that supports a patient’s sense of choice and power (52, 68, 77). A 
culturally safe health service was an enabling factor for chronic condition management, 
whereas lack of a culturally safe service was a barrier (53). Services provided by health 
professionals need to be equitable, respectful and responsive to need, offering effective 
Figure 1.1: Stages of the cultural competence continuum to cultural proficiency 
Source: Australian Government Closing the Gap Clearinghouse. Cultural competency in 
the delivery of health services for Indigenous people (1). 
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communication and professional competence, appreciating difference, and empowering 
patients. 
Pharmacist medication counselling will be ineffective if pharmacies remain culturally unsafe 
environments and if pharmacists are not culturally competent. 
1.7 Aboriginal medication programs 
The Australian government has funded a number of specific Aboriginal and Torres Strait 
Islander medication programs. These programs have been introduced to address the 
financial barriers to Aboriginal and Torres Strait Islander people’s access to medicines (14). 
As these programs mainly relate to accessing medicines rather than medication 
management they are discussed here only briefly.  
The Remote Area Aboriginal Health Service program (RAAHS), often referred to as Section 
100, was introduced in 1999.The RAAHS program provides Pharmaceutical Benefits Scheme 
(PBS) medicines, without charge, to clients of approved remote area AHSs, without the 
need for a prescription(5). The RAAHS medicines are supplied in bulk from the pharmacy to 
the AHS and then dispensed to patients by a medical practitioner, or an AHW or nurse 
working under the supervision of a medical practitioner, where consistent with the law of 
the relevant State or Territory (5). Although the program has increased Aboriginal and 
Torres Strait Islander people’s access to medicines there is some concern that under this 
program, clients have little or no interaction with pharmacists, and that medication supply 
and advice may be sub-standard, thus increasing the risk of medication-related problems 
or medication misadventure (78). 
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In response to concerns related to this bulk supply of medicines to remote Aboriginal and 
Torres Strait Islander communities, the Department of Health introduced the S100 
Pharmacy Support Allowance for the provision of some pharmacist services to remote 
AHSs. The details of this program and other Aboriginal-specific pharmacy programs can be 
found on the Pharmacy Guild website at http://6cpa.com.au/aboriginal-and-torres-strait-
islander-specific-programmes. 
Pharmacists report that the amount of funding provided by the S100 pharmacy support 
allowance is insufficient to allow regular visits to the remote AHSs. The majority of the 
pharmacists’ visits to remote AHSs report interactions with AHS staff, rather than with 
patients, and so often do not adequately address patient issues of medication management 
(79). There has been no comprehensive evaluation of the outcomes of S100 Pharmacy 
Support Allowance. 
In 2011 the Australian Senate conducted an enquiry into the effectiveness of special 
arrangements of PBS medicines to remote AHSs. The resulting report recommended further 
data collection, data transparency and research to enable evaluation of clinical impact of 
this “no charge” RAAHS medication supply scheme. The report also recommended that 
remote area AHSs be given funding for Dose Administration Aids (DAAs), that medication 
dispensing, recording and labelling processes be improved and that there should be funded 
positions for pharmacists in remote AHSs. The report also called for integration of all the 
different medication access schemes (80). 
The QUMAX program began in 2008 and provided subsidised DAAs and PBS medicines for 
some Aboriginal and Torres Strait Islander people attending ACCHOs. The Closing the Gap 
(CTG) Pharmaceutical Benefit Scheme Co-payment measure was introduced in 2010 as a 
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more comprehensive and equitable scheme which subsidised PBS medicines for Aboriginal 
and Torres Strait Islander people with chronic disease. The QUMAX and CTG programs are 
facilitated through community pharmacies and thus should encourage pharmacists’ 
interactions with their Aboriginal patients. 
The QUMAX program initially funded the employment of Quality Use of Medicine Support 
Pharmacists (QUMSP). These pharmacists assisted in brokerage of relationships between 
AHSs and community pharmacies, as well as establishing some medication management 
programs and education within AHSs. The QUMAX program resulted in some community 
pharmacists receiving cultural training and led to stronger working relationships between 
some pharmacists and AHSs (8). The QUMAX program evaluation reiterated that there is a 
clear need for individuals within AHSs who can drive change and help AHSs and clients strive 
for better medication management (8). 
The QUMAX evaluation report, conducted by Urbis for the Department of Health, noted 
that the provision of financial assistance for accessing medicines resulted in more patient-
clinician interactions as it removed the embarrassment of the patient having to report to 
the doctor that they had not been taking their medications. It reported that this increased 
regularity of communication between the AHSs and their patients led to improvement in 
the patients’ understanding of their health and medication management (8). 
For the CTG Co-payment measure, the CTG-endorsed prescriptions must be dispensed at a 
community pharmacy. This allows the pharmacist to interact with the patient, and 
undertake clinical interventions and/or medication counselling. However, the pharmacy 
environment has been described by some Aboriginal people as impersonal, confusing and 
uncomfortable and thus can be a barrier to effective engagement with pharmacists (12). 
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Although the RAAHS, QUMAX and CTG programs remove some of the financial barriers to 
accessing medicines, poor medication access and management may still occur as a result of 
program complexity, polypharmacy (the taking of multiple medicines) and inadequate 
delivery of medicine information (62). 
1.8 Medication management 
Over 80% of all Australians aged 65 years and over, and about 70% of Australians aged 45-
64 years regularly use pharmaceuticals (81). Although medicines contribute to significant 
improvements in health when used appropriately, they can also be associated with harm 
as a result of errors and adverse events. 
Medication-related hospital admissions have been estimated to comprise 2-6% of all 
Australian hospital admissions, and for people aged 65 and over it is estimated that 20-30% 
of admissions are medication-related (82). Medication-related problems account for about 
230,000 hospitalisations annually, costing an estimated $1.2 billion in 2011-2012 (82).  
There is much medication confusion and mismanagement in the elderly and other 
populations with multiple chronic diseases. Ninety percent of the elderly cohort in one 
study recorded at least one medication-related problem, and between 9% and 12% of 
people attending general practice have reported an adverse medication event in the 
previous 6 months (2). In Australia the data indicate that patients who participated in HMR 
were found to have had between two and five medication-related problems per person, 
and 40-50% of elderly people in the community had been prescribed inappropriate 
medicines (82). 
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There are many factors which may contribute to medication-related problems such as 
patient confusion, medication non-adherence and poor communication. Adverse drug 
events can be a particular problem in the post-hospital-discharge period (83). There is 
growing acceptance that prescribing should be conducted in partnership with patients. 
However, in some instances lack of GP time may limit discussions about medication 
treatment when patients are with their GPs (84). Despite the increasing availability of 
medicine information on the internet, doctors and pharmacists are still the preferred 
source of medicines information for consumers (85). 
Social circumstances and deficiencies in health service delivery mean many Aboriginal and 
Torres Strait Islander people suffer even greater challenges in medication management 
than non-Indigenous Australians. Complex medicine regimens associated with multiple co-
morbidities result in some Aboriginal and Torres Strait Islander patients finding medicines 
confusing and difficult to manage, and there are many factors which may inhibit Aboriginal 
and Torres Strait Islander people’s effective use of medications. These include issues of 
access, lack of continuity of care, low health literacy, poor communication, and lack of 
understanding of safe medication principles. These factors may contribute to low 
medication adherence and unsafe medication practices (4, 9, 11, 15).  
Larkin reported that barriers to effective medication management included failed patient-
clinician interactions, poor healthcare delivery systems and complex therapeutic 
medication regimens (14). Davidson et al described poverty and social disadvantage, 
racism, fatalism, patient mobility, the shame involved in accessing subsidised medicines, 
inadequate health professional support, and the disempowering stigma associated with a 
diagnosis of chronic disease, as barriers to medication adherence (15). Murray also 
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reported educational disadvantage and shared crowded households as significant factors 
that influenced an individual’s ability to manage medications (51). 
Emden et al found that social and emotional wellbeing issues deeply pervade the lives of 
Aboriginal people and may diminish the value that some individuals place upon medicines 
and the potential of these medicines to improve their quality of life (9, 10). Experiences of 
racism, causing lack of assertion, self-worth and hope, can also result in an absence of 
positive attitudes towards health and medications. Some patients were found to make 
medication management a low priority as they prioritised family responsibility over 
personal health problems (9). The South Australian research into the medication needs of 
Aboriginal patients with mental health disorders also found that issues of AHS staff stress 
and workload, inadequacies of mainstream health services to meet Aboriginal patients’ 
needs, and inadequate living arrangements impeded effective medication management (9). 
Emden et al also found that that the majority of the participants did not understand their 
medical diagnosis, the action, dosage instructions or potential side-effects of their 
medicines, or the consequences of not taking their medicines. Many were unable to 
correctly interpret instructions on medicine labels or to identify when repeat medications 
were required (9). 
De Crespigny et al found that her study participants mainly recognised their medications by 
shape and colour, and often relied on this form of recognition to select and manage their 
medication each day (11). The patients of remote GPs, Murray and Brown, reported that 
generic brand substitution and/or frequent changing of treatments were common causes 
of medication confusion (51). 
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Many instances of unsafe medication usage were reported by Kowanko, De Crespigny et al 
in a study of Aboriginal people with mental health disorders (10). They attributed these to 
lack of Aboriginal and mainstream workforce training on safe medication management and 
recommended that AHSs should employ Aboriginal health personnel to co-ordinate and 
support safe medication management for Aboriginal clients. They also recommended that 
all personnel with any role in handling, transporting, and providing or assisting in the 
administration of medication should receive training in safe medication management (10). 
These researchers also reported that cost, feelings about the value of medicines and side-
effects, sharing of medicines, and drug and alcohol misuse negatively impacted on safe 
medication usage (10). 
1.8.1 Medication adherence 
Poor adherence to prescribed medication is well-documented and associated with adverse 
health outcomes in all population groups (15). There are many studies which indicate that 
medication adherence for many non-Indigenous patients with chronic disease is extremely 
poor (86-90). It is estimated that 30-50% of prescribed medicines for long-term conditions 
are not taken as recommended (86). 
Risk factors for non-adherence with medication include older age, increasing number of 
medicines, frequency of dosing regimen (especially 12 or more doses per day), patient 
dissatisfaction with prescribers, and multiple prescribers and pharmacies (91). 
Improving medication adherence is complex and requires interventions at the system, 
provider and patient levels (15). Pharmacists have a role to play at each of these levels. 
Haynes et al’s systematic review of interventions to enhance medication adherence 
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identified that for short-term drug treatments, counselling, written information and 
personal phone contact were found to promote adherence. For long-term treatments, no 
simple intervention, and only some complex ones, such as counselling, regular 
communication and follow-up, and family engagement, have led to improvements in health 
outcomes (3). 
A recent Cochrane review on “Ways to help people follow prescribed medicines” suggested 
that more advanced methods for researching ways to improve medicine adherence were 
needed. This review hypothesised that as physicians have limited time, and sometimes 
skills, to counsel patients on medication adherence, medication counselling should be 
undertaken by pharmacists (92). Consultations between pharmacists and patients have 
demonstrated positive improvements in medication adherence (93). The United States 
Institute of Medicine has recommended that patients should have increased access to 
pharmacist medication management services as these have been shown to resolve 
medicine-related problems and improve health outcomes (94). In Van Wijk et al’s literature 
review, some studies reported that weekly or monthly consultations with a pharmacist 
were most effective in improving medication adherence (95). 
Motivational interviewing and collaboration between pharmacists and patients have been 
shown to increase medication adherence (96). Individualised patient education, together 
with strategies such as DAAs, regular pharmacist follow-ups, medication review and 
medication regimen simplification, were also found to improve medication adherence (97). 
Barriers for Aboriginal and Torres Strait Islander people to medication adherence may 
include poor access to pharmacists and pharmacy services. This poor access to pharmacists 
occurs in remote settings where there are few pharmacies and pharmacists, but also in 
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urban and rural settings when Aboriginal and Torres Strait Islander people find pharmacies 
to be unsafe environments (12). Poor access to primary care, deficits in trust between 
patient and health professionals, and failure of health professionals to address patient 
understanding, are also seen as factors which may contribute to poor medication 
adherence for Aboriginal Australians (4). 
Researchers claim that pharmacists, through active patient counselling, clarifying concepts 
and using education tools, together with regular communication, follow-up and family 
engagement, could greatly assist Aboriginal and Torres Strait Islander people with 
medication adherence (15). Davidson et al also stated that clinicians should strive to 
promote adherence through simplifying dosages, organising medications in Dosette boxes 
or Webster packs, and conveying to the individual the importance of the medication (15). 
Larkin and Murray believe effective communication and simplification of drug regimens 
may improve medication adherence by Aboriginal Australians in the Kimberley. They also 
commented that it was important for patient education to emphasise the need to take 
medicines regularly, as this idea may not fit the patients’ understandings of how medicines 
were to be used (14). 
Some literature suggests that lack of treatment adherence or compliance by Aboriginal 
people is a measure of dissonance between western medicine and Indigenous culture, and 
this gap can be narrowed only through the development of shared knowledge and cultural 
beliefs (98). 
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1.8.2 Health literacy and medication management 
Health literacy is often described as the range of cognitive and social skills needed to obtain, 
understand and use information to enhance health and wellbeing and engage in clinical 
decision-making (99). Literacy, numeracy and language skills influence a patient’s health 
literacy and responsiveness to established health education and self-management 
programs (100). Low health literacy often coexists with lack of education and with social 
disadvantage, and this can be seen in many Aboriginal communities (101). 
Low health literacy can result in decreased ability to read and interpret medication labels 
and medication information, and thus can result in unsafe use of medicines (102). Lower 
health literacy is associated with less understanding of medication regimens and a higher 
likelihood of medication error (103). Low health literacy is a significant and independent 
predictor of medication adherence (101). There has been limited success in addressing the 
issues and impact of low health literacy in community pharmacies in Australia (104). 
Low health literacy contributes to the communication gap between clinicians and patients 
(105). Low health literacy skills are associated with poorer health knowledge, poorer health 
status, higher mortality, increased hospitalisations and higher healthcare costs (101). Data 
on health literacy in Australian Indigenous populations are lacking. A team of researchers 
are currently undertaking an intervention trial, using education sessions, in Indigenous 
primary care services to assess the impact of cardiovascular medication health literacy 
among Indigenous people in New Zealand, Australia and Canada (106). 
Health practices need to allow adequate consultation time and implement strategies to 
manage complex consultations and multi-morbidities, and have follow-up systems in place 
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(107). Pharmacists need to be aware of low health literacy when advising patients about 
their medication use, labelling medications and providing information on medicines. Health 
professionals, including pharmacists, need to develop communication aids and resources 
that are useful for people, regardless of their health literacy skills (100). 
1.8.3 Health resources 
Many Aboriginal patients have limited access to appropriate and understandable 
medication information (11, 108). Written information about medicines, i.e. consumer 
medicine information, is thought to play an important role in educating consumers about 
medicines and influencing treatment adherence. (85) De Crespigny et al also felt there was 
an urgent need for more culturally safe written medication information, as well as more 
education and support for patients (11). 
In Hamrosi and Taylor’s study, AHWs reported that clients frequently used medications in 
an inappropriate way due to limited understanding, literacy and information. Participants 
in their study found the consumer medicine information leaflets difficult to read, confusing 
and too long (12). Dr Alex Brown in his Heart Foundation research found that the majority 
of patients had poor knowledge of their cardiovascular disease and medicines. He stated 
that currently available medicines information resources were inadequate and lamented 
the lack of culturally appropriate audiovisual aids that could assist with medication 
management in AHSs (4). The involvement of Aboriginal and Torres Strait Islander people 
in the development of information is essential to ensure appropriate language and imagery 
are used (4). 
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1.9 Communication and relationships 
Miscommunication can have adverse consequences, including poor adherence to 
treatment and persistent health-damaging behaviours (35). Few researchers have studied 
the extent of miscommunication in Aboriginal healthcare, but there are indications that 
there may be serious and often unrecognised miscommunication between non-Aboriginal 
health professionals and Aboriginal patients (109). Miscommunication may be contributed 
to by language differences and differing belief systems regarding illness (52). 
Miscommunication may also result from lack of shared understanding. As shown in the NT 
Sharing True Stories project, failure to achieve a shared understanding of health concepts 
among patients and clinicians often inhibits the delivery of effective healthcare (109). 
In a study of Western Australian(WA) Cancer Service providers and their Aboriginal 
patients, lack of knowledge about the cultural, social and health needs of Aboriginal people, 
the marginalisation of Aboriginal people within the system, and Aboriginal patients’ distrust 
of the health system and language and communication styles were identified as barriers to 
communication (110). Strategies identified in the WA study to improve service providers’ 
communication with Aboriginal patients included more Aboriginal staff, cultural training for 
service providers, continuity of care, and clear, empathic, simple and jargon-free 
communication (110). 
A UK study identified that insufficient patient counselling about medications was a main 
cause of preventable drug-related hospital admissions. It revealed that communication 
failures between patients and healthcare professionals, and between different health 
professionals, and knowledge gaps about patients’ medications were significant 
communication problems which contributed to hospitalisation of patients (111). 
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Kowanko, de Crespigney et al’s report on Better medication management for Aboriginal 
people with mental health disorder and their carers (2003) recommended more 
communication between Aboriginal clients and pharmacists. It recommended that all 
Aboriginal clients and their carers/families needed to receive sufficient time, 
understandable information and education to make informed decisions about their 
medication regimens and how to safely manage their medications, at every episode of care 
from all health professionals (112). 
Greater understanding and empowerment about medicine choices seem to be likely to 
improve medicine adherence (3). McConnel, a remote NT physician, found that treatment 
compliance improved where there was a shared understanding between health 
professional and patient of health problems and treatment goals (98). 
Good interpersonal relationships between health professionals and patients allow 
information exchange, facilitate treatment-related decision-making, and improve health 
outcomes (109). Communication techniques, such as motivational interviewing and 
patient-clinician collaborative goal-setting, are thought to be useful when counselling 
patients about their medications (15). However, many health professionals have poor skills 
in assisting patients to set goals (113). To effectively assist Aboriginal patients manage their 
medicines, pharmacists need to implement motivational interviewing and goal-setting 
strategies. 
Pharmacists need to establish rapport and trust with Aboriginal and Torres Strait Islander 
clients before effective negotiation of medicine adherence targets can be achieved (62). 
Pharmacists also need to establish stronger relationships and communication pathways 
with other health professionals. 
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The Price Waterhouse Coopers Professional Collaboration project found a lack of 
collaboration between community pharmacists and other health professionals can result in 
adverse medication events. Whilst health professionals cited a willingness to collaborate, 
there was a lack of understanding and respect among professions, except when located in 
close proximity. Timely and effective communication among all stakeholders was needed 
for effective collaboration to occur (96). 
Inadequate communication among different health services and among health 
professionals across the continuum of care was identified by Brown as a major impediment 
to medication management for Aboriginal people. Most of the AHSs in his study reported 
that often the hospital discharge information was of poor quality, slow to arrive, and 
insufficient to explain future care, follow-up strategies, medicines management, and 
treatment targets. Similarly, he identified that poor communication among health services 
impeded good continuity of care for patients who were mobile and moved between 
communities (4). 
Building rapport and therapeutic relationships takes time, especially where there is a 
cultural divide between health professional and patient (109). Motivational interviewing 
and collaborative goal-setting also take time. Lack of remuneration for community 
pharmacists’ delivery of professional services and client counselling may be a barrier to 
pharmacists’ effective engagement with Aboriginal and Torres Strait Islander clients. 
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1.10 Pharmacies and pharmacists 
There is a network of over 5500 community pharmacies across Australia. Pharmacists play 
a key role in ensuring that most Australians have ready access to essential medicines. Whilst 
their traditional function in treatments for minor ailments and the provision of medicines 
remains, there is now greater emphasis on provision of medicines information, advice on 
prevention and management of chronic disease, and medication management services 
(114). 
Pharmacies must become health solution destinations, and remuneration from 
professional pharmacy services, such as medication reviews, clinical interventions and 
immunisations, is needed to support decreasing profit margins from dispensing (115). 
Pharmacy practice change is seen by many as imperative and inevitable (116). 
Whilst many GPs are accepting of the changing professional roles of pharmacists, some 
perceive the changes as a threat to GPs’ autonomy and control (117). Some GPs consider 
the community pharmacist role as a “shopkeeper” and distant from direct patient care (84). 
Research has shown that whilst some GPs were content for pharmacists to provide 
information regarding medicines, many were less happy for them to be involved in 
prescribing decisions and adjusting ongoing pharmacotherapy (59, 118). One New Zealand 
(NZ) study indicated that there has been a significant and positive change in the way GPs 
view the role of community pharmacists (119). Another study from The Netherlands 
suggested that GPs would welcome more structured cooperation between GPs and 
pharmacists to create more opportunities for advisory and interventional input from 
pharmacists (120). In the 2015 evaluation report of the Fifth Community Pharmacy 
Agreement (5CPA) programs, GPs and other health professionals stated that usually they 
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did not communicate with pharmacists about the management of their patients’ health 
(47). 
Pharmacist interventions in primary, secondary and tertiary care settings can improve 
prescribing practices, improve medication adherence through therapeutic monitoring, 
simplify medication regimens, and optimise therapeutic outcomes, and so reduce 
hospitalisations, and/or hospital stay times and healthcare costs (19, 121-124). Pharmacy 
services such as patient medicine education, medicine reviews, drug interaction checking, 
dosage and adverse-effect monitoring, medication reconciliation and clinical interventions, 
have been proven to make valuable contributions to improving health outcomes (125). 
Whilst some patients highly value the importance of the pharmacist’s role in their 
healthcare team (47), there are many people who have little understanding of the role of 
pharmacists as “medicine experts” or chronic disease managers (126). Pharmacists and 
their professional organisations need to better inform health professionals and patients 
about the services pharmacists can offer. Aboriginal and Torres Strait Islander people have 
reported very little understanding of the pharmacist’s role in their healthcare (62). 
In Australia, there is growing evidence for multi-disciplinary approaches to improving 
primary healthcare and medication management, and a number of leading health 
advocates are advocating for system reform. Professor Duckett, Director of the Health 
Program at the Grattan Institute, stated: 
“…there needs to be revitalization of primary care, helping this sector adapt to the 
increased prevalence and importance of chronic conditions. The skills of health 
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professionals are not being used properly. Use of all the skills of other professionals, 
such as nurses and pharmacists, needs to be encouraged. (127) 
The need for a more multi-disciplinary approach to chronic disease management in 
Australia’s ageing population and the cost of poor medication management are 
encouraging health service reform. One reform being trialled in a few sites in Australia is 
the co-location of non-dispensing pharmacists in general practice settings. 
1.10.1 Pharmacists co-located in general practice 
The international literature demonstrates that pharmacists in many countries, including NZ, 
UK, Canada and the United States of America (USA), are successfully providing clinical 
services and improving medication adherence from within general practice settings (128). 
The 2010 UK PINCER and PRACtICE studies (129, 130) found that pharmacists play a critical 
role in reducing medicine errors in general practice. In the UK, GPs reported that having an 
in-house consultant pharmacist reduced patient waiting time, improved screening and 
monitoring of minor ailments and chronic disease, reduced medication wastage and over-
use, and improved patients’ medication safety (131). 
The Australian report of the National Review of Mental Health Programmes and Services 
supported changes to maximise the potential of non-dispensing pharmacists to work with 
doctors and other health practitioners to meet health needs, relieve the strains on the 
health budget and improve health outcomes of patients (132). The Senate Inquiry into the 
RAAHS medication access scheme recommended more access to pharmacists by remote 
clients to ensure safe medication use (133). 
33 
 
Despite the lack of a sustainable remuneration model, a small number of pharmacists in 
Australia are now working in general practice settings and AHSs. Currently, AHSs and 
general practices are cobbling together funding from HMR income, chronic disease 
programs and Practice Incentives Program payments to try to maintain their pharmacy 
services. However, such a funding model is complex and time-consuming, and often only 
results in 1 or 2 days’ employment of a pharmacist, no matter the size of the primary health 
service (134, 135). 
Freeman, a practice pharmacist, demonstrated that a pharmacist within general practice in 
Australia can increase medication safety and adherence, improve patient health outcomes 
and quality of life, reduce medicine wastage and/or inappropriate medication use, and 
assist with transition of care across healthcare settings (136). Practice pharmacists in 
Australia have described their tasks as assisting with medication enquiries from patients 
and health professionals, conducting staff education, reviewing prescribing, mentoring new 
prescribers, case conferencing and liaising across health sectors. With patients they also 
conduct medication counselling, undertake medication reviews and evaluate drug 
utilisation to ensure optimal therapy. (137) Other roles pharmacists undertook included 
point-of-care testing, monitoring, clinical audits, health assessments, immunisation, 
transitional care, facilitation of shared medical appointments, and liaison with community 
pharmacies (138, 139). 
Australian practice pharmacists have noted that being able to access a patient’s medical file 
for a complete patient history enables meaningful, informed clinical interventions 
optimising patient care. Being integrated within the practice also increases pharmacist–GP 
rapport and communication (135, 137, 140, 141). Because the practice pharmacist develops 
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relationships with the GPs in the practice, the GPs are more likely to act on the pharmacist’s 
recommendations (142). 
The successful integration of pharmacists into primary care practices in Canada required 
development of relationships and trust, clear definition of the pharmacist’s role, 
appropriate pharmacist orientation and support, ongoing presence and visibility of the 
pharmacist and sustainable reources and funding (128). Whilst many pharmacists in 
Australia, Canada and the USA have reported that they are keen to work more closely with 
mainstream GP practices and deliver inter-professional healthcare, some are unsure as to 
how to facilitate the process (128, 134, 143). 
Some Australian pharmacists, although not being co-located within general practice, have 
been collaborating with GPs when conducting medication reviews. Although GP 
engagement with community and accredited pharmacists in the provision of programs and 
services has improved, the review of the 5CPA Medication Management programs (2015) 
found that collaboration still remains sub-optimal (47). 
1.10.2 Australian Medication Management programs 
Medication management programs, funded by the Australian Commonwealth 
Government, were established to address the high prevalence of medication-related illness 
in the community (144). 
Four of the medication management programs (47) which were funded under the Fifth 
Community Pharmacy Agreement 2010-2015 include: 
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 Home Medicines Reviews (HMRs) ‒ conducted by an accredited pharmacist in a 
patient’s home, after referral from the patient’s GP 
 Residential Medication Management Reviews (RMMRs) – conducted by an 
accredited pharmacist in the patient’s residential aged care facility, after referral 
from the patient’s GP 
 MedsCheck – an in-pharmacy review of a patient’s medication by registered 
pharmacists 
 Diabetes MedsCheck – an in-pharmacy review of Type 2 diabetes patients’ 
medicines and devices and understanding of their diabetes. 
This suite of medication management programs was developed to address differing levels 
of consumer medication complexity and need (47). MedsCheck services were intended to 
assist consumers with less complex medication needs, with a focus on consumer education 
and self-management. The HMRs were intended to assist consumers with more complex 
medication needs by delivering a higher-intensity, multi-tiered intervention in collaboration 
with a patient’s GP (47). 
The 2015 evaluation of these medication management programs found health professionals 
and patients perceived these medication management programs had many benefits. They 
perceived that they improved medication adherence and confidence, assisted GPs with 
pharmacology, and resulted in de-prescribing of medicines (47). However, despite the HMR 
and RMMR programs being available since 2001, stakeholders reported that both 
consumers and GPs had low awareness of the programs, and this made the programs 
difficult to access, particularly for Aboriginal and Torres Strait Islander and Culturally and 
Linguistically Diverse (CALD) people (47). 
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This research investigates the usefulness of the HMR program for Aboriginal and Torres 
Strait Islander people. Before the HMR program is discussed in some detail, the 
effectiveness of varied medication reviews, according to the literature, is briefly discussed. 
Details and guidelines for the Australian medication management programs can be found 
on the website of the Pharmacy Guild of Australia at http://6cpa.com.au/medication-
management-programmes/. 
1.11 Medication review 
Medication review has been proposed as an important strategy to constrain the negative 
effects of polypharmacy and to ensure the safe and effective use of medicines (145). It is 
defined as a structured, critical examination of a patient’s medicines with the objective of 
optimising the impact of medicines and minimising the number of medication-related 
problems (146). The main purpose of medication review is to ensure that each medicine, 
prescribed and not prescribed, is appropriate for the patient, is being used appropriately, 
and is well-tolerated and effective (117) 
Various medication review programs exist internationally, with variations in name and 
program delivery rules. The evidence demonstrates that medication reviews can detect 
medication-related problems and reduce potential harms, but there is varied evidence on 
their impact on clinical outcomes (147, 148). There are conflicting study outcomes regarding 
reduction in mortality and hospital admissions (149-154). Stewart et al in the USA found 
that counselling patients about their medicines in hospital before discharge and one week 
post-discharge reduced hospital readmissions (155). Roughead’s study of Australian 
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patients treated with warfarin found that regular medication reviews, about six-monthly, 
were needed to sustain delays in hospital readmissions (20). Roughead also found that 
HMRs were effective in delaying time to next hospitalisation in patients with chronic heart 
failure (156). However, Royal et al’s systematic review found only weak evidence that 
medication reviews reduce hospital admissions (157). 
Milos et al in Sweden found evidence that medication reviews reduced polypharmacy and 
increased the appropriateness of medicine choice in aged care (158). Saez-Benito et al in 
their systematic review of cognitive pharmacy services found conflicting evidence of the 
effect of medication review on adherence (159). Hatah’s systematic review and meta-
analysis of studies showed improvements in medication adherence after medication review 
(151). Mackeigan and Nissen in their review of the literature found that improved 
medication adherence was the only consistent outcome shown in trials evaluating home-
based medication review (160). Another systematic review found that pharmacist 
interventions in the pharmacy improved medication adherence in patients with 
cardiovascular disease or diabetes (161). 
Some of the variations in study findings may be due to the different models and variable 
standards or quality of medication reviews. In some models, for example Medicines Use 
Reviews (MUR) in UK and NZ and MedsChecks in Australia, the pharmacist does not undergo 
accreditation training, and these reviews occur within the pharmacy. The MUR service is not 
intended to be a full clinical review and is modelled on the concept of concordance where 
patients are encouraged to become increasingly empowered in their own medicine-taking 
decisions in order to achieve the most effective use of their medicines (162). These MUR 
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services are not conducted in collaboration with the patient’s doctor and may not result in 
GP follow-up or medication changes. 
The NZ MUR program and separate Adherence Support Services can be conducted in the 
pharmacy, at the patient’s home or via telephone. The NZ MUR involves four quarterly 
consultations between a patient and their pharmacist, with follow-up services being shorter 
in length than initial consultations. The two follow-up consultations assess the effectiveness 
of the implemented medicines management care plan, initiates any further changes and 
confirms there are no new medicine-related problems (163). Various international 
medication review program evaluations have shown that patient follow-up after the initial 
review service improves patients’ health outcomes (95, 97, 164). 
In NZ the most frequent medication-related problems documented during medication 
reviews were low health literacy and non-adherence to medications (165). In NZ Bryant’s 
randomised controlled trial of medication reviews in community pharmacies found that only 
40% of pharmacists’ recommendations were implemented. This percentage has found to 
significantly increase if pharmacists have closer collaboration with GPs. This trial also 
concluded that pharmacies were not a good setting for conducting medication reviews 
(166). 
Population groups that could most benefit from medication reviews have been examined. 
The Australian, UK, NZ and Canadian literature has identified the following consumers as 
the most likely to benefit from medication review (163). These are people: 
 taking 5 or more medications on a regular basis 
 taking 12 or more doses of medicine a day 
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 with chronic medical conditions 
 living in the community 
 recently discharged from hospital, with possible medication changes 
 with multiple prescribers 
 taking medicines associated with high risk of adverse events 
 with language, cognitive, dexterity or other physical difficulties. 
An evaluation of the NZ medication review program identified that pharmacists’ 
recruitment of patients excluded low socio-economic and Indigenous groups (167). 
Australian evaluations of medication review programs have also identified that those at 
greatest risk of medication misadventure and the most likely to benefit from medication 
management programs are the least likely to be able to access the service (23, 47, 163, 168). 
These include patients after hospital discharge, patients living in remote locations, CALD 
patients, patients who are intentionally and unintentionally highly non-adherent with their 
medicines, people who are transient or homeless, and Aboriginal and Torres Strait Islander 
people (163). 
International studies of pharmacist-led medication reviews have shown that positive 
facilitators of medication reviews include established pharmacist-GP relationships, using a 
patient’s regular pharmacist, adequate clinical training of the pharmacist, and face-to-face 
meetings (case conferencing) between GP and pharmacist (24, 166, 169, 170). In some 
models, for example, MURs in the UK, there is concern by GPs that these medication reviews 
are conducted in isolation by pharmacists rather than in collaboration with GPs (84). 
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The Australian HMR model is a highly collaborative model in which the GP is responsible for 
the HMR referral and the patient’s final Medication Management Plan. The features of the 
HMR model are discussed in 1.12. 
1.12 Home Medicines Review 
The HMR program (17) was introduced in Australia in 2001 by the Commonwealth 
Government and is a collaborative model of medication review. It is one of a suite of 
medication management programs in Australia funded under Community Pharmacy 
Agreements and managed by the Pharmacy Guild of Australia.  
The objectives of an HMR are outlined on the website of the HMR pharmacist accrediting 
body, the Australian Association of Consultant Pharmacy (171).  
The objectives are to: 
  achieve safe, effective and appropriate use of medicines by detecting and 
addressing medicine-related problems that interfere with the patient's desired 
outcomes 
  improve the patient's quality of life and health by using a best practice 
approach, that involves cooperation among the GP, pharmacist, other relevant 
health professionals and the patient (and where appropriate, their carers) 
  improve the patient's and health professional's knowledge and understanding 
about the patient's medicines 
 build cooperative working relationships between members of the healthcare 
team in the interests of patient health and wellbeing (171). 
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An HMR is a comprehensive medication review conducted by a “medication management 
review accredited pharmacist”, usually in a patient’s home, and only by referral from the 
patient’s GP. Figure 1.2 shows the flow of HMR processes according to the program 
guidelines as defined by the Department of Health. To be accredited to undertake HMRs 
and RMMRs, a pharmacist has to participate in a regulated training and examination 
process. The number of accredited pharmacists fluctuates annually, but there were 
almost 1000 accredited pharmacists in Australia in 2014 (171).  
Studies show that HMRs can improve patient safety through minimisation of medication 
errors when targeted at patients at high risk (18-20). The HMRs provide an opportunity to 
educate patients, identify and resolve issues associated with sub-optimal patient 
understanding of medicines, identify under-use of medicines and untreated indications, 
and conduct medication reconciliation (83, 172, 173). Benefits of HMR also include 
increased health literacy and medicine education, and emotional reassurance, validation 
and affirmation (174). 
Sorenson et al’s randomised controlled trial of the HMR program in 2004 identified potential 
adverse drug reactions, sub-optimal monitoring, and medication adherence issues with 
patients’ medications. This trial found that more than 70% of pharmacist recommendations 
from the HMRs had positive outcomes, preventing possible medication danger and leading 
to improvements in symptoms, function and disease (175). 
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Figure 1.2:  Home Medicines Review flowchart 
 
Source: Pharmaceutical Society of Australia’s Guidelines for pharmacists providing HMR 
services, www.psa.org.au/downloads/practice-guidelines/home-medicines-review-
services.pdf 
 
A number of research studies have assessed barriers, facilitators and health professional 
and patient perceptions of the HMR program. The 2005 Urbis Keys Young evaluation of the 
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HMR program commissioned by the Pharmacy Guild cited a lack of awareness of HMRs 
among consumers as a key barrier to participation (24). A number of other Australian 
studies also found low levels of awareness among consumers (176-178). White et al were 
commissioned by the Pharmacy Guild in 2010 to create a marketing plan to increase patient 
demand for HMRs (179). 
 
 
The 2005 Urbis Keys Young evaluation of the HMR program recommended simplifying the 
HMR processes. However, the HMR process and program rules have increased in complexity 
rather than becoming simplified under the Fifth Community Pharmacy Agreement, as seen 
in Figure 1.3. The 2005 evaluation report suggested introducing a two- to three-tiered 
payment structure to reflect the varying levels of complexity from case to case (24). The 
latter has occurred to a degree with the introduction of the MedsCheck and Diabetes 
MedsCheck programs, which are in-pharmacy medicines consultations between consumers 
and community pharmacists. However, a recent evaluation of the MedsCheck service found 
that although the service provided valuable education to patients it did not necessarily 
change behaviour (163). 
Medscheck participants reported increased confidence in managing medicines and better 
understanding of their health conditions and medicines (163). However, the consumers 
most likely to benefit from MedsCheck programs, those at risk of medication misadventure 
and those whose adherence to medication regimen was poor, were the least likely to access 
MedsCheck services (163). Barriers to MedsCheck services included consumers not being 
able to access community pharmacies. This was due to distance, lack of transport, being 
housebound or feeling uncomfortable about discussing health in the pharmacy (61, 163). 
Australian Bureau of Statistics data (2010) showed that only 50% of Aboriginal and Torres 
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Strait Islander people can access pharmacies when needed (180). Also, intentionally non-
adherent patients are the least likely consumers to consent to having a MedsCheck (163). 
The Campbell evaluation commissioned by the Department of Health & Ageing in 2008 (23) 
found that consumers who had received HMRs were positive about their experience and 
found it informative but did not always see it as making a significant difference to their 
health. This was thought to be largely a result of lack of correlation between the HMR 
interview and the final medication plan implemented by the GP (163).  
The Campbell evaluation identified that the business rules were barriers to heath 
professional participation in the HMR program. A recommendation was made to broaden 
the health professionals who could refer patients for HMRs. It was thought that referrals for 
HMR by nurses and other professionals would enable post-hospital-discharge patients, 
Indigenous patients and patients who did not use GP or pharmacy services to have greater 
access for referral to the HMR program. Lack of integration of HMRs into pharmacy and GP 
business practices were seen as barriers to HMR referral. Direct referrals to accredited 
pharmacists, rather than always to a community pharmacy, were recommended. This direct 
referral to an accredited pharmacist was the only recommendation from the report which 
was implemented (in 2011) (23). The 2015 5CPA evaluation explored broadening the referral 
pathway, but only included hospitals, nurse practitioners and specialists (47). To date, no 
changes to the types of health professionals who can refer patients for an HMR have been 
made and so GPs are still the only referring practitioners.  
In 2008-2009 the Unit for Medication Outcomes Research and Education at the University 
of Tasmania conducted The Economic Value of Home Medicines Review (VALMER) study 
which assessed the economic benefits of HMRs (144). It concluded that some patients 
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benefited substantially from resolution of medication issues as a result of HMRs, and this 
resulted in considerable savings to the healthcare system. However, for many patients, 
changes in drug therapy did not result in appreciable short-term savings, and it was 
inconclusive whether findings might extrapolate to long-term savings (144). 
Chen et al from the University of Sydney, Faculty of Pharmacy, found that pharmacists, 
working through HMRs, could greatly assist GPs to rationalise prescribing and implement 
evidence-based medicine (18). Chen et al also found that although medication review had 
been shown to improve the quality of medicine use, medication management plans arising 
from the medication review process were often not implemented by GPs. This was thought 
to result from a lack of existing pharmacist-GP relationships and a lack of routine face-to-
face interactions between pharmacists and GPs (181). Freeman, as a pharmacist and 
researcher working within a GP practice, confirmed this finding. His research found that 
there was a significantly higher rate of uptake of the practice pharmacist medication review 
recommendations by the GP when medication reviews conducted by a practice pharmacist 
working within a GP practice were compared with those conducted by an external 
pharmacist (140). Ahn’s study of HMRs in a western Sydney area found that there was often 
a lack of medication review follow-up by the GP, and thus patients received their HMR 
results incidentally when they made visits for other purposes (174). 
Carter et al, also a University of Sydney pharmacy research team, found that many patients 
viewed HMR as an information resource. Their willingness to use HMR was driven by 
expectation regarding the HMR’s capacity to provide them with useful information (182). 
Consumers who were worried about their medicines were more willing to use HMR services. 
Consumers were significantly influenced by their GPs’ willingness to use the medicine 
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management service (182). These researchers found that understanding and awareness of 
the HMR program were key motivators to having an HMR, and thus both GPs and 
pharmacists had a role to play in educating consumers about the HMR program (183). The 
lack of adequate description of the HMR program, and the lack of understanding of what a 
medication review actually was, were found to be deterrents for patients to participate in 
the HMR program (182, 184). 
By 2012-2013 the numbers of HMRs in Australia had increased significantly, with more than 
80% growth from 2010-2011 levels (185). The Pharmacy Guild of Australia in 2013 called for 
a moratorium on provision of HMRs due to a perceived program over-spend of the allocated 
budget. In response, many consumer and professional health organisations lobbied the 
government for continuation of the HMR program. To curtail any potential budget over-
spend, the guidelines for the HMR program were tightened in 2013-2014. It was mandated 
that HMRs occur in a patient’s home unless prior approval was granted, patients could only 
receive one HMR in any 24-month period unless the referring GP considered an HMR 
clinically necessary, and the number of HMRs an individual pharmacist can provide is now 
capped to twenty per month (47). The changes made to the program rules and processes 
are outlined in Figure 1.3. 
Across Australia, the majority of medication review/management programs and services 
occurred in the major cities. Less than 15% were located in outer regional areas, and less 
than 2% occurred in remote and very remote areas (47). Lack of accredited pharmacists in 
rural and remote communities, and the cost and travel time to undertake HMRs in rural and 
remote areas are often barriers to HMR services in these areas (47). 
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Figure 1.3: Guide to changes through 5CPA 
Source: Combined Review of Fifth Community Pharmacy Agreement Medication 
Management Programmes (47). 
The Consumer Health Forum of Australia (CHF) produced a paper which explored issues 
related to uptake and sustainability of the HMR program. The CHF found the HMR program 
was valued by consumers and was an essential tool for cutting hospital admissions. They 
stated that the HMR program should be made more accessible for high-risk consumers and 
specific population groups, such as people from CALD backgrounds, older Australians and 
Indigenous Australians (186). 
The consumers participating in the Fifth Community Pharmacy Agreement medication 
management program evaluation (47) noted that HMRs were a core part of their 
preventative healthcare strategy and should be available annually. The consumers stated 
that HMRs, when performed well, provided positive health outcomes, education on 
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medication safety and adherence, and cost savings to the health system through de-
prescribing and preventing hospital admissions due to medication misadventure (47). 
With the rate of HMRs growing and outstripping the capped budget, there have been some 
suggestions to prioritise HMR recipients according to need. The suggested need 
categorisation included identification of a patient being at risk of medication misadventure 
due to having a chronic disease and/or complex management requirements. In addition, 
the patient must have a number of other criteria, such as instability of health status and/or 
medicines therapy, using a high-risk medicine, and/or having compromised adherence 
(185). These suggestions have not as yet been mandated. 
The Fifth Community Pharmacy Agreement medication management program evaluation 
stated that barriers to access, current referral pathways and administrative arrangements 
needed to be addressed. The reported barriers to access were the limited awareness of 
HMR by consumers and GPs, lack of availability of HMR-accredited pharmacists in rural and 
remote areas, being a person of CALD background or of low socio-economic status, and 
cultural barriers to conducing HMRs in the homes of Aboriginal and Torres Strait Islander 
people (47). 
The inequity of medication review service delivery results partially from lack of consultation 
during program design with health professionals who service at-risk communities (23). 
Flexibility of programs is needed to allow for cultural difference and improved program 
access and reach (47). 
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1.12.1 Home Medicine Reviews and Aboriginal and Torres Strait Islander 
people 
The Urbis Keys Young (2005) and Campbell (2008) evaluations of the HMR program both 
identified that the current HMR program may not be an appropriate model to address 
medication issues in remote Indigenous communities (23, 24). However, no action to date 
has been taken to develop a more appropriate model for Aboriginal and Torres Strait 
Islander people, although changes are now being discussed for a new medication review 
program under the Sixth Community Pharmacy Agreement. 
The Campbell report stated that Indigenous Australians were the most likely of all 
Australians to miss out on effective access to HMRs despite having high rates of 
hospitalisation due to medication misadventure (187). Whilst no hard data are available, it 
appears that HMRs for Aboriginal patients did increase slightly when the QUMAX program 
was implemented in 2008. It appears that these HMR increases were due largely to 
relationship building between the QUMAX support pharmacists, employed by the QUMAX 
program, and AHSs (8). Despite this increase in HMRs, Aboriginal and Torres Strait Islander 
people in urban, rural and remote areas are still very low users of the HMR program. 
Strategies for providing alternative models of HMR and pharmacy services aimed at 
reaching Indigenous consumers need to be explored and new programs developed (23). 
The Campbell evaluation reported that its research only included four interviews with AHWs 
and two pharmacists who conducted HMRs for Aboriginal patients, and it recommended 
further research be undertaken specifically focusing on Indigenous communities. The 
Campbell report recommended that Aboriginal and Torres Strait Islander patients should 
have multiple visits with a pharmacist. These visits would facilitate the continual building of 
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knowledge and understanding of medications and reinforce medication adherence 
patterns. The concerns expressed in the Campbell report for Indigenous Australians have 
still not been addressed. This thesis aims to contribute increased evidence for the need for 
HMR program improvement. 
Only two pharmacists to date have reported on conducting HMRs for Aboriginal and Torres 
Strait Islander clients. Both these pharmacists were in the rare position of being employed 
by an AHS. One of these, Sanberg, evaluated the HMR processes within the AHS in which 
she was working and made recommendations for effective HMRs for her Aboriginal 
patients. Her recommendations included the attendance at the HMR interview of an AHW 
who speaks local language, and funding from the program to the service for the AHW 
participation. She also recommended that lack of medication compliance be listed as a 
trigger for HMR referral, and that the pharmacist should use appropriate written and 
pictorial resources. Further recommendations for program change included allowing AHS 
pharmacists to write HMR referrals, extra funding for regular follow-up visits, and funding 
for more pharmacists to be directly employed in salaried positions by AHSs (16). Sanberg 
reported that a one-off annual service does not allow for rapport building and the tiered 
education delivery that is needed (16). 
Larkin commented that in the Kimberley, AHWs play an important role in the delivery of 
HMR to Aboriginal patients as AHWs provide valuable information about the health of the 
patient and about social circumstances that may influence medication management. 
Participation of AHWs in the interview stage ensured appropriate communication (14). 
Larkin suggested that it may be preferable to conduct HMRs in primary care clinics, as 
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location within the clinic allowed for recommendations to be actioned more quickly 
through the involvement of the primary care team (14). 
Brown’s research found that improving medication management within Aboriginal 
communities and AHSs requires a sustainable systems-based approach with an 
organisational commitment to medication management activities, such as medication 
review (4). Brown’s research found that system-level reform needed clearly articulated 
medication management strategies, and clinical and management leadership in quality use 
of medicines. Multi-disciplinary knowledge sharing, functional patient information and 
recall systems, improved linkages between health services, and improved medication 
management skill capacity for staff, together with integrated patient records, prescribing 
software and electronic educational resources, were also seen as imperative in improving 
medication management. (4) 
The AHS staff interviewed by Brown strongly supported an increasing role for pharmacists 
in AHSs. The Pharmaceutical Society of Australia Budget submissions in 2014, 2015 and 
2016 requested that the Australia Government fund salaried positions for pharmacists in 
AHSs (188, 189). The AHS staff in Brown’s study also suggested enhanced outreach 
pharmacist services, primary care medication facilitator positions, patient and staff 
medication education services and increased medication review services within AHSs (4). 
1.13 Conclusion 
The health of Aboriginal and Torres Strait Islander people remains poor. The literature 
suggests that improved trust and rapport between health professionals and Aboriginal 
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clients, and more culturally responsive health professionals, will assist more effective 
communication, and empower patients to engage in healthcare choices. 
Many Aboriginal and Torres Strait Islander people are at high risk of medication 
misadventure and poor medication adherence. Despite Aboriginal people’s high burden of 
chronic disease, they are low users of medication management programs such as HMR and 
MedsCheck. 
Pharmacists need to be culturally competent before they can effectively communicate with 
Aboriginal and Torres Strait Islander clients. Culturally responsive pharmacists are well-
placed to provide education about medicines and medicines management strategies to 
Aboriginal and Torres Strait Islander people and AHS staff (73). 
The Australian HMR model appears to minimise medication error and share medication 
knowledge with patients and health professionals. However, the current HMR model 
appears to be inaccessible to many Aboriginal and Torres Strait Islander people. This study 
will investigate how medication management programs, such as HMR, can better address 
the needs of Aboriginal and Torres Strait Islander people. 
This chapter has introduced the rationale and the supporting literature as a background to 
the research questions that are explored in this thesis. The literature discussed in the 
introduction was used to situate this study. 
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1.14 This research study 
This research was conducted in three phases. 
In Phase 1, Aboriginal and Torres Strait Islander focus groups were used to investigate 
patient challenges with managing their medicines and the perceived benefits, if any, of 
HMR. The focus groups explored the satisfaction of Aboriginal and Torres Strait Islander 
patients with their experience of an HMR, assessed why patients may elect not to have an 
HMR, ascertained patient perceptions of the suitability of the current HMR model and 
collected patient suggestions for improvements to the existing HMR model. 
Phase 2 explored the attitudes and perceptions of health professional employees working 
within AHSs towards the HMR program. It examined barriers to HMR referral and explored 
strategies for HMR program improvement. 
The objectives of Phase 3 were to identify pharmacists’ relationships with AHSs and AHS 
clients and to explore the barriers and facilitators, from the pharmacists’ perspectives, for 
the provision of HMRs and other pharmacy services to Aboriginal people attending the 
AHSs. 
1.14.1  Research questions 
This study addresses the following research questions: 
1. What are the experiences and perceptions of Aboriginal and Torres Strait 
Islander people with regard to taking medicines? 
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2. What are the experiences and perceptions of Aboriginal and Torres Strait 
Islander people of the HMR program? 
3. What are the attitudes and perceptions of AHS health professionals and 
service providers to the HMR program? 
4. What are the barriers and facilitators, from pharmacists’ perspectives, for the 
provision of HMRs and other pharmacy services to Aboriginal and Torres Strait 
Islander people attending AHSs? 
5. What strategies or program changes are needed to increase utilisation of 
medication review programs by Aboriginal and Torres Strait Islander people? 
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Chapter 2 
Methods and methodology 
2.1 Methods and methodology 
In this chapter I provide the background and rationale for the overall methodology and 
methods used for this thesis. Methods for each phase of the research are described in each 
related publication. To prevent repetition, details of methods specific to each paper are not 
described in this chapter. 
2.2 Background 
Research and researchers have had a strongly negative reputation in many Indigenous 
settings (1). As a non-Indigenous researcher, I am aware that the process of undertaking 
ethically sound research with Indigenous people is complex. Despite extensive reading, 
some cultural immersion and attempting to be culturally sensitive and respectful, I may not 
always truly reflect the Indigenous epistemologies (ways of knowing), axiologies (ways of 
doing) and ontologies (ways of being) for all Aboriginal and Torres Strait Islander people (2, 
3). 
When conducting this research I was aware that Aboriginal and Torres Strait Islander people 
have been over-researched, without corresponding improvements in health (4). I was 
cognisant that I needed to produce research which could benefit the participants and other 
Aboriginal and Torres Strait Islander people. I was mindful to heed the Aboriginal Health & 
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Medical Research Council guidelines which state that research should be ethical, 
meaningful and useful to Aboriginal people (5). The research also needs to be culturally 
sensitive, be controlled by Aboriginal communities, and enhance the skills and knowledge 
of Aboriginal people and organisations whilst employing principles of reciprocity (5). The 
ethical research practices used in this study are outlined in Table 2.1. 
Before commencing this research, I sought community engagement and support. Written 
consent from the manager and/or board of each AHS was obtained. See Appendix B for 
letters of support from AHSs. Ethics approval was sought and granted from the University 
of Sydney Human Research Ethics Committee and also from the relevant Aboriginal 
research committees, the Aboriginal Health & Medical Research Council (NSW), the 
Menzies School of Health Research (NT) and the Aboriginal Health Research and Ethics 
Committee (South Australia  and Victoria). 
2.3 Study design 
This is a collaborative, descriptive study which used focus groups, semi-structured 
interviews and a cross-sectional survey to collect data. Collaborative and participatory 
research is generally identified as providing appropriate methodologies for research with 
Indigenous people (6). 
An Aboriginal advisory group was established at the commencement of this study to guide 
the study design and data collection protocols. This group consisted of an AHS manager, an 
Aboriginal elder, an Aboriginal state health program manager and a senior Aboriginal health 
education officer. The advisory group provided cultural guidance and community expertise. 
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This advisory group discussed strategies for community engagement, and advised on 
principles of reciprocity and effective communication. They assisted with communiques to 
AHSs and designing focus group and interview questions. Work commitments, new job 
relocations and family illnesses resulted in the advisory group having less input after the 
data collection phase. Their input to project design and sage advice throughout were 
invaluable. 
An Aboriginal Torres Strait Islander clinical counsellor undertook part-time research training 
on this project for six months, learning about research, and taking this learning and 
experience back to her local community and her clinical practice, thus building capacity in 
her community. She assisted by researching background information for some of the 
research sites. This included information on the traditional owners, the history of each AHS 
and other key Aboriginal organisations in each area. This information informed the 
researcher and assisted in the building of trust. The Aboriginal researcher was involved in 
data collection at one of the early focus groups and provided the researcher with feedback 
and suggestions for leading subsequent focus groups with Aboriginal participants. This 
Aboriginal researcher has now enrolled in her own PhD study. 
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For clarity of description I have divided the study into three phases: 
Phase 1: Focus groups with Aboriginal and Torres Strait Islander people who use 
multiple medicines 
Phase 2: Semi-structured interviews with health professional staff at Aboriginal 
Health Services 
Phase 3: A cross-sectional survey of HMR-accredited pharmacists. 
2.3.1 Phase 1 
Focus group methodology was chosen to explore Aboriginal and Torres Strait Islander 
patients’ views as it built collaboration through yarning and the sharing of ideas in 
conversation and storytelling (7). I was very aware that power imbalance, Aboriginal 
shyness and disempowerment, and distrust of the white stranger researcher could be 
barriers to effective information sharing (8). 
Table 2.1 below outlines how ethical research practices were employed in this study. The 
Values and Key elements columns listed in Table 2.1 are based on Table 3 in a paper written 
for the Indigenous Injustice Clearing House entitled Conducting research with Indigenous 
people and communities (9). This Indigenous Clearing house paper explored the core values 
and approaches, adopted in Indigenous justice research, which produced meaningful 
research outcomes. 
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Table 2.1 Ethical research practices in this study design 
Values Key elements Examples in this research 
Culturally 
appropriate 
Alternative methodologies 
such as yarning 
Yarning – focus groups 
Use of AHSs and AHWs to 
facilitate research 
Indigenous 
engagement or 
control 
Direction and management of 
research including reference 
groups, partnership 
approaches 
Advisory group 
AHS board consent 
Involvement of AHS in research 
management 
Investment in local capacity Training of Indigenous researcher 
during the initial stages of project 
Involvement of AHWs in 
medicines discussions at focus 
groups 
Training of AHS staff regarding 
HMR program 
Reciprocity Providing individual and/or 
community benefits 
Individuals received information 
regarding their specific medicine 
issues and how to organise HMRs 
Research into practice*  
Communicating results to 
participants/communities 
All AHSs received a summary of 
findings from focus groups and 
interviews at their service 
All AHSs received copies of 
research publications 
Key: AHS=Aboriginal Health Service; AHW=Aboriginal Health Worker; HMR=Home 
Medicines Review 
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*See Epilogue 
To reduce barriers to rapport building I chose not to formally collect demographic data, and 
not to ask participants to share private health information or provide any written 
responses. Patients did have to sign consent forms. The process of signing consent forms 
indicated that although all participants spoke English, only about 70% of participants had 
fluency in written English. I read the consent form and answered all queries. The AHWs and 
family members assisted those with poor literacy. All participants gave verbal and written 
consent. All participants were informed of their rights to withdraw from the study at any 
time without penalty. 
 I conducted all the focus groups myself to ensure consistency of approach. 
Phase 1 methodology is outlined in some detail in the publication entitled Exploration of 
Aboriginal and Torres Strait Islander perspectives of Home Medicines Review in Chapter 4. 
2.3.2 Phase 2 
Semi-structured interviews were used to explore AHS health professional staff’s 
perceptions of the HMR program. Interviews allowed one-on-one in-depth conversations 
with AHS GPs, nurses and AHWs, and allowed me to probe meaning and increase 
understanding. Open-ended questions allowed exploration of participants’ behaviours, 
opinions, feelings and knowledge. 
As GPs are integral to the HMR referral process it was essential to learn why or why not GPs 
supported the HMR program for their patients. Similarly, at most AHSs, AHWs play an 
important role in assisting patients to manage their medicines. They provided a cultural, as 
well as a clinical perspective, of patients, medicines and HMR processes. 
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2.3.3 Phase 3 
As well as understanding AHS patient and health professional perspectives of the HMR 
program, it was important to explore any barriers to pharmacists’ conducting HMRs with 
Aboriginal and Torres Strait Islander people. 
An online survey was used to gather data from the HMR-accredited pharmacist 
respondents, who are geographically distributed across Australia. Findings from Phases 1 
and 2 were used to guide survey design. The recurrent themes related to pharmacist-
patient relationships, the role of AHWs and HMR processes were incorporated into the 
survey. Survey questions can be found in Appendix C. 
The online survey link was emailed with study information to all online registered HMR-
accredited pharmacists. Email was chosen as it allowed anonymity and ease of completion 
for respondents, timeliness and low cost. 
2.4 Setting 
2.4.1 Phases 1 and 2 
The AHSs were chosen as the sites for recruitment of patients and data collection, as AHSs 
are culturally safe environments which support Aboriginal patients’ sense of choice and 
power (10). Each AHS was given verbal and then written information about the project, and 
their management and boards were asked to approve participation in the study. The AHSs 
brokered the relationships with the Aboriginal and Torres Strait Islander communities and 
assisted with participant recruitment and focus group organisation. Some AHSs provided 
transport to assist patients to participate in focus groups at the AHS. 
87 
 
The 12 AHSs in Phases 1 and 2 were purposively chosen for their diversity in location, size 
and governance (as shown in Table 2.2 below), and their willingness to participate. The 
AHSs are not named to protect confidentiality of participants. The research settings 
included Aboriginal Community Controlled Health Services and government-funded AHSs, 
both large and small services, with a range of staff and service delivery models. The AHSs 
prescribed and dispensed medicines under different schemes, including Section 100, 
QUMAX and Closing the Gap. Two sites had in-house pharmacists. Three Northern 
Australian sites were chosen to include Torres Strait Islander people representation. 
I had a relationship with two of the AHSs in the study through my previous QUMAX role. 
However, with the other ten AHSs I was not known and needed to establish the trust and 
support of the AHS management and staff. It was necessary to convey to them that this 
study would benefit the participants, their communities and the AHS itself. As a researcher 
I worked hard to establish the centrality of relationship and reciprocation (11). 
Table 2.2: Aboriginal Health Service demographics 
State PhARIA* 
MM** 
 
Governance 
Medication 
Programs 
 
Patient 
Focus 
Groups 
HMR Users 
Patient 
Focus 
Groups 
HMR 
Non Users 
Health 
Professional 
Interviews 
NSW Rural 
PhARIA 1 
MM 4 
ACCHS 
QUMAX 
3 9 1 AHW 
1 nurse 
 1 GP 
NSW  Rural 
PhARIA 3 
MM 5 
ACCHS 
S100 
1 8 1 AHW 
2 nurses 
1 Practice 
Manager 
1 GP 
NSW Urban 
PhARIA 1 
MM1 
ACCHS 
QUMAX 
0 13 1 AHW 
1 GP 
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State PhARIA* 
MM** 
 
Governance 
Medication 
Programs 
 
Patient 
Focus 
Groups 
HMR Users 
Patient 
Focus 
Groups 
HMR 
Non Users 
Health 
Professional 
Interviews 
NSW Regional 
PhARIA 1 
MM 3 
ACCHS 
QUMAX 
3 6 1 AHW 
1 GP 
Qld Regional 
PhARIA 1 
MM 2 
ACCHS 
QUMAX 
0 10 2 AHWs 
1 GP 
Qld Remote 
PhARIA 6 
MM 7 
Queensland 
Health 
S100 
0 4 0 
NT Regional 
PhARIA 1 
MM 2 
ACCHS 
QUMAX  
S100 
2 6 1 AHW 
1 GP 
NT Remote 
PhARIA 6 
MM 6 
ACCHS 
S100 
3 7 1 AHW 
1 GP 
Vic Urban 
PhARIA 1 
MM 1 
ACCHS 
QUMAX 
3 5 1 AHW 
1 GP 
SA Rural 
PhARIA 3 
MM 4 
ACCHS 
QUMAX 
8 3 3 AHWs 
1 GP 
SA Remote 
PhARIA 6 
MM 7 
SA Health 
S100 
0 8 1 AHW 
1 nurse,  
1 GP 
SA Urban 
PhARIA 1 
MM 1 
ACCHS 
QUMAX 
  1 AHW 
1 nurse,  
1 GP 
All States 
and 
Territories 
  23 79 14 AHWs 
5 nurses,  
1 Practice 
Manager 
11 GPs 
 
Key: ACCHS=Aboriginal Community Controlled Health Service; AHW=Aboriginal Health 
Worker; GP: General practitioner, QUMAX=Quality Use of Medicines Maximised for 
Aboriginal and Torres Strait people 
* PhARIA (the Pharmacy Accessibility Remoteness Index of Australia), the pharmacy 
measure for remoteness. PhARIA 6 is the most remote (12). 
** Modified Monash categories which use the Australian Bureau of Statistics remoteness 
classification system, with MM7 being the most remote (13). 
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In very remote areas there is often a higher percentage of Aboriginal people who speak 
local languages, and who may not speak English. Participants in this study needed to be 
able to converse in English. Lack of funding resulted in no interpreters being used. Two of 
the settings used are classified as remote (MM7), according to the Modified Monash model 
of remoteness (13). However, the remote settings used had an AHS and pharmacy and so 
are not viewed by the researcher as very remote. No research was conducted in very 
remote locations due to lack of funding for travel and lack of AHSs to assist in facilitation of 
the research. Thus, the views of Aboriginal people who do not speak English and the views 
of Aboriginal people living in very remote settings have not been explored in this study. 
In this study, participants in the remote settings did have access to community pharmacies 
and pharmacist services, as well as regular GP services, and therefore were able to express 
their views on their relationships with their pharmacists and GPs. In many remote and very 
remote areas there are no community pharmacies, and supply of bulk medications under 
the remote Aboriginal Health Services scheme results in minimal or no interactions with 
pharmacists (14) . 
Eleven of the 12 AHSs were sites for patient focus groups. Eleven of the 12 AHSs were sites 
for health professional interviews. As can be seen in Table 2.2, at one site there were no 
patient focus groups. This was due to community attendance at a funeral and costs 
associated with travelling to this site. At a different site there were no health professional 
interviews as a result of staff shortages due to sickness. 
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2.5 Sample 
2.5.1 Phase 1 
Eighteen focus groups were conducted with Aboriginal and Torres Strait Islander patients 
(n=102) at 11 AHSs in Queensland, NT, SA, NSW and Victoria. 
Focus group participants (n=102) were recruited through AHSs. Patients attending the 
participating AHSs, who were multiple medication users and had a reasonable 
understanding of the English language, were recruited to the study by AHS staff. 
Demographic information was not formally collected. Field notes showed that 75% of 
patient participants were female and approximately 90% appeared to be over 40 years of 
age. 
2.5.2 Phase 2 
Thirty-one semi-structured interviews were conducted at 11 AHSs. The numbers of each 
profession participating were influenced by size of service, staff availability and willingness 
to participate at each AHS visited. Fourteen AHWs, five nurses, one practice manager and 
11 GPs were interviewed. 
Health professional staff assisting with patient recruitment for focus groups were provided 
with information about the study. They were asked to share this information with 
colleagues and ask them to participate in interviews. Most staff, however, did not commit 
prior to my visit to their AHS and were opportunistically recruited when I visited the AHS to 
conduct the focus groups. 
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2.5.3 Phase 3 
Only HMR-accredited pharmacists can deliver HMRs. For this reason, only these 
pharmacists were asked to participate in the research. 
The survey was sent to 983 HMR-accredited pharmacists listed on the Australian 
Association of Consultant Pharmacists’ database. Questions in the survey explored 
pharmacists’ engagement with AHSs.  
A total of 187 pharmacists responded to the survey. However, not all of these respondents 
answered all questions, as many had no engagement with AHSs. Only 88 respondents 
answered all the specific questions on working with AHS staff and conducting HMRs for 
Aboriginal patients. This appears to reflect the small sample of pharmacists who are actually 
engaged in delivering services to AHSs. 
The results represent only a small percentage of accredited pharmacists and cannot be 
extrapolated to all pharmacists. 
2.6 Data collection 
2.6.1 Phase 1 
Eighteen focus groups were conducted with 102 patients. These consisted of 11 focus 
groups for patients (n=79) who had not had an HMR previously (HMR Non Users) and seven 
focus groups for those patients (n=23) who had had an HMR (HMR Users). 
At the beginning of each focus group, time was devoted to developing rapport, and sharing 
stories and connections to land, place and family. I was aware that: 
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“In sharing stories it is necessary to share our own, starting with self-location. The 
researcher’s self-location provides an opportunity for the participant to situate and 
assess the researchers’ motivations for the research, thus beginning the 
relationship” (9) pg. 98. 
Although focus group participants had received information about the research, I reiterated 
the objectives and details to ensure complete clarity, especially for those participants with 
low literacy. Patient information and consent forms can be found in Appendix D. 
Each participant was given the opportunity to share their individual experiences and 
feelings about the taking of medicines, before group discussion occurred on specific issues. 
Most participants were keen to tell their stories, often wanting to share their individual 
experiences and some even wanting to talk about their own specific medicines. For a few 
participants from more remote areas, where English was their second or third language, 
communication was more difficult. I endeavoured to create a relaxed, respectful 
atmosphere conducive to the exchange of knowledge and ideas. Holding the focus groups 
within the familiar and comfortable surrounds of the AHS also helped to engender trust and 
communication. 
Participants were offered travel expenses, and lunch was provided at the end of each focus 
group. Interactions over lunch allowed me, as a pharmacist, to assist participants with their 
specific medication queries. These interactions were not recorded but were offered in a 
spirit of reciprocation. Thus, the focus groups provided a forum for the sharing of 
information about medications, as well as the opportunity to collect information about 
patient perceptions and experiences. Many participants enquired after the focus groups 
about how they could organise an HMR for themselves or family members. I assisted by 
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providing information to patients as to how to organise an HMR referral. It is hoped, but 
not measured, that there was an increase in HMRs in communities where research was 
conducted. 
The core questions discussed by focus group participants can be found in the two 
publications in Chapters 3 and 4. 
Focus group discussions were recorded. These recordings were de-identified and sent to a 
professional transcriber. I then checked transcriptions prior to analysis. Field notes were 
made immediately after the focus groups were held. 
Ideally, transcriptions and themes derived from analysis should have been checked by 
participants. The researcher elected not to burden participants and AHS staff further by 
recalling focus groups but made an agreement with participants to report back findings to 
the AHS at the conclusion of analysis and relied on the AHS to disseminate information 
about the findings. All AHSs received a summary of the findings from their patient focus 
groups and AHS staff interviews. 
2.6.2 Phase 2 
In-depth semi-structured interviews (n=31) were conducted with professional staff who 
were available and willing to give their time during my visit to their health service. The 
AHWs were particularly interested in speaking with me to learn more about medication 
review and chronic disease management. I spent time with nurses and AHWs before and 
after focus groups and interviews to build relationships and share information about quality 
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use of medicines and medication review. It is hoped that this reciprocity enabled and 
empowered the AHS staff to engage with patients to discuss medicines and organise HMRs. 
The semi-structured interview guide can be found in Chapter 5. 
Interviews were recorded. These recordings were de-identified and sent to a professional 
transcriber. I then checked transcriptions prior to analysis. 
2.6.3 Phase 3 
The online survey consisted of 39 items which included closed and open-ended questions 
and Likert scale questions. 
A copy of the survey can be found in Appendix C. 
2.7 Analysis 
2.7.1 Phases 1 and 2 
Interviews and focus groups were recorded, de-identified and transcribed verbatim. 
Transcripts were coded and analysed for themes that recurred throughout the interviews. 
Analysis was conducted concurrently with data collection and fed back into continual 
refinement of this process. Themes were identified by repetition of words and phrases, and 
shared meanings, evident across data. Focus groups and interviews continued and concepts 
were explored until no new findings were being generated and saturation of data had 
occurred. Open coding of focus group and interview transcriptions was used to identify, 
categorise and describe recurrent themes. Field notes and summaries written at the end of 
each focus group and interview were also incorporated into the analysis. 
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Using multiple data sources, that is patients, health professionals and pharmacists, and 
different methods such as focus groups, interviews and a survey, contributed to a holistic 
and comprehensive understanding of the findings and helped verify conclusions. 
The AHS settings varied in their geographic and governance. Differences by location were 
examined. 
2.8 Reciprocity 
A “thank you” letter and a summary of findings from the focus groups and interviews were 
provided to each participating AHS after my visit. It is hoped that sharing of the findings will 
assist AHSs’ understanding of medication management challenges faced by their patients 
and staff and thus assist AHSs to improve medication management strategies and build 
capacity of their staff regarding medication management. 
I have shared my publications with all participating AHSs, NACCHO, the Department of 
Health and the Pharmacy Guild of Australia in an attempt to change current HMR program 
rules and promote development of a more effective medication review program for 
Aboriginal and Torres Strait Islander people. 
2.9 Candidate’s contribution to the research and thesis 
I designed the project, completed ethics applications, and organised information and 
consents from all AHSs and participants. 
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I conducted all focus groups and interviews. Recordings from focus groups and interviews 
were transcribed verbatim by a professional transcriber. 
I designed the pharmacist survey in collaboration with a pharmacy Honours student and 
her supervisor. The Honours student organised the distribution and collection of survey 
data. 
I conducted all the analysis of data and coding for themes. 
I wrote all the publications and this thesis with guidance and advice from my primary 
supervisor. 
2.10 Next chapter 
In Chapter 3 the findings from the patient focus groups in Phase 1 about medication 
management issues for Aboriginal and Torres Strait Islander patients are reported and 
discussed. 
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Chapter 3 
Aboriginal and Torres Strait Islander people’s 
experience with medicines 
3.1 Introduction to chapter 
The papers in both Chapters 3 and 4 report the findings of the data analysis of 18 semi-
structured focus groups with 102 Aboriginal and Torres Strait Islander participants. 
This chapter contains an original research paper that has been published in a peer-reviewed 
journal. This paper shares some important findings about Aboriginal people’s perspectives 
on medicine taking and sets the scene for Chapter 4 which contains more in-depth 
discussions related to patients’ perspectives of medication reviews. As the paper in Chapter 
4 is longer, it contains a more detailed description of the focus group methodology than 
found in Chapter 3. 
Each focus group began with a sharing of experiences about medicines. Participants were 
encouraged to “yarn” about how they felt about taking medicines, how they managed their 
medicines and how they engaged with health professionals. This yarning about medicines 
helped establish a convivial environment for sharing opinions before I drilled down with 
more focused questions. These general findings about medicine taking helped situate the 
rest of this study. 
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3.1.1 What is known on this subject? 
Whilst numerous studies report the social, economic, emotional and physical determinants 
of Aboriginal and Torres Strait Islander health, and some studies have evaluated medication 
access schemes, very little research has been conducted into Aboriginal and Torres Strait 
Islanders’ experiences with medicines. Previously, there has not been national research into 
Aboriginal and Torres Strait Islanders’ perceptions and understanding of medicines. 
 3.1.2 What does this study add? 
The study outlines Aboriginal and Torres Strait Islander people’s views on medication use. 
These findings should be used to inform health professionals as to how they can better 
assist these patients to manage their medications and treatment choices. 
3.1.3 Reference 
Swain L, Barclay L. “They’ve given me that many tablets, I’m bushed. I don’t know where 
I’m going.” Australian Journal of Rural Health. 2013;21:216-9. 
A copy of the published paper can be found in Appendix E. 
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3.2 Manuscript abstract: “They’ve given me that many tablets, I’m 
bushed. I don’t know where I’m going.” 
Objective 
To explore Aboriginal and Torres Strait Islander patients’ experiences with medicines, and 
the barriers and facilitators to their effective use of medicines. 
Design 
A descriptive, qualitative study, using 18 semi-structured focus groups with 102 Aboriginal 
and Torres Strait participants. Groups were conducted at 11 Aboriginal Health Services 
(AHSs). These were recorded and transcribed and a thematic analysis performed. 
Settings and Sample 
Participants were Aboriginal and Torres Strait Islander patients, taking multiple medicines, 
who attended AHSs, and who spoke English. AHSs varied in governance, size and service 
delivery models as well as their locations which were across urban, regional, rural and 
remote settings. 
Results 
Major themes identified were consistent across all settings and patients. These were 
confusion over medicines, perceived lack of advice from health professionals to patients 
about medicines, and challenges in having effective interactions with medical practitioners 
and pharmacists. Participants wanted more information about medicines, indications for 
medicines, how they should be used, potential side-effects, drug interactions and duration 
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of therapy. They also reported an absence of appropriate medication labelling and written 
information. 
Conclusion 
Many Aboriginal and Torres Strait Islander patients take multiple medicines and often find 
managing their medicines difficult and worrying. These patients require more 
comprehensive information, verbal and written, and more effective communications from 
doctors and pharmacists about medication indications, mechanisms, side-effects, drug 
interactions and duration of treatment. Pharmacists have an opportunity to play a greater 
role in improving understanding of medicines and treatment choices. 
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3.3 Manuscript full text 
They’ve given me that many tablets, I’m bushed. I don’t know where 
I’m going.” Aboriginal and Torres Strait Islander people’s 
experiences with medicines 
3.3.1 Introduction 
Despite a higher burden of acute infections and chronic diseases, under-use of medicines is 
evident in Australian Aboriginal populations (1, 2). Poor control of chronic disease states 
and subsequent higher hospital admissions, morbidity and mortality may be directly 
attributable to poor medicine management in Indigenous communities (3). 
Very little research has been conducted into Aboriginal and Torres Strait Islander patients’ 
perceptions, experience and understanding of medicines. Similarly, little is known about 
the role of pharmacists in Aboriginal health. Published research confirms this proposition 
and has been used to situate this research. 
Poor adherence to prescribed medicines is well-documented and associated with adverse 
health outcomes in all population groups (4). Social circumstances, and deficiencies in 
health services and systems mean Indigenous Australians often suffer even greater 
challenges in medicine management than non-Indigenous Australians. Barriers to accessing 
medicines include financial and geographic constraints, failed patient-clinician interactions, 
poor healthcare delivery systems and complex therapeutic regimens (5). Social and 
emotional wellbeing issues deeply pervade the lives of many Aboriginal people and may 
diminish the value that individuals place upon medicines and the potential of these 
medicines to improve their quality of life (6). 
104 
 
With the introduction by the Commonwealth Government of the Aboriginal Health Service 
Remote Access scheme (known as Section 100) in 1999, and Close the Gap in 2010, some 
of the financial barriers preventing access to medicines for a number of Aboriginal people 
have been removed. There have been some evaluation studies relating to medication 
access and supply. Cognitive pharmacy services and medication education, encouraging 
safe and efficacious use of medicines for Aboriginal and Torres Strait Islander people, now 
need to be addressed (7). 
3.3.2 Method 
Aboriginal Health Services (AHSs) were selected to include urban, regional, rural and 
remote settings. They included Aboriginal Community Controlled Health Services and 
government-funded AHSs. Each AHS was given verbal, then written information about the 
project. The AHSs’ management and boards were asked to approve the research 
participation before approval was sought and granted from the University of Sydney Human 
Research Ethics Committee, the Aboriginal Health & Medical Research Council (NSW), the 
Menzies School of Health Research and the Aboriginal Health Research & Ethics Committee 
(SA). 
Patients who were multiple medication users and had a reasonable understanding of the 
English language were recruited to the study by AHS staff, independently of the researcher. 
Patient consent was sought by staff and repeated by the researcher. 
Focus group methodology was chosen as this allows a semi-structured “yarning” process 
across the group. This gathers information through conversation. Yarning is compatible 
with Indigenous cultural process and enables the telling of stories (8, 9). The focus groups 
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provided a forum for the sharing of information about medications as well as the 
opportunity to collect information about patient perceptions and experiences. Focus 
groups were conducted by the first author, a pharmacist. She established a reciprocal 
relationship (10) with participants sharing information and assisting participants with their 
specific medication queries at the end of each session. 
Focus groups’ questions were designed to be non-leading and to encourage open 
discussion. They were modified slightly as a result of early groups, to achieve increased 
engagement and to explore concepts more in depth. Field notes and summaries were 
recorded after each session and incorporated into the analysis. Areas of interest were 
explored in subsequent groups, until data saturation occurred. Internal validity and 
reliability were achieved by questions about the same issues being asked numerous times, 
in an appropriate, non-leading way, producing similar findings in different settings. Core 
questions are found in Table 3.1. 
Focus groups’ discussions were recorded, de-identified and transcribed verbatim. 
Transcripts were coded and analysed for themes. 
The study incorporated standards of integrity, beneficence, and respect. The need for 
community consultation, community benefit and cultural sensitivity were acknowledged 10 
with participating AHSs receiving written and verbal reports about their own data. System 
information, not individual information, was shared to assist quality improvement. 
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Table 3.1: Core questions asked about medicines 
Item Question 
1. How do you feel about taking medicines? 
2.  Do you know what your medicines are for and how to take them? 
3. Would you like any further information about your medicines? 
4. If you need to know more about your medicines, who do you ask, and why? 
5.  How do you manage your medicines? 
6. What challenges do you face around managing your medicines? 
7. Does the pharmacist or doctor give you any written information about your 
medicines? 
8. What role does the pharmacist play in helping you with your medicines? 
9. What would help you to manage your medicines? 
 
3.3.3 Results 
Eighteen semi-structured focus groups were conducted with 102 Aboriginal and Torres 
Strait patients at 11 AHSs in Queensland, Northern Territory, South Australia, New South 
Wales and Victoria. 
All participants wanted to know more about their specific medicines and about medicines 
generally. Most participants felt they received minimal or no information about their 
medicines. Many had very little understanding of why they took medicines and the purpose 
of these medicines. The statement, “I don’t know why I take them”, was echoed by over 
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70% of participants. Some participants knew that they took medicines for their “heart” or 
for their “diabetes” and knew when they had to take these medicines, but no participants 
felt they had had potential side-effects or drug interactions adequately explained. 
Most of the focus group participants expressed a strong dislike for taking multiple 
medicines. Comments such as “I don’t like taking medicines” and “I hate them, there are 
too many” were common. One participant echoed the concerns of many in her statement, 
“I get a bit concerned because I’m taking a lot of things. Is it necessary to take all these 
things?” 
The taking of multiple medications simultaneously and the potential for drug interactions 
concerned participants. Many discussed spreading the doses of their tablets as they 
believed this might negate or minimise potential interactions. 
 “I don’t know if my tablets all go together. Does one tablet knock out the benefit of 
another?” 
Issues relating to duration of therapy, dosage and allergy were also discussed. There was 
some confusion over when and if medications could be ceased. Many participants 
expressed interest in lifestyle measures that might reduce medication usage, for example, 
“When I had my cholesterol checked it was good, so I was thinking if it was good, why should 
I be taking them?” 
Most participants acknowledged that it was important to take their medications, and many 
endeavoured to take their medications regularly. Despite this, many said that on occasions 
they forgot. Many relied on Dose Administration Aids (Webster packs or Dosette boxes), or 
reminders from family members and carers, to assist them to manage complex medication 
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regimens. “When I have to take them three times a day, that’s when I muck up because 
every other thing comes in the way.” 
 Managing multiple medicines when travelling away from home was problematic for most, 
especially when it meant negotiating across both Section 100 and Close the Gap medication 
schemes. “I get my tablets free at home but when I go to the city I have no prescription and 
then they want me to pay.” There was also criticism of the rules and dispensing protocols 
at the pharmacy and the difficulty of seeing a doctor for a new prescription. 
Many of the participants acknowledged that others in their communities also struggled to 
manage their medicines. Some community members elected not to take medicines; others 
tried to be adherent with their medications but found the barriers too great. Distrust and 
fear of western medicine, family trauma, financial difficulties, lack of transport, distance to 
the pharmacy and lack of understanding about medicines were reasons given for lack of 
medication adherence. 
”Some people are not very interested in their medicines. They have too much worry.” 
“Some people are frightened of taking tablets, thinking if you take them, you die.” 
The majority of the focus group participants said that they did not ask questions about 
their medicines because they either did not know what to ask, were too shy or found it 
“shameful to take so many tablets”. Those that did ask questions, usually did so of the 
doctor rather than the pharmacist as most participants felt they had a better relationship 
with the doctor than with their pharmacist. Some remote participants had little or no 
access to a pharmacist. Some participants felt the pharmacist was too busy. A number of 
participants commented on the lack of privacy in many pharmacies, stating, “It is 
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embarrassing if everyone hears your business.” The few participants who had had a Home 
Medicines Review found it an extremely useful and empowering experience. “Time with a 
pharmacist empowers you to ask more questions.” 
All the participants stated that they found generic brand substitution, the varied tablet 
appearances and different names, very confusing. Some rural and urban participants were 
prepared to pay for the more expensive branded product but were rarely given the 
opportunity. 
 “I’d rather pay for the one I know. Often I say I don’t want the cheaper brand but they give 
it to me anyway.” 
All participants stated that they were rarely given written information about their 
medications. Often they tried to read package insert information but found the print too 
small, the information hard to understand and the lists of side-effects worrying. Simplified, 
jargon-free written resources were preferred. “It would be good to have something to take 
home, that I can read and understand, without too many big, technical words, that I can 
show my family.” 
All participants agreed that communications by doctors and pharmacists with Aboriginal 
and Torres Strait Islander people about medicines were often incomplete or ineffective. 
“He tells me the basics but I want to know more.” Most felt that if they were given more 
information, improved medication adherence would result. “If I know more, I feel more 
confident and try harder to take my medicines.” 
The majority of focus group participants in this study were proactive in the management of 
their medicines and were keen to have better understanding of their medicines. 
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3.3.3 Discussion 
Aboriginal and Torres Strait Islander people are hugely diverse and they are not all 
represented in the study. Therefore, it is difficult to extrapolate findings to all Aboriginal 
and Torres Strait Islander people. However, the sample size was larger and more 
representative than many studies with Aboriginal participants, and therefore this study has 
merit. 
Consistent themes were identified across all settings. These themes were: the difficulty of 
managing multiple medicines; the need for more information, written and verbal, about 
medicines, to inform patient choices; disempowerment to ask doctors and pharmacists for 
information about medicines; lack of satisfaction of interactions with doctors and 
pharmacists about medicines; and the difficulty of negotiating the health system. The 
extent of the homogeneity of findings about medication issues was surprising across the 
varied settings and adds validity to findings. 
Further studies should aim to capture a broader range of participants by using translators. 
Further investigation is needed to determine whether the findings from this study apply to 
non-represented groups. 
3.3.4 Conclusion 
Complex medicine regimens result in many Aboriginal and Torres Strait Islander patients 
finding medicines confusing and difficult to manage. More comprehensive information, 
verbal and written, about medicine indications, mechanisms of action, potential side-
effects, drug interactions and duration of therapy, is needed. Currently, communications by 
the doctor and the pharmacist with these patients about medicines are often incomplete 
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or ineffective. More culturally appropriate, jargon-free written resources about medicines 
are required. Greater understanding and empowerment about medicine choices seem to 
be likely to improve medicine adherence. 
Dispensing protocols, the lack of pharmacist interaction, and the physical settings of 
community pharmacies have made it difficult for some Aboriginal and Torres Strait Islander 
patients to have productive relationships with pharmacists. Pharmacists through cognitive 
pharmacy services, such as Home Medicines Review, have an opportunity to build 
relationships, increase patients’ knowledge about their medicines, and assist Aboriginal and 
Torres Strait Islander patients with medication understanding and treatment choices. 
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Chapter 4 
Aboriginal and Torres Strait Islander perspectives of 
Home Medicines Review 
4.1 Introduction to chapter 
The paper in this chapter reports the findings of the data analysis of 18 semi-structured 
focus groups with 102 Aboriginal and Torres Strait Islander participants in 11 Aboriginal 
Health Services. 
This chapter contains an original research paper that has been published in a peer-reviewed 
journal. This paper shares some important findings about Aboriginal and Torres Strait 
people’s perspectives of the Home Medicines Review program (HMR). It explains the HMR 
program and reports the participants’ awareness, opinions, and perceived benefits of and 
barriers to HMR. In the paper I also explore participants’ suggestions for an “improved” or 
more accessible medication review model. 
This study confirmed reports that most Aboriginal and Torres Strait Islander people had 
little or no access to HMR. Seventy-seven percent of participants had not experienced an 
HMR. They are referred to in this paper as “Non Users”. The processes of HMR were 
explained to Non User participants before their opinions were sought. I specifically chose 
to conduct some focus groups in Aboriginal Health Services (AHSs) in which I knew HMRs 
were being conducted so that I could explore experiences of “User” participants who had 
had an HMR. This resulted in a skewed sample, with 20% of participants in this study having 
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an HMR. The number of participants in User and Non User focus groups can be seen in Table 
4.1. There are no accurate, available data on how many Aboriginal and Torres Strait Islander 
people have had HMRs, but it is far less than 20% of the Aboriginal and Torres Strait Islander 
population. 
4.1.1 What is known on this subject? 
There have been numerous studies examining the efficacy, and the barriers against and 
facilitators to HMR uptake in non-Indigenous population groups. There has been some 
evaluation and reporting that Aboriginal and Torres Strait Islander people are under-
utilising the HMR program. However, there has been very little research to explore why 
Aboriginal clients are not accessing HMRs and how an increase in HMR accessibility for 
Aboriginal and Torres Strait Islander people might be achieved. 
 4.1.2 What does this study add? 
This study explores Aboriginal and Torres Strait Islander perspectives on the usefulness or 
otherwise of HMR. It informs design for a medication review program which is more 
accessible, acceptable and effective for Aboriginal and Torres Strait Islander people. 
4.1.3 Reference 
Swain L, Barclay L. An exploration of Aboriginal and Torres Strait Islander perspectives of 
Home Medicines Review. Rural and Remote Health 15:3009 (Online) 2015. 
A copy of the published paper can be found in Appendix E. 
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4.2 Manuscript abstract 
Exploration of Aboriginal and Torres Strait Islander perspectives of 
Home Medicines Review 
Introduction 
In Australia, Home Medicines Review (HMR) has been found to be an important tool to raise 
awareness of medication safety, reduce adverse events and improve medication 
adherence. Aboriginal and Torres Strait Islander people are “under-serviced” by the HMR 
program and are the most likely of all Australians to miss out on HMRs despite their high 
burden of chronic disease and high rates of hospitalisation due to medication 
misadventure. 
The goal of this study was to explore Aboriginal and Torres Strait Islander perspectives of 
the Home Medicines Review program and their suggestions for an “improved” or more 
readily accessible model of service. 
Methods 
Eighteen semi-structured focus groups were conducted with 102 Aboriginal and Torres 
Strait Islander patients at 11 Aboriginal Health Services (AHSs). Participants who were 
multiple medication users and understood English were recruited to the study by AHS staff. 
Seven focus groups were conducted for people who had already used the HMR program 
(User, n=23), and 11 focus groups were conducted for people who had not had an HMR 
(Non User, n=79). Focus group discussions were recorded, de-identified and transcribed. 
Transcripts were coded and analysed for themes.  
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Results 
Focus group participants who had not had an HMR had little or no awareness of the HMR 
program. All the participants felt that lack of awareness and promotion of the HMR program 
were contributing factors to the low uptake of the HMR program by Aboriginal people. 
Most participants felt that an HMR would assist them to better understand their medicines, 
would empower them to seek information about medicines, would improve relationships 
with health professionals and would increase the likelihood of medication adherence. Most 
of the User participants reported that the HMR interview had been very useful for learning 
more about their medicines. However, many reported that they found the process 
confusing and confronting. 
The majority of participants felt HMRs for Aboriginal patients should be organised by 
Aboriginal Health Service staff, with patients being offered a choice of location for the HMR 
interview. Participants identified that Aboriginal Health Workers should play a key role in 
communication, knowledge translation, referral and follow-up. 
Conclusion 
Current HMR rules impede rather than facilitate HMRs for Aboriginal people. Tailoring and 
remodelling of the HMR program is needed to increase the awareness, accessibility, 
acceptability and effectiveness of the HMR program for Aboriginal and Torres Strait Islander 
people.  
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4.3 Manuscript full text 
Exploration of Aboriginal and Torres Strait Islander perspectives of 
Home Medicines Review 
4.3.1 Introduction 
The rate of potentially preventable hospitalisations for Indigenous people is 4.9 times the 
rate for other Australians, with more than half (55%) of these hospitalisations being for 
chronic conditions (1). Under-use of medicines contributes to poorer control of chronic 
disease states and higher hospital admissions, morbidity and mortality for Aboriginal and 
Torres Strait Islander people (2, 3). 
Factors which impact Aboriginal people’s engagement with health services and medicines 
are various. They may include the cost of multiple medicines, the distance to services, 
poverty, racism, dispossession, lack of control, the stigma associated with a diagnosis of 
chronic disease, educational disadvantage, shared crowded households, increased patient 
mobility, and inadequate health professional support (4, 5). Compounding these may be 
issues of language, health literacy, cultural issues, concurrent use of bush or traditional 
medicines, lack of continuity of care and the absence of strong relationships with health 
practitioners (6). Failed patient-clinician interactions, poor healthcare delivery systems, 
complex medicine regimens and struggles with social and emotional wellbeing decrease the 
likelihood of effective management of medicines (7, 8). 
The Aboriginal Health Service Remote Access (AHSRA) program was established in 1999, 
providing free Pharmaceutical Benefit Scheme (PBS) medicines, and so improving 
medication access, for remote Aboriginal people. Two other PBS co-payment schemes, the 
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QUMAX or Quality Use of Medicines Maximised for Aboriginal People (9) and the Close the 
Gap (10) programs, were commenced in 2008 and 2010 to provide non-remote Aboriginal 
people with financial assistance with their medicines. These programs, whilst reducing 
some financial barriers to medicine access, are not sufficient to address all barriers. Without 
improved understanding of medicines and increased medicine adherence, chronic disease 
will remain poorly controlled (11, 12). Engagement of patients in their healthcare goals, 
communication of medicine information and simplification, of complex therapeutic 
medicine regimens also need to be achieved (5). 
Clinical pharmacists and the cognitive pharmacy services they deliver, such as patient 
medicine education, medicine reviews, drug interaction checking, dosage and adverse-
effect monitoring, medication reconciliation and clinical interventions, can make valuable 
contributions to improving health outcomes (13). Pharmacists need to develop increased 
understanding of Aboriginal culture, Aboriginal Health Services and their Aboriginal Health 
Worker staff, as well as to better understand the needs of their local community, in order 
to deliver effective primary health care to Aboriginal people and so maximise the 
therapeutic effects of prescribed medications (14). 
The Home Medicines Review (HMR) program (15) is a cognitive pharmacy service, which 
was introduced in Australia in 2001 by the Commonwealth Government. This home-based 
program is designed to assist patients maximise the benefits of their medication regimens 
and prevent the harmful consequences of medication misuse (16). On a referral from the 
general practitioner (GP), an HMR trained and accredited pharmacist will visit the patient at 
home, and interview the patient about their medication. The pharmacist would explain the 
medications and their usage, and provide appropriate medication information to the 
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patient. The pharmacist then prepares a report of their findings, using information provided 
by the patient, medical information provided by the GP and the patient’s dispensing history 
from the pharmacy. The accredited pharmacist reports the findings and their 
recommendations to the referring GP. This report forms the basis of the Medication 
Management Plan which the GP may implement with the patient on their next visit. The GP 
and pharmacist claim payment from Medicare Australia. 
Most patients would benefit greatly from an HMR consultation after discharge from hospital 
when medication confusion and incidents of medication misadventure increase. There may 
also be occasions when patients are unable to access primary health care services and 
consult a GP. For these reasons there has been some debate around the need for various 
health professionals to be permitted to initiate and refer patients for Home Medicines 
Review. To date, program rules still allow only GPs to refer patients for HMRs. 
Home Medicine Reviews have been found to be an important tool. They raise awareness of 
medication safety and ultimately reduce adverse events and unnecessary hospital 
admissions (16). Lack of medication information often leads to failure of the patient taking 
the medicine correctly, which can in turn lead to therapeutic failure or unwanted/dangerous 
effects from medications (5). An HMR creates an opportunity for the patient to receive 
medication counselling from an accredited pharmacist. The HMR is the perfect platform to 
improve medication concordance and reduce medication misadventure in those who have 
complex medication needs (17, 18). Whilst most HMR studies have found very positive 
consumer acceptance of the HMR program, some others have reported consumer 
ambivalence (19). 
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Evaluations of the Home Medicines Review program provided by consultants employed by 
the government (16, 20) identified that Aboriginal and Torres Strait Islander peoples had 
been “under-serviced” by the HMR program and are the most likely of all Australians to miss 
out on HMRs, despite having the highest rates of hospitalisation due to medication 
misadventure (16, 20). There are no accurate, accessible data documenting the number of 
HMRs being undertaken with Aboriginal patients. However, anecdotal evidence suggests 
that the number is still small, despite marginal increases as a result of some pharmacists 
working with Aboriginal Medical Services (AMSs) during the implementation of the QUMAX 
program from 2008 to 2012. The 2007 Campbell report (16) commissioned by the Australian 
Government called for the urgent introduction of a more culturally appropriate model of 
HMRs and for expanded HMR services to Aboriginal Australians. To date these 
recommendations have not been implemented. 
The goal of this study was to explore Aboriginal and Torres Strait Islander perspectives of 
the Home Medicines Review  program and their suggestions for an “improved” or more 
readily accessible model of service. This paper reports the analysis of the views of the 
Aboriginal and Torres Strait Islander people who participated and informs policy and 
medication initiatives for these Australians. 
Very little research has been conducted in the area of medication management and 
cognitive pharmacy services for Aboriginal and Torres Strait Islander people or the role of 
pharmacists in Aboriginal health. Published research has been reviewed and has been used 
to situate this study. 
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4.3.2 Methods 
This is an exploratory study of Aboriginal and Torres Strait Islander patients’ perceptions of 
the Home Medicines Review model. An Aboriginal advisory group was established to guide 
the design and data collection phases of this study. The advisory group members consisted 
of community elders, an Aboriginal Health Service (AHS) Chief Executive officer and two 
health administrators. The group advised on engagement with AHSs, focus group 
management, language, culture and question design. 
As research and researchers have had a poor reputation in many Indigenous settings (21), 
AHSs were chosen as the sites for recruitment of patients and data collection because AHSs 
provided a culturally safe environment (22). Shyness and distrust of the unknown, non-
Aboriginal researcher, was diminished by holding the focus groups in the familiar 
surroundings of the AHS. 
Aboriginal shyness, poverty, effects of long-term discrimination and powerlessness have 
been identified as barriers to generating information with Aboriginal participants (23). 
Focus group methodology was chosen as this allows minimally structured “yarning” that 
gathers information through conversation and storytelling. Storytelling is the preferred 
communication method for many Indigenous Australians (24). 
Each Aboriginal Health Service was given verbal, then written information about the 
project, and their management and boards were asked to approve participation in the 
study. Aboriginal staff members were asked to assist with patient recruitment and focus 
group organisation and acted as cultural brokers managing the relationship between 
participants and the researcher. They were vital to establishing trust and cooperation. 
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 Eighteen semi-structured focus groups were conducted with Aboriginal and Torres Strait 
Islander patients (n=102) at eleven AHSs in Queensland, Northern Territory, South 
Australia, New South Wales and Victoria. The sites were selected for diversity and included 
urban (n=2), regional (n=3), rural (n=2) and remote (n=4) settings. They ranged across 
language groups and they varied in governance, size and service delivery models. The AHSs 
prescribed and dispensed medicines under different schemes, including Section 100, 
QUMAX and Close the Gap, and two sites had in-house pharmacists. Three Northern 
Australian sites were chosen to include Torres Strait Islander people representation. Table 
4.1 indicates number of participants in each focus group. 
Table 4.1: Participants at focus groups 
 
Location 
Governance No. of participants in 
HMR Users Focus 
Group 
No. of participants in HMR 
Non Users Focus Group 
Rural ACCHS 3 9 
Remote ACCHS 1 8 
Urban ACCHS 0 13 
Regional ACCHS 0 10 
Remote State Health 0 4 
Regional ACCHS 2 6 
Remote ACCHS 3 7 
Urban ACCHS 3 5 
Rural ACCHS 8 3 
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Location 
Governance No. of participants in 
HMR Users Focus 
Group 
No. of participants in HMR 
Non Users Focus Group 
Remote State Health 0 8 
Regional ACCHS 3 6 
Total  23 79 
Key: ACCHS=Aboriginal Community Controlled Health Service; HMR=Home Medicines 
Review 
 
The researcher specifically targeted some AHSs where HMRs were being conducted so that 
she could explore participants’ HMR experiences at these sites, and thus twenty percent of 
focus group participants in this research had received an HMR. The overall percentage of 
Aboriginal and Torres Strait Islander peoples having had an HMR in Australia is much lower 
than this figure. 
Participants (n=102) of AHSs (n=11) who were multiple medication users and understood 
English were recruited to the study by AHS staff. Although no formal demographic data 
were collected, the researcher recorded in field notes that 75% of participants were female, 
approximately 90% of participants appeared to be aged over 40 years, and about 70% 
appeared literate in written English. 
Participants were given written material explaining the study by AHS staff, before consent 
was sought. The researcher confirmed understanding, willingness to participate and 
permission to record proceedings at the beginning of each focus group before formal 
consent was obtained. 
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Two types of focus groups were conducted. Seven focus groups were conducted for people 
who had already used the HMR program (User, n=23) and 11 focus groups were conducted 
for people who had not had an HMR (Non User, n=79). All focus groups were conducted by 
the first author. The challenge of conducting high quality focus groups was not 
underestimated, and analysis of participant interaction as well as content was recorded in 
field notes after each group session. 
In the User focus groups Home Medicine Review Users were asked to reflect on their 
experience of having an HMR, and then on their satisfaction or lack of satisfaction with their 
experience, as well as what they believed might be barriers and facilitators for other 
Aboriginal and Torres Strait Islander people in accessing the HMR program. Non User focus 
groups received a description of the HMR program rules and processes. The group then 
discussed their perceptions of the HMR program, the barriers and facilitators of the HMR 
model, and strategies to increase accessibility of the HMR program for Aboriginal and 
Torres Strait Islander people. 
Focus group questions were modified slightly as a result of early groups and concurrent 
analysis, to ensure all content raised in early groups was explored. See Table 4.2 for Focus 
Group Questions. 
Focus group recordings were de-identified and transcribed verbatim. Transcripts were 
coded and analysed for themes. Analysis occurred concurrently. Themes were identified by 
repetition of words and phrases, and shared meanings, evident across data. Findings were 
discussed with my other researchers to ensure the meanings generated were agreed and 
mutually shared. 
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Table 4.2: Core Home Medicines Review questions 
Item Questions 
HMR Non Users 
1. How do you manage your medicines? 
2. Have you ever heard of a Home Medicines Review? 
3.  Now that I have explained how a Home Medicines Review works, what do 
you think might be the advantages or disadvantages of such a program? 
4. Who do you think should organise the HMR interview? 
5. How do you feel about the HMR pharmacist visiting you at home? 
6. If available, would you or one of your family consider having an HMR? If yes, 
what do you hope some of the outcomes might be? 
7.  Why do you think Aboriginal and Torres Strait Islander people are low users 
of this program? 
8. Can you suggest ways we could increase the number of Aboriginal and Torres 
Strait Islander people having HMRs? 
HMR Users 
1. How do you manage your medicines? 
2.  What were your thoughts when your Doctor organised you a Home 
Medicines Review? 
3.  Who organised your HMR? 
4. How did you feel about the pharmacist visiting you at home 
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Item Questions 
5. How was the pharmacist interview?  
6. What did you find were the outcomes of the HMR? 
7. Would you recommend a HMR to others? Why/why not? 
8. What do you think were the advantages/disadvantages of having an HMR? 
9.  Why do you think Aboriginal and Torres Strait Islander people are low users 
of this program? 
10. Can you suggest ways we could increase the number of Aboriginal and Torres 
Strait Islander people having HMRs? 
 
 Focus groups continued and concepts were explored until no new findings were being 
generated and thus saturation of data had occurred (25). Field notes and summaries written 
at the end of each focus group were also incorporated into the analysis. 
Questions about the same issues produced similar findings in different settings despite 
urban/rural variability. The homogeneity of most findings was surprisingly strong across the 
varied settings and groups, adding strength to the findings. There was some small variability 
relating to more general issues of remoteness, such as lack of availability of health 
professionals and increased usage by patients of local Aboriginal language. There was no 
significant difference in understanding of medicines or perceptions of the Home Medicines 
Review program across the varied geographical settings, and thus it has not been necessary 
to discuss findings according to location. 
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Ethics approval was sought and granted from the University of Sydney Human Research 
Ethics Committee (11504), the Aboriginal Health & Medical Research Council (NSW), the 
Menzies School of Health Research (NT, SA) and the Aboriginal Health Research & Ethics 
Committee (Victoria). 
4.3.3 Results 
Most participants reported difficulties in managing their multiple medicines, and many 
expressed a desire to better understand their medicines (26). 
Most of the User participants reported that the HMR interview had been very useful for 
learning more about their medicines. However, many reported that they found the process 
confusing and confronting, as no one had explained what was to happen or for what 
purpose an HMR was being conducted. Most commented they would have liked some 
follow-up from the pharmacist after the HMR interview, such as a phone call, written 
report, written medicine information or another meeting. 
The majority of the Non User participants believed that Home Medicines Review could be 
a useful tool for Aboriginal people, if the process was managed in a culturally appropriate 
way. Six participants felt the need for an HMR implied “You are not doing the right thing”. 
User and Non User participants suggested ways the HMR program needed to be 
implemented to increase the uptake of this program by Aboriginal and Torres Strait Islander 
people as cultural issues and living circumstances are not currently addressed by the rules 
governing the process. 
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Findings from the Aboriginal patients about Home Medicines Review are grouped into two 
main themes and their subthemes. The main themes are cultural considerations and 
adapting the HMR process to suit Aboriginal peoples’ needs. 
Cultural considerations for HMRs with Aboriginal patients 
“It works to be organised by the health service”: Most participants, both HMR Users and 
Non Users, were adamant that they would only agree to having an HMR if it was suggested 
and organised by their AHS, because “then you can trust that the pharmacist is appropriate 
and that it [HMR] is for your benefit”. The AHS was described as a culturally safe service 
that understood the needs of its Aboriginal patients. 
Aboriginal people’s shyness was seen as a barrier to some patients having a HMR. “Some 
people are shy, some people feel threatened by people they don’t know.” The patients 
often relied on the AHS to assist them organise appointments, navigate the health system 
and broker relationships with health professionals. 
The health service people are people you trust, people that look after you, people 
you know. If they organise it then it must be okay. Also they know about our family, 
where to find us and can organise transport and the right time. 
 “It can’t just be anyone”: As long as the HMR interview had been organised by the AHS the 
participants were happy to engage with the pharmacist, even when he/she was a 
“stranger”. 
Participants felt that it was important for the AHS to form a working relationship with a 
specific pharmacist, so that this pharmacist could learn to relate to AHS staff and patients. 
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“I would just like to be given one pharmacist.” It was important that the pharmacist had a 
good attitude and respected Aboriginal patients. Many felt it would be desirable, and some 
felt imperative, for this pharmacist to receive cultural awareness training from the AHS. “It 
can’t just be anyone. They have to be culturally appropriate or they could offend someone.” 
“Sometimes you don’t want someone in your home”: Participants were evenly divided 
about whether they would be comfortable to have an HMR interview occur in their home 
or prefer to have it conducted at the health service or clinic. Some discussed the 
convenience of having it at home for the very elderly and disabled, and others said the 
benefits included “You’re comfortable in your own home” and that “In my house I’ll open 
up, I’m the boss kind of thing.” Fifty per cent, however, were adamant that “Sometimes you 
don’t want someone in your home” and stated that “A lot would rather have it at the clinic” 
because “A lot of people don’t like strangers in their house” and “Aboriginal people do get 
shamed if they haven’t cleaned up” and “I have a large family coming and going and 
sometimes it would be noisy and not very private.” 
All participants agreed that to give people having an HMR “a choice [of location] would be 
a good idea”. Some participants discussed the possibility of having an HMR in the garden, 
in the park or down by the river. The majority felt that a private space at the AHS was 
probably a very suitable option for many Aboriginal patients. The majority of study 
participants agreed that the name “Home Medicines Review would put some people off 
having one because they think they have to have it in the home”. 
“The health worker is the key”: Most participants indicated that they would like to have an 
Aboriginal Health Worker (AHW) present at the HMR interview with the pharmacist. It was 
felt that an AHW would break down barriers and aid understanding. They “break the ice” 
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and “they know about you” and “diffusing people’s fear helps them to understand”. It was 
also felt that an AHW would aid communication by prompting the right questions, 
translating and interpreting jargon and explaining concepts. “The health worker breaks 
things down for us, so that we can understand.” 
The AHW, as the most “continuous” member of the health care team, was seen as a useful 
resource for follow-up questions and reminders. “They can help us remember to take our 
medicines” and “They can ask the doctor for us” and “They can explain it later if we don’t 
understand”. 
Having an AHW present at a HMR interview was seen as even more imperative when the 
pharmacist was of a differing gender from the patient. A male AHW should attend a male 
patient and a female AHW attend a female patient to ensure sensitivities around “men’s 
business” and “women’s business” are respected. Most stated that the gender of the 
pharmacist didn’t matter as long as they were accompanied by the appropriate AHW. 
However, a few male participants stated that they would not discuss private health matters 
with a female pharmacist, even if an appropriate AHW was present. 
It was considered important to give patients the choice of a specific AHW to attend the 
HMR interview. Sometimes the AHW was a community member and the patient stipulated, 
“I don’t want her to know my business” and “sometimes because it’s not nice in front of 
that health worker if they’re not comfortable with that health worker” or if there is “family 
friction”. The choice of which health worker should be present was very important. 
Group HMRs: Family members, carers and other community members were often seen as 
integral to the management of medication and assisting in reminding patients to take their 
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medicines. A number of participants said when having an HMR they would prefer a family 
member or carer also to be present. “Sometimes it would be good to have someone else 
there to help me remember.” It was suggested that family members and carers, as 
nominated by the patient, should be formally invited to attend the HMR so they feel 
“welcome”. A small number of participants also stated they would like to have their HMR 
or a medication session in a group. “Being with other people with similar problems helps us 
to learn. They might ask things we need to know about.” They commented that it would be 
“great to get together with other diabetics to see if they have the same issues”. 
Adapting HMRs to Aboriginal patients’ needs 
Explain the process: Focus group participants who had not had an HMR had little or no 
awareness of the HMR program. All the participants felt that lack of awareness and 
promotion of the HMR program were contributing factors to the low uptake of the HMR 
program by Aboriginal people. “What is an HMR?” and “No one knows that it is available” 
were common sentiments. It was also suggested that the name, “Home Medicines Review”, 
would deter some patients as they would not be comfortable with having a pharmacist visit 
them at home. 
Participants who had had an HMR spoke of some “nerves” and apprehension before the 
pharmacist’s visit and some stated that they were unclear as to the purpose of the 
pharmacist’s visit. More communication and fact sheets outlining the process would have 
been helpful. 
A few participants expressed the view that more consultation and communication between 
government and community around health program design would have been “helpful”. 
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About half of the participants said they would like follow-up, and feedback from the HMR 
pharmacist after the interview, and a few even said they would like to see a copy of the 
report sent to the doctor. 
Most participants who had had an HMR thought that an HMR was just a “chat” with a 
pharmacist about their medicines. Only two participants realised that the pharmacist wrote 
a report for the doctor and that subsequent medication changes might relate to the 
pharmacist’s recommendations. Mostly they felt that “Afterwards nothing happened. I 
don’t think anything changed”. 
Referrals: Participants felt that many patients were unlikely to take referral documents 
from a doctor to the pharmacy and then directly liaise with an accredited pharmacist to 
make an appointment, as is suggested in the HMR program rules. They felt that “If it’s too 
much mucking around for us, it won’t happen.” 
Many participants, and all those from the more remote areas, suggested that an Aboriginal 
Health Worker (AHW) or AHS nurse should be able to write an HMR referral, as it was the 
AHWs and nurses who knew them “best”, and were the health professionals with whom 
they interacted most often. It was the AHWs and nurses who offered continuity of care, 
whilst many doctors “come and go”. 
 It was the AHW who they felt best understood if they needed assistance with medication 
management, assistance with transport to attend the HMR interview, which family member 
to invite and when to make an appointment with the GP. As the AHW was seen as the 
person who would be mostly likely to follow up after the HMR, it was viewed as important 
that the AHW was also involved in and aware of the HMR referral. 
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Medication specialists: AHWs were seen as the most accessible and most approachable of 
the health professionals at the AHS, and a few participants commented, “We need a health 
worker that specialises in medicines”. 
We need health workers to be trained as experts, to be able to have this knowledge 
to link between the pharmacy, the doctor and the patient’s journey in the community 
so that all the questions can be answered. 
Written resources: None of the participants who had had an HMR had received any written 
material. Most believed “It would have been good if the pharmacist had left some written 
information, simple to understand, to show to my family and read later”. A number of 
participants throughout the focus groups commented on the need for simple, jargon-free, 
culturally appropriate medication resources to assist in the understanding of their 
medication and health management. 
Many participants expressed the desire for a comprehensive medicines list that could be 
kept in their wallet or bag. 
4.3.4 Discussion 
This study showed that many Aboriginal people were keen to have a pharmacist working 
within their health service. They felt that a pharmacist working with their Aboriginal Health 
Service would be someone with whom they could develop rapport and trust, and who 
would be available to deliver medication reviews, medical education and other clinical 
services to Aboriginal patients. 
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The current HMR model and associated rules are restrictive and not conducive to utilisation 
of the program by Aboriginal and Torres Strait Islander people. Issues of referral, 
organisation, location, reimbursement and follow-up need to be addressed to increase the 
number of Aboriginal people who can use this program. As in studies with non-Indigenous 
patients, barriers to HMR included pride and independence, confidence issues with an 
unknown pharmacist, concerns regarding the home visit, and lack of information about the 
program (27). There are facilitators identified in this study which may increase the uptake 
of HMRs with Aboriginal and Torres Strait Islander patients, improve health and have 
economic benefits. 
Home Medicine Review rules dictate that referrals can only be written by a GP (15). 
Previous studies have identified that GPs’ lack of understanding of the HMR process and 
GPs’ time constraints have resulted in low HMR initiation rates (28, 29). In remote areas of 
Australia GPs are often scarce or on short-term contracts, resulting in lack of rapport and 
lack of continuity of patient care. Remote GPs need to prioritise acclimatisation, cultural 
orientation, medical emergencies and acutely ill patients, as well as manage chronic 
disease. Referrals for HMRs are very low in such areas. In urban and rural AHSs the GPs are 
often overloaded with complex patients with high disease burden. Long and complex 
patient consultations may result in low prioritisation of HMRs and low numbers of HMR 
referrals. Participants in the study identified that they most commonly discussed their 
medicines with the nurses or AHWs, with whom they more frequently engaged, than with 
their GPs. AHWs and nurses are best placed to identify patients at risk of medication 
mismanagement, and therefore program rules need to allow AHWs and AHS nurses to write 
an HMR referral. 
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The study confirmed the important role that Aboriginal Health Services play in the primary 
healthcare for Aboriginal and Torres Strait Islander people (30). AHSs were described as 
comfortable, safe environments which understood and addressed Aboriginal patients’ 
needs, and acted as the broker of services to the community. Study participants identified 
that it was the AHS who should organise the HMR interview and organise follow-up after 
the interview. It was through the AHS that culturally appropriate information about the 
HMR process and written information about medicines should be distributed. It was the 
AHS, commonly described as the clinic, which was identified as the most culturally safe 
place for the HMR interview to occur. Studies show that having pharmacists integrated in 
clinics or medical practices has strong patient support and results in improved patient 
outcomes (31, 32). 
The role of Aboriginal Health Workers was seen as pivotal to the success of an HMR by the 
study participants, reinforcing previous literature which has described the important role 
of AHWs in brokering communication between health professionals and Aboriginal patients 
(33). AHWs were described by participants as the health professionals who could best 
identify the patient need for an HMR, the most trusted organisers, the most effective 
communicators and the most likely ongoing source of information about medicines. There 
is currently no reimbursement for AHW involvement in the HMR process. Often, AHWs 
work across numerous programs within the AHS, including early childhood, sexual health, 
mental health and healthy lifestyle promotions. They are often overburdened with work 
commitments, and often attend to community health needs out of work time. To ensure 
the AHWs’ time is allocated to medication issues and involvement in HMRs, the HMR 
program needs to be able to reimburse the AHSs for their involvement in medication 
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management roles. A number of participants suggested the need for some AHWs to 
specialise in medicines, reinforcing previous studies which have suggested more AHW 
medication training (34, 35). 
Group medical consultations are a new innovation being used to enhance patient 
engagement and to address issues of GP shortage and overload due to ageing populations 
and increasing burdens of chronic disease (36, 37). Patients who have received care in 
groups reported improvement in health outcomes, improved sense of trust in physicians, 
better co-ordination of care, better community orientation, and more culturally competent 
care [38]. A few participants in this study identified that they would like to receive 
medication information as a group. They felt an HMR interview could be a more effective 
education session if conducted with a group of patients with similar medical conditions, and 
with the pharmacist, AHW and possibly the nurse and doctor also participating. 
Study participants strongly supported the HMR program, stating that the HMR program or 
similar could greatly assist Aboriginal people manage their medicines and improve their 
health. More funding and significant time and resources need to be invested in medication 
management programs for Aboriginal patients. The current HMR program has been 
designed with little or no understanding of Aboriginal culture and little or no input from 
Aboriginal people. There is a need to design and implement cognitive pharmacy services 
which can effectively deliver medication assistance in urban, rural and remote settings and 
to Aboriginal and Torres Strait Islander communities. The funding for this program needs to 
be uncapped to ensure viability, sustainability and confidence is invested in this program. 
The study was limited by English language requirement for participation. The participants 
were selected by the AHS staff, not randomly drawn or selected. It is suspected that AHS 
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staff approached those with whom they had stronger relationships and those they felt 
would be effective focus group participants. This may have caused some bias. A wide range 
of sites were used to try to maximise variability. Despite diversity of settings there was 
considerable consonance across responses. The views of Aboriginal people who do not 
attend AHSs have not been captured and therefore it is difficult to extrapolate findings to 
all Aboriginal and Torres Strait Islander people. However, the sample size was larger and 
more diverse than many studies with Aboriginal participants and therefore has merit. 
4.3.5 Conclusion 
Increasing HMRs for Aboriginal and Torres Strait Islander people has the potential to 
increase medication knowledge and medication adherence, and therefore improve chronic 
disease management. 
The current HMR program rules impede rather than facilitate HMRs for Aboriginal people. 
Changes needed to increase the uptake of HMRs by Aboriginal and Torres Strait Islander 
people include promotion to increase awareness of HMRs; providing leaflets to patients 
outlining the HMR process; allowing an HMR referral to be written by a nurse or AHW; 
facilitating the HMR interview by allowing choice of location, AHW and family member; and 
reimbursing AHSs for staff organisation and attendance at HMR interviews and providing 
HMR follow-up to patients. It is suggested that the HMR program be remodelled and 
renamed after consultation with Aboriginal and Torres Strait Islander people. 
Solutions which would assist with health workforce shortages, managing the increasing 
burden of chronic disease and funding shortfalls, include employing pharmacists within 
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AHSs, training AHWs to specialise in medicines and reimbursing pharmacists to conduct 
individual or group medication education sessions. 
If the Australian Government is serious in addressing the health inequities that exist for 
Aboriginal and Torres Strait Islander people it needs to invest in medication education 
strategies which will assist Aboriginal people to manage their medicines. The Home 
Medicines Review program could be a useful tool, but tailoring of this program is needed 
to increase awareness, accessibility, acceptability and effectiveness for Aboriginal and 
Torres Strait Islander people. Until the government engages Aboriginal people to assist in 
health program design it will continue to exclude Aboriginal people from mainstream 
programs, such as Home Medicines Review, and continue to increase the inequity. 
4.3.6 Acknowledgements 
Sincere thanks to the members of the Aboriginal advisory panel, the Aboriginal Health 
Service staff and focus group participants who gave of their time so generously to assist this 
research. Travel for this project, was partially funded by a Small Projects Grant from the 
Department of Health and Ageing as part of the Research and Development Fund managed 
by the Pharmacy Guild of Australian under the Fourth Community Pharmacy Agreement 
2010.  
141 
 
4.3.7 References 
1. Australian Institute of Health and Welfare. Access to health services for Aboriginal 
and Torres Strait Islander people. Canberra: AIHW; 2011. Available from: 
http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737418951&libID=
10737418 (Accessed 1 December 2013). 
2. Australian Institute of Health and Welfare. Expenditure on health for Aboriginal and 
Torres Strait Islander people 2008-9. Health and welfare expenditure series no. 44 
Cat.no. HWE 53. Canberra: AIHW; 2011. Available from: 
http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737419253&libID=
10737419252 (Accessed 1 December 2013). 
3. Kelaher M, Dunt D, Taylor-Thomson D, Harrison N,O’Donoghue L, Barnes T, et al. 
Improving access to medicines among clients of remote area Aboriginal and Torres 
Strait Islander Health Services. Australian & New Zealand Journal of Public Health. 
2006;30:177-83. 
4. Murray R. Prescribing issues for Aboriginal people. Australian Prescriber. 
2003;26:106-9. 
5. Davidson PM, Abbott P, Davison J, Digiacomo M. Improving medication uptake in 
Aboriginal and Torres Strait Islander peoples. Heart, Lung & Circulation. 
2010;19:372-377. 
6. Commonwealth Government of Australia. The effectiveness of special 
arrangements for the supply of Pharmaceutical Benefits Scheme (PBS) medicines to 
remote area Aboriginal Health Services. Senate Community Reference Committee: 
Senate Printing Unit, Parliament House, Canberra; 2011. Available from: 
http://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community
_Affairs/Completed_inquiries/2010-13/pbsmedicines/report/index (Accessed 1 
December 2013) 
7.     Larkin C, Murray R. Assisting Aboriginal patients with medication management. 
Australian Prescriber.2005;28:123-5. 
142 
 
8.        Emden C, Kowanko I, De Crespigny C, Murray H. Better medication management for 
Indigenous Australian: findings from the field. Australian Journal of Primary Health. 
2005;11:80-90. 
9. NACCHO. QUMAX ‒ Quality Use of Medicines Maximised for Aboriginal and Torres 
Strait Islander Peoples Program. Available from: 
http://www.naccho.org.au/promote-health/qumax/ (Accessed 1 December 2013). 
10. Australian Government Department of Human Services. Closing the Gap ‒ PBS co-
payment measure. Available from: 
http://www.medicareaustralia.gov.au/provider/pbs/pharmacists/closing-the-
gap.jsp (Accessed 1 December 2013). 
11. Price Waterhouse Coopers for Medicare Private. Health Literacy, Implications for 
Australia. 2011. Available from: 
http://www.medibank.com.au/Client/Documents/Pdfs/Health_literacy_-
_implications_for_Australians.pdf (Accessed 1 December 2013). 
12. World Health Organization. Adherence to Long Term Therapies: Evidence for Action. 
Geneva: WHO; 2003. Available from: 
http://www.who.int/chp/knowledge/publications/adherence_report/en/ 
(Accessed 1 December 2013). 
13. Tan ECK, Stewart K, Elliott RA, George J. Pharmacist services provided in general 
practice clinics: a systematic review and meta-analysis. Research in Social & 
Administrative Pharmacy. 2013;10(4):608-22.   
14. Stoneman J, Taylor SJ. Pharmacists' views on Indigenous health: is there more that 
can be done? Rural & Remote Health. 2007;7(3):743 (Online) (Accessed 1 December 
2013). 
15. Commonwealth Government Medicare. Home Medicines Review (HMR). 2013. 
Available from: 
www.medicareaustralia.gov.au/provider/pbs/fifth-agreement/home-medicines-
review.jsp. (Accessed October 30, 2013) 
143 
 
16. Campbell Research & Consulting. Home Medicines Review Program. Qualitative 
Research Project. Final Report. Department of Health & Ageing; 2008. Available 
from: 
https://www.health.gov.au/internet/main/publishing.nsf/Content/D341DA146481
106ACA257BF00020A7CD/$File/HMR%20Final%20Report.pdf (Accessed 3 January 
2014). 
17. Ponniah A, Shakib S, Doecke CJ, Boyce M, Angley M. Post-discharge medication 
reviews for patients with heart failure: a pilot study. Pharmacy World & Science. 
2008;30:810-815. 
18. Kairuz T, Bye L, Birdsall R, Deng T, Man L, Ross A, et al. Identifying compliance issues 
with prescription medicines among older people: a pilot study. Drugs & Aging. 
2008;25:153-162. 
19.  Carter SR, Moles R, White L, Chen TF. Patients’ willingness to use a pharmacist-
provided medication management service: the influence of outcome expectancies 
and communication efficacy. Research in Social and Administrative Pharmacy. 
2012;8(6):487-8. 
20. Urbis Keys Young. Evaluation of the Home Medicines Review Program – Pharmacy 
component. 2005. Available from: 
http://beta.guild.org.au/uploadedfiles/Medication_Management_Reviews/Overvi
ew/Urbis%20Keys%20Young%20evaluation.pdf (Accessed 3 January 2014). 
21. Smith LT. Decolonising methodologies. Research and Indigenous peoples. Second 
ed. London and New York: Zed Books Ltd; 2012. 
22. Belfrage M. Why "culturally safe" health care? Medical Journal of Australia.  
2007;186:537-8. 
23. Leipoldt E. Aboriginal people with disability and their use of advocacy: a 
phenomenological approach. (Bachelor of Social Science Honours thesis). Perth, 
WA.: Edith Cowan University; 1998. Available from: 
http://ro.ecu.edu.au/theses_hons/757  
144 
 
 24. Gorman D TM. Matching Research Methodology with Australian Indigenous Culture. 
Aboriginal and Islander Health Worker Journal. 2009;33(3):4-7. 
25. Walker JL. The use of saturation in qualitative research. Canadian Journal of 
Cardiovascular Nursing. 2012;(22):37-46. 
26. Swain L, Barclay L. They've given me that many tablets, I'm bushed. I don't know 
where I'm going. Australian Journal of Rural Health. 2013;21:216-219. 
27. White L, Klinner C, Carter S. Consumer perspectives of the Australian Home 
Medicines Review Program: Benefits and barriers. Research in Social & 
Administrative Pharmacy. 2012;8:4-16. 
28. Emblem G, Miller E. Home Medicines Review – The how and why for GPs. Australian 
Family Physician. 2004;33:49. 
 29. Roughead E, Pratt N, Peck R, Gilbert A. Improving medication safety: influence of a 
patient specific prescriber feedback program on rate of medication reviews 
performed by Australian general practitioners. Pharmacoepidemiology and Drug 
Safety. 2007;16:797-803. 
30. Baeza JI, Lewis JM. Indigenous health organizations in Australia: connections and 
capacity. International Journal of Health Services: Planning, Administration, 
Evaluation. 2010;40:719-42. 
31. Rigby D. Collaboration between doctors and pharmacists in the community. 
Australian Prescriber. 2010;33:191-3. 
32. Freeman C, Cottrell W, Kyle G, Williams I, Nissen L. Integrating a pharmacist into the 
general practice environment: opinions of pharmacists, general practitioners, health 
care consumers, and practice managers. BMC Health Services Research. 
2012;12:229. 
33. Abbott P, Gordon E, Davison J. Expanding roles of Aboriginal health workers in the 
primary care setting: seeking recognition. Contemporary Nurse. 2007;26:66-73. 
145 
 
34. Hamrosi K, Taylor SJ, Aslani P. Issues with prescribed medications in Aboriginal 
communities: Aboriginal health workers' perspectives. Rural & Remote Health. 
2006;6:557.   
35. McRae M, Taylor SJ, Swain L, Sheldrake C. Evaluation of a pharmacist-led, medicines 
education program for Aboriginal Health Workers. Rural & Remote Health. 2008; 
8:946.  
36. Bronson DL, Maxwell RA. Shared medical appointments: increasing patient access 
without increasing physician hours. Cleveland Clinic Journal of Medicine. 
2004;71:369-70. 
37. Yehle KS, Sands LP, Rhynders PA, Newton GD. The effect of shared medical visits on 
knowledge and self-care in patients with heart failure: a pilot study. Heart & Lung. 
2009;38:25-33. 
38. Clancy DE, Brown SB, Magruder KM, Huang P. Group visits in medically and 
economically disadvantaged patients with type 2 diabetes and their relationships to 
clinical outcomes. Topics in Health Information Management. 2003;24:8-14.  
146 
 
Chapter 5 
Perspectives of Aboriginal Health Service health 
professionals on Home Medicines Review 
5.1 Introduction to chapter 
This chapter reports the findings of the data analysis of 31 semi-structured interviews with 
14 Aboriginal Health Workers (AHWs), five nurses, one practice manager and 11 GPs in 11 
Aboriginal Health Services (AHS). 
This chapter contains an original research paper that has been published in a peer-reviewed 
journal. 
This paper analyses the attitudes and perceptions of AHS service providers towards 
medication review, and specifically the Home Medicines Review (HMR) program, for their 
clients. Although there was strong health professional support for HMRs, very few HMR 
referrals were written or organised for their clients. Lack of relationship, heavy workloads 
and complicated HMR processes were some of the barriers to implementation of HMRs by 
the AHSs. Perceptions that pharmacists lacked cultural sensitivity were also reported. Table 
5.2 in the paper contains a number of health professional quotes which summarise the main 
perceived benefits and barriers of the HMR program. 
Aboriginal Health Service health professionals made recommendations for changes to the 
medication review model. The findings and AHS service provider suggestions are discussed 
in some detail and have been represented diagrammatically to show the components 
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needed for an Aboriginal and Torres Strait Islander medication review model (See Figure 
5.1 in the paper). 
The perspectives of Aboriginal and Torres Strait Islander patients from Chapter 4, when 
combined with findings from AHS health professionals, as discussed in Chapter 5, inform 
how the HMR model needs to be modified to become more culturally appropriate, and 
therefore more accessible, for Aboriginal and Torres Strait Islander people. 
5.1.1 What is known on this subject? 
Previous research has analysed GP attitudes to HMR for their non-Indigenous clients. There 
is no published research which has analysed the views of AHS health professionals about 
the use of HMR for their Aboriginal and Torres Strait Islander clients. 
5.1.2 What does this study add? 
This study explores both attitudinal and procedural barriers and enablers to HMR usage, 
thus informing future design of medication review models for Aboriginal and Torres Strait 
Islander people. 
5.1.3 Reference 
Swain L, Barclay L. “Medication reviews are useful, but the model needs to be changed”: 
perspectives of Aboriginal Health Service health professionals on Home Medicines Review. 
BMC Health Services Research. 2015;15:366. 
A copy of this published paper can be found in Appendix E. 
148 
 
5.2 Manuscript abstract 
“Medication Reviews are useful, but the model needs to be changed”: 
perspectives of Aboriginal Health Service health professionals on 
Home Medicine Reviews 
Background 
The Australian Home Medicines Review (HMR) program consists of a pharmacist reviewing 
a patient’s medicines at their home and reporting findings to their general practitioner (GP) 
to assist optimisation of medicine management. Previous research has shown that the 
complex HMR program rules impede access to the HMR program by Aboriginal and Torres 
Strait Islander clients. 
This study explores the attitudes and perceptions of health professional employees working 
within Aboriginal Health Services (AHSs) towards the HMR program. The goal was to 
identify how the HMR program might better address the needs of Aboriginal and Torres 
Strait Islander people. 
Methods 
Thirty-one semi-structured interviews were conducted with health professionals at eleven 
diverse AHSs. Fourteen AHWs, 5 nurses, 1 manager and 11 GPs were interviewed. 
Interviews were recorded, de-identified and transcribed verbatim. Transcripts were coded 
and analysed for themes that recurred throughout the interviews. 
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Results 
This study identified a number of barriers to provision of HMRs specific to Aboriginal and 
Torres Strait Islander clients. These included paternalistic attitudes of health professionals 
to clients, heightened protection of the GP-client relationship, lack of AHS‒pharmacist 
relationship, need for more culturally responsive pharmacists and the lack of recognition of 
the AHS’s role in implementation of culturally effective HMRs. 
Changes to the HMR model, which make it more effective and culturally appropriate for 
Aboriginal and Torres Strait Islander people, were recommended. Improved relationships 
between GPs and pharmacists, between pharmacists and the AHS, and between 
pharmacists and Aboriginal and Torres Strait Islander clients were identified as key to 
increasing HMRs for Aboriginal and Torres Strait Islander people. 
Conclusions 
Aboriginal Health Services are well-placed to be the promoters, organisers, facilitators and 
implementers of health programs, such as HMR, for Aboriginal and Torres Strait Islander 
clients. 
Imbedding a pharmacist within an AHS addresses many of the barriers to HMRs. It ensures 
pharmacists are culturally mentored and that they build strong relationships with health 
professionals and clients. 
The HMR program rules needed to be changed significantly if medication review is to be an 
effective tool for improving medication safety and adherence for Aboriginal and Torres 
Strait Islander people. 
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5.3 Manuscript full text 
“Medication Reviews are useful, but the model needs to be changed”: 
perspectives of Aboriginal Health Service health professionals on 
Home Medicine Reviews 
5.3.1 Background 
The Australian Home Medicine Review (HMR) has been found to be an effective tool for 
improving medication safety, reducing adverse events and unnecessary hospital admissions 
(1-3). It consists of a pharmacist reviewing a patient’s medicines and reporting findings to 
the patient’s general practitioner (GP) to assist optimisation of medicine management. It is 
a “free to patient”, Australian Government managed program. An HMR referral is initiated 
by the patient’s GP, and then an HMR-accredited pharmacist is organised to visit and 
interview the patient in their home. The pharmacist sends a report of his/her findings to the 
GP, who then discusses recommendations and makes any appropriate medication changes 
in collaboration with the patient (4). 
To claim funding from the Australian Government for an HMR, the GP and pharmacist must 
adhere to program rules (4). In the 2008 evaluation report (5) the complexity of business 
rules and the number of steps involved in the HMR process were identified as barriers to 
initiation of HMRs. The program rules stipulate the HMR referral can only be written by a 
GP. The GP must obtain the patient’s consent, a GP can only claim funding through the 
Medical Benefits Scheme after a second visit from the patient to discuss the pharmacist’s 
HMR report and formulate the Medication Management Plan, and the GP can only bill one 
out of the two consultations relating to the HMR. The suggested HMR referral form requires 
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the GP to specify detailed patient information, medical and medication history. GPs often 
confuse the suggested indications on referral forms, such as taking 5 or more regular 
medications, with the specific rules for HMR program eligibility (5). Rules state that a 
patient may only receive an HMR every 24 months or if a GP deems an HMR is specifically 
necessary due to significant changes to the patient’s condition or medication regimen. The 
latter part of this rule is rarely applied, for most GPs and pharmacists are concerned they 
will not receive payment if they step outside the specified 24 months. Thus, some eligible 
patients are not being referred for HMRs. The 24-month rule appears to have been applied 
due to budgetary restrictions of the program rather than as a result of any data that 
determine that this is an appropriate timeline for maximising medication management (6). 
The HMR program rules and claim lodgement processes are also restrictive for pharmacists. 
The program rules have actually increased rather than decreased under the recent Fifth 
Government‒Community Pharmacy agreement (4). HMR payments can only by claimed by 
pharmacists if the HMR is conducted by an HMR-accredited pharmacist, if the patient is 
living in a community setting, if the claim is submitted within 30 days of conducting the 
patient interview and the HMR-accredited pharmacist has conducted fewer than 20 HMRs 
within the month. Rules state that an HMR interview must occur in the patient’s home 
unless prior approval has been obtained. This prior approval has to be sought by the 
pharmacist on a case to case basis, giving full patient details, at least 10 days prior to the 
proposed interview date (4). 
The evaluation of the HMR program in 2008 (5) included health professionals’ perspectives 
of the HMR program. Those interviewed described how whilst HMRs were a “good idea”, 
the program was not working well. Dominant themes in the evaluation report included the 
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complexity of business rules, time delays between HMR initiation and completion, and 
communication difficulties between GP and pharmacist. It reported that whilst the health 
professionals who had experienced HMRs were very positive, the others were mostly 
ambivalent. Many valued HMRs as a lower priority than a health assessment (5). 
The 2008 HMR evaluation report, commissioned by the Department of Health (5), also 
identified that Aboriginal and Torres Strait Islander people, despite their high burden of 
chronic disease, were the most likely of all Australians to miss out on an HMR and that the 
HMR current model was not appropriate for Aboriginal and Torres Strait Islander people 
(5). A recent study (7) has explored the views of Aboriginal and Torres Strait Islander 
patients of the Home Medicines Review program. The Aboriginal and Torres Strait Islander 
patients in that study felt an HMR would assist them to better understand their medicines 
and empower them to seek information about medicines, would improve relationships with 
health professionals and would increase the likelihood of medication adherence. These 
Aboriginal and Torres Strait Islander patients concluded, however, that current HMR rules 
impeded rather than facilitated HMRs for Aboriginal and Torres Strait Islander people (7). 
This study explores the attitudes and perceptions of health professional employees working 
within Aboriginal Health Services towards the Home Medicines Review program. The goal 
was to identify how the HMR program might better address the needs of Aboriginal and 
Torres Strait Islander patients. No previous HMR studies have analysed the views of health 
professionals working with Aboriginal and Torres Strait Islander patients. 
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5.3.2 Method 
This qualitative descriptive study explored Aboriginal Health Service (AHS) employees’ 
perceptions of the HMR model. The design was appropriate for this study because it 
facilitated the gathering of rich, contextual data related to service delivery in AHSs. 
Participants included general practitioners, nurses, Aboriginal Health Workers (AHWs) and 
an AHS manager. 
Eleven AHSs in Queensland, Northern Territory, South Australia, New South Wales and 
Victoria participated. The sites were selected for diversity and included urban (n=2), 
regional (n=3), rural (n=2) and remote (n=4) settings. They varied in governance and size. 
Some AHSs were initiating HMRs for their patients whilst others were not. 
Each AHS was given verbal, then written information about the project, and their 
management and boards were asked to approve participation in the study. An interview 
guide was designed with key open-ended questions to encourage a natural exploratory 
conversation with the interviewee. The interviewer used the questions to prompt the 
sharing of participants’ experiences and ideas. All interviews were face to face and all 
conducted by the same researcher. Questions were modified to ensure all content raised 
in early interviews was explored subsequently. 
Thirty-one semi-structured interviews were conducted at eleven AHSs. The numbers of 
each profession participating was influenced by staff availability and willingness to 
participate at each AHS. Fourteen AHWs, 5 nurses, 1 manager and 11 GPs were interviewed. 
See Table 5.1 for interview guide. 
  
154 
 
Table 5.1: Semi-structured interview guide 
1. Explore attitudes to 
HMR program 
How do you feel about the HMR program? 
 
How likely are you to order a HMR for a patient? 
 
How often do you order HMRs? What determines this? 
 
2. Explore 
understanding of 
HMR processes 
Who do you order HMRs for? Why? 
 
How do you find the HMR process? 
 
Do you have assistance from other staff members in 
organising HMRs? If so, how? 
 
3. Identify reasons for 
ordering HMRs 
(benefits) 
How useful have you found HMRs? or How useful do you 
think an HMR could be? 
 
What is the most useful aspect of an HMR? 
 
What feedback have you had from your patients about the 
HMR?  
 
How do you find the pharmacists’ reports? 
 
4. Identify barriers to 
initiating HMRs 
Is there a reason why you don’t order more HMRs? Please 
explain. 
 
Would you like to order more HMRs? Please explain. 
 
What are the limiting factors in referring patients for an 
HMR? 
 
Why do you think there are not many HMRs being 
conducted for Aboriginal and Torres Strait Islander 
patients? 
 
5. Encourage 
recommendations 
Do you believe the current HMR model is effective/not 
effective? Please explain. 
 
How appropriate is the HMR model for your patients? 
 
Are there any ways the model could be improved? If so, 
how? 
Key: HMR=Home Medicines Review 
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Of the 11 participating AHSs in this study, three were conducting HMRs regularly, 4 
occasionally and 4 not at all. Only at the three AHSs where there was a contracted 
pharmacist were patients being referred regularly for HMRs. One of these AHSs had a 
salaried pharmacist employed by the AHS for a range of clinical pharmacy roles, including 
HMRs. The other two had each contracted an HMR-accredited pharmacist to work to 
conduct HMRs, with one using a chronic care nurse and the other an AHW to co-ordinate 
the program. Although only 3 GPs were referring patients for regular HMRs, all interviewed 
GPs were aware of the HMR program although some lacked understanding of the HMR 
referral processes. The majority of nurses and AHWs interviewed were unaware of the HMR 
program. 
Interviews were recorded, de-identified and transcribed verbatim. Transcripts were coded 
and analysed for themes that recurred throughout the interviews. Analysis occurred 
concurrently. 
Ethics approval was sought and granted from the University of Sydney Human Research 
Ethics Committee (11504), the Aboriginal Health & Medical Research Council (NSW), the 
Menzies School of Health Research (NT, SA) and the Aboriginal Health Research & Ethics 
Committee (Victoria). 
5.3.3 Results 
The study participants who had experienced an HMR were extremely supportive of the 
program. The four GPs who had never referred patients for HMRs expressed reservations 
about the value of HMRs and concerns over the need to burden patients with another 
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referral. Two of the nurses interviewed were not supportive of HMRs. These nurses 
believed that although HMRs were “good in theory” Aboriginal patients were “not 
interested” and “there’s no point filling them up with a huge amount of education if they 
are not going to take the medicines anyway”. The Aboriginal Health Workers who had not 
previously been involved in HMRS were very keen to understand the details of the HMR 
program as they felt it would greatly assist their clients who they believed often “don’t 
understand how the medicines work, when they work, and they don’t take them at the right 
times or the right way”. Most of the interviewees were positive regarding the potential 
benefits of HMRs for their patients’ health. 
The emergent themes, and the perceived benefits and barriers of the HMR program, are 
discussed below and are summarised in Table 5. 2. 
Table 5.2: Most common perceived benefits and barriers of the HMR program 
Benefits of HMRs AHS staff comments 
Increased patient 
understanding 
and confidence  
The HMR interview is a good opportunity to iron out some confusion 
about medicines. (AHW) 
The clients need to know the importance of taking medicines and 
why they are taking them. (AHW) 
It helps my patients understand their medicines a bit more. (GP) 
Just having another person go over it, having a bit more time and in 
different words can be very useful. (GP) 
There’s the empowerment they [the patients] get from a more clear 
understanding. (nurse) 
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Benefits of HMRs AHS staff comments 
Improve 
medication 
adherence 
Because the people don’t feel they’re working, they tend not to take 
them. (AHW) 
If you explain to them [the patients] what it is, how it works and what 
to watch out for, then there’s some informed decision-making and 
they’re more likely to take them (medicines). (AHW) 
It gave my patient more confidence to take his medicines, just having 
someone reassure him that the medicines he was taking were 
appropriate. (GP) 
Supporting GP 
practice 
You get to learn stuff that you wouldn’t normally know about your 
patient. You learn about the gap, about what you think is going on 
and what is really going on, and you also learn stuff about medicines 
that you didn’t know. (GP) 
The reports can be revelationary. You find out people are taking all 
sorts of things, some that you ceased months ago. (GP) 
When a locum comes, and we have lots, they just prescribe the drugs 
because the patient asks for them. They don’t review them or work 
out if they really need them. (AHW) 
Lack of 
awareness 
None of us here know about Home Medicines Review. (AHW) 
People are not aware they can ask for, or should ask for their 
medicines to be reviewed. (AHW) 
They [the patients] don’t know that pharmacists can do things like 
reviews. (AHW) 
Workload Time is the main thing that has put me off. (GP) 
We are already inundated with administrative tasks. (GP) 
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Benefits of HMRs AHS staff comments 
Aboriginal Medical Service workloads are pretty demanding. A lot of 
these people that qualify for an HMR also qualify for EPC, care plans, 
health assessments and that kind of stuff, so that might be where 
they’re going first. (nurse) 
One of the difficulties is having enough health workers on board to 
do it [participate in an HMR]. Having a health worker who is trained 
enough to go with the pharmacist, who is trained in quality use of 
medicines and who understands what the pharmacist is talking 
about and take a lead in the whole process would be the ideal. ( AHS 
manager)  
Protection of the 
clinician-client 
relationship 
They’re [patients] already getting referred to lots of different people 
for lots of different things. So another referral might just feel like too 
much. (GP) 
Gaining someone’s confidence and trust and having a meaningful 
clinical interaction requires proper cross-cultural training and 
working with the community over some time. (GP) 
Doctors are concerned about overloading the patient. (nurse) 
Lack of 
Clinician/AHS 
pharmacist 
relationship 
The GPs aren’t driving it [HMR referral] as they don’t have a 
relationship with a pharmacist who can do it for them. (GP) 
The relationship between the doctor and the pharmacist might not 
be established. If they had a rapport and a referral pathway going 
already that would really help. (nurse) 
The community pharmacists around here are very busy. I don’t think 
they have time to get it done. (GP) 
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Benefits of HMRs AHS staff comments 
It would be important for the pharmacist to have some cross-cultural 
training. (AHW) 
The chronic health nurse or AHW needs to have a direct link with the 
accredited pharmacist, not the pharmacy. (nurse) 
Generally our clients do not have a relationship with a pharmacist. 
(nurse) 
Lack of an HMR 
facilitator/driver/ 
program manager 
We need someone at the health service allocated to encouraging the 
Home Medicines Review, co-ordinating it, blocking out time for GPs 
to do referrals, taking on the role of doing the consent. (GP) 
It needs something set in place so that it can be done regularly. (GP) 
We rely on a co-ordinator to organise all the logistics. (GP) 
There needs to be a single point of contact, health worker to patient. 
(AHW) 
Somebody who is well-known to the patient needs to ring and 
explain the process. (AHW) 
Complex HMR 
model and rules 
It took a while to make sense of the steps. (GP) 
I think the criteria are a bit restrictive. (GP) 
It was not clear that all pharmacists were not accredited. I was 
sending off referral letters and nothing happened. (GP) 
It would be better if someone else could refer. For a multi-disciplinary 
team to work effectively everything should not be done by the GP. 
(GP) 
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Benefits of HMRs AHS staff comments 
A lot of them think it is all done once the pharmacist has left the 
house. (AHW) 
The health service should promote it [HMR] and align it with other 
programs or something they do already. (nurse) 
We don’t organise Home Medicine Reviews for all sorts of reasons – 
around privacy, judgement, people not being home, lots of people 
being transient or homeless, lots of people in one household and 
people not wanting strangers in their home. (nurse) 
We need a flexible mixed model where some people can come here 
on an appointment, or we can go there if it suits today or where a 
pharmacist can just add on to an existing program. (AHW) 
Lack of financial 
reimbursement 
The AMS should be able to claim something for organising an HMR. 
(AHS manager) 
It should be the AMS who is doing all the organising who gets a cut, 
not the pharmacy. (nurse) 
AHWs are very important to the process. They need to be reimbursed 
for their time, just like the pharmacists and GPs. (GP) 
Key: AHW=Aboriginal Health Worker; GP=General practitioner; HMR=Home Medicines 
Review 
“Home Medicines Reviews are useful” 
Three of the five nurses and all AHW interviewees described increased medicine knowledge 
and empowerment of patients to make medicine choices as the potential benefits of the 
program, stating “HMRs were good for understanding what they’re taking and why they are 
161 
 
taking medicines and the importance of medicines”. They also felt HMRs would assist 
patients learn about potential dangers in storing medicines and sharing medicines. Most of 
the interviewees strongly agreed that a Home Medicine Review  could be useful in reducing 
medication “fear and worries about the unknown”. 
All the AHW interviewees expressed concern about patient confusion around their 
medicines stating, “Generics confuse the hell out of people” and “In hospital they start 
swapping and changing medications. It gets very confusing.” 
The majority of the GP interviewees also felt patients would benefit from increased 
medicine knowledge and that patients would benefit from having “someone else 
reinforcing information that the doctor has given”. The majority of GPs believed that HMRs 
could assist their patients to feel more confident about taking their medicines and felt 
HMRs would “elevate the medications up the priority list”. The majority of participants 
believed that most patients would be “really keen” to have an HMR, although there may be 
a few patients who “see it as a failure to have someone come and talk to them”. 
The GP interviewees who had referred patients for HMRs praised how HMRs had identified 
potential drug interactions and had identified “an astounding number of discrepancies 
between what we had on our system and what clients were taking”. Also, these GPs valued 
how HMRs assisted their therapeutic decision-making, assisted them to sometimes cease 
medications and increased their own understanding of medicines. The GPs liked the HMR 
reports as the “pharmacists fed back lots of information about whether there are lots of 
other medications from other places and whether there is confusion and that sort of thing”. 
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Other benefits of HMRS stated by the GP interviewees included improved understanding of 
whether their patients had high falls risk, were medication adherent, and were sharing or 
hoarding medicines. A few GP participants also commented that they felt HMRs would 
assist with building relationships between patients and pharmacists. 
“I just don’t get around to ordering HMRs” 
Despite most of the participating AHS GPs agreeing that HMRs would be very useful for 
their complex patients and for supporting their therapeutic decisions, only 3 of the 11 GPs 
interviewed were actually referring their patients for HMRs regularly. 
The most common reasons for the GPs not “getting around” to ordering HMRs for their 
patients included lack of time, protection of their client-clinician relationship, lack of 
relationship with pharmacists, and cultural inappropriateness of the HMR program. Some 
other reasons included complex HMR processes, not prioritising medicines in their patient 
discussions, GP ownership of their role in advising on medicines, and perceived lack of 
evidence for the value of HMRs. Two of the GPs reflected paternalistic attitudes, 
commenting “they [their Aboriginal patient] are not particularly interested in having an 
intervention like a HMR” and “In terms of education, which I know is one of the really 
important parts, I’m not sure. I’m not convinced that those people think it is a high priority 
and that we have any way of educating these people about their medications”. Two GPs 
commented that reviewing patients’ medicines was part of their practice, stating, “If a 
patient had concerns about their medicines they would come and talk to us about it. The 
clinic has primary responsibility for those things” and “I do a lot of it [medication review] 
myself actually.” 
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All the GP interviewees commented that the biggest barrier to writing HMR referrals was 
“being pushed for time”, and half of the doctors felt that writing an HMR referral was a 
barrier as it was “just another bureaucratic, red tape thing to do when you’re seeing 
patients”. Patients at the AHSs often had complex co-morbidities, and although most 
interviewees agreed that HMRs were desirable, the doctors felt they had “to sort out the 
multiple things a patient presents with, do a GP plan and a team arrangement and a health 
check first. An HMR is just another thing on a list of things that you know you need to do”. 
At times some felt they were “snowed under with the acute stuff before you even get to 
the chronic stuff”. In the 3 AHSs where GPs were writing regular HMR referrals they had 
found other staff members to assist the process and one commented “It takes time to offer 
and explain it [HMR] and do the referral. That is just too onerous to fit into an appointment, 
so I get the health worker to do it”. 
The 8 GPs who were not regularly referring patients for HMRs made comments which 
reflected their wish to protect their clinician-client relationship. “There are lots of 
practitioners with lots of clinicians involved already” and “We need to make sure we are 
not overburdening them [the patients] with our efforts”. These GPs particularly showed 
some uncertainty about referring their patients to a pharmacist, indicating a lack of GP-
pharmacist relationship. Five GPs perceived that their local pharmacists were too busy to 
do HMRs, commenting, ”We think that some pharmacists are too busy. I guess we worry 
that the pharmacist might not be very receptive.” Two GPs had had their HMR referrals 
ignored or returned by pharmacies. “I was sending off referral letters and nothing 
happened.” 
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Seven of the GPs commented that pharmacists needed to be culturally sensitive, have some 
cultural training and/or show an interest in working with Aboriginal people before they 
would feel comfortable referring their Aboriginal patients to them. Comments included, “I 
am not sure how culturally aware the pharmacists are” and “If we [the AHS] had a 
relationship with a particular pharmacist who we knew our people were comfortable with 
that would really help.” The nurses also felt that the lack of pharmacist-client relationship 
was problematic stating that “It’s not very often that you will have a relationship between 
the client and the pharmacist.” Conversely, in the AHSs where a pharmacist had been 
contracted, the pharmacists were highly valued and regarded. “They [the doctors] really 
like having the pharmacist here. The doctors specially allocate time when she is here for 
the day. Now that they have built up a rapport the doctors will actually ring her up and ask 
her questions about medications.” The AHWs also commented, “It would be important for 
the pharmacist to have some cross-cultural training. For them to be good at it, for it to be 
worthwhile they need proper cultural training. That would be key.” A few of the 
interviewees bemoaned the lack of Aboriginal or Torres strait Islander pharmacists. The 
majority of AHWs commented on their clients’ lack of understanding of a pharmacist’s role 
and on their lack of established relationship with the local community pharmacist. 
The GPs, nurses and AHWs all showed some misgivings about a pharmacist visiting an 
Aboriginal or Torres Strait Islander person’s home. “I think sending a pharmacist cold to a 
patient’s house is inappropriate” and “Many Aboriginal people are not comfortable with 
non-Aboriginal people going to their home”. Half the GPs did, however, state a preference 
for the HMR interview being conducted at the patient’s home whenever possible as they 
cited the advantage of being “able to see what is really happening” and that “one of the 
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great benefits is seeing the context at home so it would be a shame to lose that.” However, 
most felt that although “It is better if it happens in the home. I wouldn’t want them to not 
get a HMR just because the home is not appropriate or suitable”, and some believed that it 
was preferable to “have something in the clinic where they’re use to coming”. A couple of 
interviewees also commented that having a pharmacist at the clinic would assist in 
establishing relationships between GPs, pharmacists and AHWs and would allow valuable 
case conferencing and discussion around patients. 
Despite most of the GPs at first stating that HMRs could be beneficial in assisting their 
patients to manage their medicines, later in their interviews, half the GPS from the AHSs 
where HMRs were not occurring, showed some scepticism around the value of HMRs. Two 
of the eleven 11 GPs perceived “if patients had concerns about their medicines they would 
come and talk to us [GPs] about it”. These GPs appeared to doubt the need for an HMR as 
they felt they adequately dealt with medication issues themselves, saying “I do a lot of it 
[medication education] myself actually” and “I believe it is my role to talk to patients about 
their medicines.” Three GPs also expressed concern that their patients “might not see the 
value in it” and stating, “The doctors spend a lot of time dealing with medicines so it might 
be seen as doubling up.” The majority of GPs who were not ordering HMRs felt that 
currently “the process isn’t in place for it to happen”. 
The AHWs perceived that their lack of awareness and their clients’ lack of awareness of the 
HMR program contributed to the low uptake of HMRs by their community. Some also 
commented on the lack of continuity of GPs and the number of health checks already being 
conducted, as barriers to implementing another program, such as HMR, in their health 
service. 
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“Need someone to be the main organiser” 
All the AHS health professionals interviewed agreed that for HMRs to become a regular 
occurrence at their AHS it required “having someone at the health service allocated to 
encouraging the Home Medicines Review, co-ordinating it, blocking out time for GPs to do 
the referral, taking on the role of doing the consent”. They all agreed that this role should 
be done by a senior health worker or a nurse who really understands the process. Each of 
the 3 AHSs where HMRs were being done had a “co-ordinator to organise all the logistics”. 
One AHS used the chronic care co-ordinator nurse, another an AHW dedicated to Quality 
Use of Medicines and the third a salaried pharmacist to organise their HMRs. 
Explaining the process to the patient and brokering trust in the process was seen as 
important in the success of the program with Aboriginal and Torres Strait Islander patients. 
The GPs explained that “Someone who is well-known to the patient, such as a health 
worker, needs to ring and explain the process” and “I think if the health worker is the first 
port of call and clearly explains everything, then I think people will take it up.” 
Across the health professional groups there was discussion as to how best manage the extra 
work load that HMRs would create. Most agreed that there should be health workers 
specifically employed as chronic disease health workers or even specifically as medication 
specialists, and part of their role should be facilitating the HMR process. All agreed, “The 
AHS should be able to claim something for their [the organiser’s] time” and stated that “It 
should be the AHS who is doing all the organising who gets a cut, not the pharmacy.” 
Most GPs agreed an AHW should accompany a pharmacist to a client interview to broker 
cultural trust and because “it provides an opportunity to up-skill the health worker”. Most 
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commented that the health worker or the AHS should receive financial reimbursement for 
the health worker’s time, in alignment with the fees received from the Government by the 
GP and the pharmacist. Many interviewees felt the organising health workers should also 
be the one attending the interview. 
 “It would be better if someone else could refer” 
A few of the GPs showed a lack of confidence and knowledge about who was eligible for an 
HMR, how to write a referral and the HMR process, as indicated by their comments, “So 
you don’t have to wait until they are on 5th medication to order an HMR?” and “It takes a 
while to make sense of the steps”. All the GPs, nurses and AHWs agreed that “It is not 
practical for the patient to have to take the referral to the pharmacy.” Most of the GPs 
indicated that as they were time-poor, they would be happy for a health worker or nurse 
to organise the HMR and even write the referral or alternatively “we could do the referral 
retrospectively.” The AHWs iterated their willingness to initiate referrals. “We know the 
patients best so it would make more sense if we organised the referral.” 
The nurses and AHWs believed that it was crucial that the AHS could select and refer to a 
specific pharmacist known to the AHS, with whom they had a relationship and who had 
been assessed by the health service for their cultural sensitivity. The GPs also expressed the 
need to establish rapport with a trusted and culturally appropriate pharmacist before they 
would refer their patients. 
 “The model needs to be changed” 
In addition to changing referral pathways, having the AHS organise the HMR and having an 
AHW attend the HMR interview, GPs also suggested other changes to the HMR model. 
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These included the pharmacists providing patients with a brief follow-up report that also 
prompted them to make an appointment with the GP to discuss, as “it is a very important 
step when the patient sits down with the GP and makes the changes that are needed”. 
Many lamented that often HMR patients did not revisit the clinic to discuss a revised 
medication plan with the GP. 
Half the study participants mentioned that HMRs should be incorporated into the 
Aboriginal health assessment process, or be part of the existing GP management plan. A 
number of health workers also stated that the HMR program would work best if it was a 
“flexible model where you can work in with existing programs rather than trying to develop 
a whole other system of doing things”. The AHWs suggested a pharmacist should join in 
existing groups, run by the AHS, such as cardiac rehab, cooking or diabetes groups or “run 
alongside a chronic disease clinic that’s happening on the day”. Most of the AHWs 
mentioned that group meetings would be favoured by many clients, and so group HMRs 
should be an option. 
All interviewers agreed that for the HMR program to work within their AHS it needed to be 
simplified. At present there are “way too many steps”. It also needed a systematised 
approach to ensure HMR referrals were written, interviews organised, and patients 
followed up. “It needs something set in place so that it can be done regularly.” The HMR 
system required a “driver” who was not too overburdened with other duties, preferably an 
AHW dedicated to chronic disease and medicines. All the AHWs interviewed stated that 
advising patients about medicines was a key part of their role and that they would like more 
training in this area. 
169 
 
The AHWs suggested that AHS need to promote the HMR program and inform their clients 
of the steps involved, through pamphlets and posters in the AHS. 
GPs and AHWs suggested changing the name of Home Medicines Review program. “The 
title is not good as some patients don’t like that home bit. Some don’t like strangers coming 
to their home. It needs an Aboriginal title or at least a bit more of a friendly title.” 
Figure 5.1 summarises the recommendations for a revised, more culturally appropriate 
HMR model. It is hoped that the findings and recommendations from this study will inform 
the Sixth Community Pharmacy agreement on HMR program rules for Aboriginal and Torres 
Strait Islander people. 
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Figure 5.1: Suggested model for Medication Review for Aboriginal and Torres Strait Islander 
people 
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5.3.4 Discussion 
Previous research has shown that consumers identified improved medicine information, 
feeling cared for and increased confidence to discuss medicines with the GP, as potential 
benefits of an HMR (7, 8). In this study, the perspectives of the nurses and GPs who had 
experienced HMRs, and the perspectives of all the AHWs, strongly supported the findings 
from research with consumers, as they identified that increased medicines knowledge and 
empowering consumers to make medicines choices were the major HMR benefits. 
Although the majority of GP participants, especially those who had experienced an HMR, 
agreed that HMRs could assist their understanding of their patients’ medicine practices and 
provide clinical support, very few HMRs were being ordered. GPs were only referring their 
patients for HMRs in three out of the 11 AHSs in this study. 
The 2008 Campbell report identified that GPs need assistance with structure around HMRs 
and that an HMR is very dependent on the relationship between GP and pharmacist (5). 
This study reinforced this need for structure and relationship, with HMRs only occurring in 
AHSs where structure had already been established, with an AHS staff member “driving” 
the process and where a pharmacist-AHS relationship had been established. This study also 
reinforced the Campbell report findings that an HMR was not seen as being high on the list 
of priorities for GPs due to competing demand for GP time, and as a result the HMR program 
existed in isolation rather than parallel to other Medicare items (6). The participants in this 
study reiterated that the HMR program workload needed to be shared and a team approach 
adopted, especially in areas where there were medical workforce shortages. 
This study confirmed a number of the barriers around provision of HMR services identified 
in previous studies by both consumers and stakeholders. These included complexity of 
172 
 
program rules, concerns regarding the home visit, lack of information about the program, 
GP workload and GP fears of pharmacists encroaching on their professional space (5, 7-9). 
It also identified a number of barriers specific to Aboriginal and Torres Strait Islander clients. 
These included paternalistic attitudes of health professionals to clients, heightened 
protection of the GP-client relationship, lack of AHS‒pharmacist relationship, need for more 
culturally responsive pharmacists and the lack of recognition of the AHS’s role in 
implementation of culturally effective HMRs. 
One-quarter (n=4) of the non-Indigenous health professionals (n=16) interviewed 
demonstrated paternalistic or racist attitudes to their clients, claiming that their clients 
were uninterested or incapable of learning more about their medicines and thus not 
suitable for an HMR. This directly contradicted research conducted with the Aboriginal and 
Torres Strait Islander patients and the AHWs at the same AHSs. The majority of patients at 
these AHSs were extremely interested in learning more about their medicines and very 
supportive of having an HMR (7, 10). The AHWs strongly believed their clients would benefit 
from HMRS as long as the HMRs were conducted in a culturally appropriate manner. The 
small sample of non-Indigenous health professionals interviewed does not allow for 
extrapolation across the AHS workforce but does support previous work which suggests 
that GPs and non-Aboriginal staff at AHSs would benefit from cultural mentoring (11). These 
attitudes require further investigation to assess if some health professionals at AHSs may 
require screening or further cultural training. 
The majority of the GPs interviewed in this study were very protective of their client-
clinician relationships, with much of the GP concern being around not overloading the 
patient with information and too many appointments. Further research is needed to 
173 
 
ascertain whether this concern about “overloading” the patient is culturally influenced. 
There was also considerable concern from the AHS GP and nurse interviewees that the 
pharmacist may be culturally insensitive and thus, by association, may damage patient 
trust. Only at the AHSs (n=3) where a pharmacist was contracted or imbedded was their 
real understanding of the clinical role of a pharmacist. The lack of relationship between the 
AHS staff, including the GP, with any pharmacist, including their local community 
pharmacist, appeared to be a major barrier to the initiation of HMRs. The lack of 
relationship with AHSs was also noted by pharmacists themselves in recent research (9). 
This supported previous research which suggested that lack of face-to-face interactions and 
established relationships between GPs and community pharmacists may be a significant 
barrier to collaboration (12). It appears that some significant work is needed to build 
bridges between pharmacists and GPs and between pharmacists and AHSs, and in the 
cultural training of pharmacists. Pharmacy organisations are currently lobbying the 
Commonwealth Government to fund salaried pharmacists within AHSs, enabling culturally 
trained pharmacists to develop relationships with AHSs and their clients (13). 
All the interviewees agreed that for many of their Aboriginal and Torres Strait Islander 
clients to feel confident in engaging with an HMR, the HMR needed to be organised and 
facilitated by AHS employees. This was also the finding of recent research which examined 
the views of Aboriginal and Torres Strait Islander patients who also identified the need to 
offer the option of having an AHW attend the HMR interview (7). Despite the 
acknowledgement by the Australian Government that pharmacies organising HMRs are 
entitled to a fee [4] there has been no acknowledgement of reimbursement for AHSs , which 
fulfil an even larger role in HMR facilitation for Aboriginal and Torres Strait Islander people. 
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Aboriginal Health Workers in this study identified the need for AHSs to have AHWs who 
specialised in assisting patients with medication management and who could facilitate the 
HMR process. Most AHWs were keen to undertake further training around medications as 
they saw assisting patients with their medications as an important part of their role. In the 
AHSs (n=3) which were initiating HMRs, a number of the AHWs were identifying patients 
and organising HMR referrals. All interviewees, including the GPs, were keen for nurses and 
AHWs to be allowed to write HMR referrals, seeing it as unnecessary for GPs to be involved 
in this process. Another study has requested community nurses be allowed to refer patients 
for HMR (14). A one-off HMR every 12-24 months was not seen as ideal. For complex 
patients with multiple medications, regular pharmacist interactions to reinforce medication 
messages is needed. 
Despite the Australian Government’s commitment to improving the health and wellbeing 
of Aboriginal and Torres Strait Islander Australians and closing the health inequality gap 
(15), Aboriginal and Torres Strait Islander health status remains poor and burdens of chronic 
diseases, such as respiratory disease, diabetes and cardiovascular disease, remain very high 
(16). A number of studies have identified that medication management is an important 
issue which urgently needs to be addressed if the progression of chronic disease and all the 
associated complications are to be slowed (10, 17-19). Although the Australian Government 
has implemented a number of programs to assist Aboriginal patients with financial barriers 
to accessing medicines, recent changes to the HMR program rules have increased the 
barriers to accessing HMRs, and thus exacerbated issues of medication management, 
efficacy, safety and adherence. Changes to the HMR program have purposively been 
implemented to curtail the number of HMRS being conducted to reduce expenditure in a 
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program with a capped budget [4]. These program changes have disproportionately 
affected those most in need, i.e. Australia’s sickest, elderly, rural and Aboriginal populations 
(6). 
The VALMER study was an economic evaluation of the HMR program by the University of 
Tasmania, which analysed 180 HMRS across Australia. It concluded that HMRs could 
significantly decrease healthcare utilisation costs as well as improving patients’ quality of 
life (20). Overall healthcare savings and benefits should be taken into consideration when 
funding for the Home Medicines Review program is assessed and guidelines rewritten in 
the Sixth Pharmacy Community Agreement 2015. New health models, such as shared 
medical appointments, which use group consultations to improve patient health, should be 
used to inform new HMR modelling and maximise outcomes from expenditure (21, 22). 
Recommendations from this study and from the 2008 Campbell evaluation report should 
be considered in developing an HMR model which is effective and culturally appropriate for 
Aboriginal and Torres Strait Islander people. 
5.3.5 Study limitations 
The sample of AHS health professionals who were interviewed was small, and the 
representatives of each profession even smaller, and therefore findings cannot be 
extrapolated to all AHS employees or across professions. The views of health professionals 
who work with Aboriginal and Torres Strait Islander people in settings other than AHSs were 
not sought. However, internal validity and reliability were achieved by questions about the 
same issues being asked numerous times, in appropriate, non-leading ways, and producing 
many similar findings in a range of different settings. Many of the findings in this study 
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endorsed results from research undertaken with Aboriginal and Torres Strait Islander 
patients (7)and pharmacists working with Aboriginal Health Services (9). 
5.3.6 Conclusion 
Increasing HMRs for Aboriginal and Torres Strait Islander people has the potential to 
increase patients’ medication knowledge and medication adherence, and thus improve 
chronic disease management (7). HMRs teach health service staff about their patients and 
about medications. HMRs provide GPs with invaluable information which assists them to 
more optimally manage their patients’ medications and health. 
Currently, very few HMRs are being conducted with Aboriginal and Torres Strait Islander 
people, largely due to lack of awareness, the paternalistic attitudes of some health 
professionals and the logistics of navigating the HMR program rules. The GPs at most AHSs 
are writing very few HMR referrals due to complexities of patients’ needs, shortage of time 
and lack of trust in pharmacists’ ability to appropriately manage their patients. 
Aboriginal Health Services, as the trusted brokers of Aboriginal social, emotional and 
physical wellbeing and with their understanding of community history and relationships, 
are well-placed to be the promoters, organisers, facilitators and implementers of health 
programs, such as HMR for Aboriginal and Torres Strait Islander clients. Within AHSs, staff 
juggle numerous programs and funding streams, and so the HMR program needs to be 
simplified, yet integrated within existing programs, and needs to have a “champion” in each 
health service to promote and drive the program. 
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The name of the HMR program and the myriad of HMR rules need to be changed and 
simplified. Referral, feedback and follow-up processes in particular need to be revised. 
Much work is needed to improve GP-pharmacist professional relationships and pharmacist-
AHS relationships. GPs, nurses and AHWs who have no previous experience with HMRs have 
little or no understanding of the role of a pharmacist. A big-picture approach is needed for 
the HMR program restructure, using evidence-based decision-making and Aboriginal 
community consultation. 
Imbedding a pharmacist within an Aboriginal Health Service, even in a part-time capacity, 
is a solution which addresses many of the barriers to HMRs which have been identified in 
this study. It enables the HMR program to be integrated with other services and assists GPs 
to offer optimal medication therapy. It ensures pharmacists are culturally mentored and 
that they build strong relationships with health professionals and patients. It encourages 
regular “coaching” of patients to assist medication adherence. If the Australian Government 
is to honour its commitment to improve Aboriginal and Torres Strait Islander health it needs 
to fund an uncapped medication review program and imbed salaried pharmacists within 
AHSs. 
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Chapter 6 
Pharmacists and Aboriginal Health Services 
6.1 Introduction to chapter 
This chapter contains an original research paper that has been published in a peer-reviewed 
journal. This paper explores pharmacists’ attitudes to the provision of pharmacy services, 
including HMR, to Aboriginal and Torres Strait Islander people and AHSs. 
This chapter reports the findings of the data analysis of a cross-sectional survey completed 
by 187 HMR-accredited pharmacists. The survey results showed that many pharmacists had 
little or no interaction with their local AHS and did not deliver professional pharmacy 
services, such as HMR, to the AHS clients. A number of survey respondents did not complete 
the survey questions pertaining to Aboriginal people. Only 88 participants completed all 
questions. It is surmised that some pharmacists did not complete all questions as they 
perceived that they had no Aboriginal clients. 
Lack of awareness of HMRs by AHS staff, and consequently a lack of HMR referrals, was the 
biggest barrier to HMR service delivery, together with lack of remuneration to pharmacists 
for professional services. The lack of relationship between the pharmacist and the AHS was 
also a significant barrier to delivery of services to the AHS. These findings concerning 
relationships and lack of referrals directly reflect the findings discussed in Chapter 5 when 
GPs expressed concerns about referring their patients to pharmacists. 
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Although most of the pharmacists had not delivered HMRs to Aboriginal people and had 
not tried to organise HMR interviews, some of the pharmacists perceived that interview 
appointments would be difficult to organise, thus exhibiting a somewhat racist perspective. 
Pharmacists reported little or no cultural understanding and training, but a real willingness 
to learn and to deliver more services to AHSs. 
6.1.1 What is known on this subject? 
Apart from a few individual pharmacist reports on their own work with Aboriginal and 
Torres Strait Islander people there is no research which examines pharmacists’ attitudes to 
service delivery to AHSs. 
6.1.2 What does this study add? 
The findings of this study will inform design of future medication programs for Aboriginal 
and Torres Strait Islander people. Pharmacists need assistance in brokering relationships 
with AHSs and GPs. The study findings confirm that pharmacists’ continuing professional 
development programs and pharmacy school curricula need to imbed cultural awareness 
training. 
6.1.3 Reference 
Swain L, Griffits C, Pont L, Barclay L. Attitudes of pharmacists to provision of Home 
Medicines Review for Indigenous Australians. International Journal of Clinical Pharmacy. 
2014;36:1260-7. 
A copy of the published paper can be found in Appendix E. 
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6.2 Manuscript abstract 
Attitudes of pharmacists to provision of Home 
Medicines Review for Indigenous Australians 
 
Background 
Home Medicines Reviews could improve the quality use of medicines and medicines 
adherence among Aboriginal people. Despite high levels of chronic disease very few Home 
Medicines Review are currently being conducted for Aboriginal and Torres Strait Islander 
people. 
Objective 
The aim of this research was to explore the barriers and facilitators from the pharmacists’ 
perspective for the provision of Home Medicines Review to Aboriginal people attending 
Aboriginal Health Services. 
Setting 
A cross- sectional survey was used to gather demographic, qualitative and quantitative data 
from 945 Australian pharmacists accredited to undertake Home Medicines Review. 
Method 
The survey consisted of 39 items which included closed, open-ended and Likert scale 
questions. Data were extracted from the online survey tool and analysed. Descriptive 
184 
 
statistics were used to explore the quantitative data, whilst qualitative data were 
thematically analysed and coded for emergent themes. 
Main outcome measure 
Number of Home Medicines Reviews conducted for Aboriginal and Torres Strait Islander 
patients. 
Results 
A total of 187 accredited pharmacists responded to the survey. They reported that barriers 
to Home Medicines Review for Aboriginal patients may include lack of understanding of 
cultural issues by pharmacists; lack of awareness of the Home Medicines Review program 
by Aboriginal Health Service staff; difficulties in implementation of Home Medicines Review 
processes; burdensome program rules; the lack of patient-pharmacist relationship, and the 
lack of pharmacist‒Aboriginal Health Service relationship. 
 Conclusion 
Changes to the medication review processes and rules are needed to improve the 
accessibility of the Home Medicines Review program for Aboriginal and Torres Strait 
Islander people. Improved relationships between pharmacists and Aboriginal Health 
Service staff, would increase the likelihood of more Home Medicines Reviews being 
conducted with Aboriginal and Torres Strait Islander patients. 
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Impact of findings on practice 
Currently, there is no comprehensive data as to why Aboriginal people are under-utilising 
Home Medicines Reviews and other pharmacy services from the pharmacists’ perspectives. 
 The findings from this study: 
 Inform future policy and medication initiatives for Indigenous Australians 
 Identify gaps in pharmacists’ education and ability to work inter-professionally 
 Identify facilitators for increasing pharmacist delivery, and patient accessibility, of 
clinical pharmacy services, such as medication review. 
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6.3 Manuscript full text 
Attitudes of pharmacists to provision of Home Medicines Review for 
Indigenous Australians 
6.3.1 Introduction 
The Australian Home Medicines Review (HMR) is a professional pharmacy service that aims 
to achieve safe, effective and appropriate use of medicines and to improve the health 
outcomes and knowledge of medicines in participating patients (1). Studies show that 
HMRs can improve medication suitability, reduce adverse drug events, increase patient 
medication knowledge and improve adherence rates (2, 3). 
The HMR program (1) was introduced in Australia in 2001 by the Commonwealth 
Government. On a referral from the GP, an HMR trained and accredited pharmacist will visit 
the patient at home, and interview the patient about their medication and lifestyle. The 
pharmacist explains the medications and provides appropriate medication information to 
the patient. The pharmacist then prepares a report of their findings, using information 
provided by the patient, medical information provided by the GP and the patient’s 
dispensing history from the pharmacy. The accredited pharmacist reports the findings and 
their recommendations to the referring GP. This report forms the basis of the Medication 
Management Plan which the GP may implement with the patient on their next visit. The GP 
and pharmacist claim payment from Medicare Australia. 
Indigenous Australians have poorer health, higher rates of chronic disease and lower 
average life expectancy than non-Indigenous Australians (4). Despite a higher burden of 
acute infections and chronic diseases, under-use of medicines is evident in Australian 
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Aboriginal populations (5). Poor control of chronic disease states and subsequent higher 
hospital admissions, morbidity and mortality may be directly attributable to poor medicine 
management in Indigenous communities (6). 
Qualitative, interview-based studies have explored perspectives of Aboriginal patients and 
Aboriginal Health Workers (AHW) as to why medications are under-utilised by Aboriginal 
and Torres Strait Islander people. They have identified lack of knowledge and 
understanding about medicines and ineffective engagement with health professionals as 
the two biggest barriers to appropriate medication use (7-11). 
Complex medicine regimens result in some Aboriginal and Torres Strait Islander patients 
finding medicines confusing and difficult to manage. Greater understanding and 
empowerment about medicine choices seem to be likely to improve medicine adherence 
(10). Pharmacists through cognitive pharmacy services, such as Home Medicines Review, 
have an opportunity to build relationships, increase patients’ knowledge about their 
medicines, and assist Aboriginal and Torres Strait Islander patients with medication 
understanding and treatment choices (10). 
Aboriginal and Torres Strait Islander patients have identified some of the reasons why the 
HMR program is under-utilised by Aboriginal people. These include the need for a GP to 
write HMR referrals, lack of relationship with a pharmacist, the inappropriateness of a 
pharmacist visiting an Aboriginal patient’s home and lack of understanding of the benefits 
of the HMR program (12,13). 
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This study explored pharmacists’ attitudes to the delivery of HMRs to Aboriginal and Torres 
Strait Islander people and contributed to knowledge of the processes and supports needed 
to enable increased HMR delivery to Aboriginal and Torres Strait Islander people. 
6.3.2 Aim 
The aim of this research was to explore the barriers and facilitators, from pharmacists’ 
perspectives, for the provision of HMRs and other pharmacy services to Aboriginal people 
attending the Aboriginal Health Service. 
Ethical approval was granted from the University of Sydney, Human Research Ethics 
Committee (approval number: 11504). 
6.3.3 Methods 
Data collection 
A cross-sectional survey was used to gather demographic, qualitative and quantitative data 
on the barriers and facilitators to the provision of professional pharmacy services and HMRs 
to Indigenous Australians. A literature review and results from preliminary qualitative 
studies (10,13) were used to guide the survey design. 
The survey was sent to pharmacists accredited to undertake HMRs in September 2012. At 
that time, email contact details were listed for 983 HMR-accredited pharmacists across 
Australia on the online database of the accredited pharmacists’ credentialing body, the 
Australian Association of Consultant Pharmacists (14). The researcher successfully 
contacted 945 of those listed online, with the other 38 having incorrect email addresses. 
Thus, the majority of accredited pharmacists listed were invited to participate in the study. 
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They were each emailed an invitation to participate in the study, containing a hyperlink to 
an online survey. 
The survey consisted of 39 items which included closed, open-ended and Likert scale 
questions. Survey questions explored types of services provided by respondents to 
Aboriginal Health Services (AHSs), pharmacist attitudes to working with AHSs, and the 
barriers and facilitators impacting on the provision of HMRs to Aboriginal and Torres Strait 
Islander people. The respondents were also asked a range of general demographic 
questions. The survey was piloted on 8 accredited pharmacists working in community 
pharmacy, hospital pharmacy and academia. As a result of the pilot the question order was 
changed slightly to make question progression more relevant, and the wording of one 
question was altered to clarify meaning. The results of the pilot were included in the 
analysis. 
Interactions and relationships between pharmacists and AHSs were explored in this study 
as AHSs have been identified as playing a key facilitating role in the successful organisation 
and implementation of HMRs for Aboriginal people (13). 
Data analysis 
Data were extracted from the online survey tool (Survey Monkey) and analysed using Excel 
2007. Descriptive statistics were used to explore the quantitative data, whilst qualitative 
data were thematically analysed and coded for emergent themes. 
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6.3.4. Results 
This study explored the pharmacist perspective on the provision of HMRs to Aboriginal 
Australians to inform better understanding of the under-utilisation of HMRs and to gain 
insight into strategies for increasing HMR provision. 
Participants 
Of the eligible participants, 187 pharmacists responded to the survey, representing a 
response rate of 19.7%. Not all respondents answered all questions. Only 88 respondents 
(n=88/945 9.3%) answered the specific questions around working with AHS staff and 
conducting HMRs for Aboriginal patients. This appears to reflect the small sample of 
pharmacists who are engaged with delivering services to AHSs. 
Approximately 23% of Australia’s pharmacists reside and work in non-urban areas, mainly 
in rural areas and their regional towns. The number of pharmacists decreases with 
increasing rurality, and only 1% of Australia’s pharmacists work in areas classified as remote 
(15). Over 50% of the survey participants were from rural areas and regional towns, 4% 
identified their workplaces as remote, and approximately 40% were from urban areas. The 
higher level of rural than urban responses may reflect the higher percentage of Aboriginal 
and Torres Strait patients in rural and remote areas, and thus a greater interest in 
completion of this survey by pharmacists in those areas. 
 Over 40% of respondents were community pharmacists, and 46.7% identified themselves 
as consultant pharmacists, thus implying that their primary occupation was to conduct 
medication reviews. 
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Most of the respondents regularly conducted HMRs, with over half conducting over 5 HMRs 
per month and about a third conducting more than 10 HMRs per month. However, only a 
quarter of respondents had conducted more than 5 HMRs for Aboriginal patients in the last 
3 years, and about half of respondents had not conducted any HMRs for Aboriginal people 
in the last 3 years. Demographics and HMR activity of respondents is summarised in Table 
6.1. 
Pharmacist engagement with Aboriginal Health Services 
More than half of the respondents (59.1% n=97/164) indicated they worked within 30 km 
of an Aboriginal Health Service (AHS). However, close to one-third of respondents (28.7% 
n=47/164) did not know how far they were from their local AHS. This may be indicative of 
limited interaction with their local AHSs. 
Despite the close geographical proximity to AHSs, most respondents and their staff (72.6% 
n=119/164) had not visited an AHS in the previous 12 months, and 55.5% (n= 91/164) had 
had no contact with the AHS. For the 45% of the respondents who had had a contact with 
the AHS, the contact was most commonly by phone (47.7% n=42/88). The main purpose for 
contact was medication supply and dispensing queries. Their most common contact was 
with the prescribing GP. Only 17% (n=15/88) of respondents indicated that their 
engagement with the AHS related to patient medication counselling, and 63% (n=55/88) of 
respondents identified that they had not provided any Quality Use of Medicine Services to 
AHSs. Thirty-two percent of respondents (n=28/88) provided Dose Administration Aids 
(DAAs, often called Webster packs) to their local AHS. 
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Table 6.1: Demographic and HMR profile of respondents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key: HMR=Home Medicines Review 
Demographic Options % of respondents  
Location Remote  3.7%(n=7/187) 
Rural 20.3% (n=38/187) 
Regional 34.8%(n=65/187) 
Urban 41.2% (n=77/187) 
Primary role Community pharmacy 
owner 
15.5% (n=29/187) 
Pharmacist in charge 11.8% (n=22/187) 
Community Pharmacist 12.3% (n=23/187) 
Hospital Pharmacist 8.0% (n=15/187) 
Consultant Pharmacist 46.0% (n=86/187) 
Other 6.4% (n=12/187) 
HMRs per month 0 6.7% (n=11/164) 
1 to 4 35.4% (n=58/164) 
5 to 10 26.2% (n=43/164) 
> 10 31.7% (n=52/164) 
HMRs over last 3 years 0 47.6% (n=78/164) 
For Indigenous 
Australians 1 to 4 
27.4% (n=45/164) 
 5 to 10 11.0%( n=18/164) 
 11 to 20  6.7% (n=11/164) 
>20 7.3% (n=12/164) 
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The vast majority of respondents (89.6% n=147/164) indicated that they would like to have 
provided more services to their local AHSs. They indicated that they would like to provide 
services such as HMRs (72.5% n=119/164), AHS staff education (49.4% n=81/164) and 
health promotion assistance (54.0% n=88/164). 
The two largest barriers to working with an AHS were identified as lack of relationship with 
the AHS (57.9% n=95/164) and lack of financial viability for delivering clinical services to the 
AHS (61.6% n=101/164). 
Home Medicines Reviews for Aboriginal and Torres Strait Islander people 
Perceived benefits: Respondents expressed high to very high agreement that an HMR would 
result in an increased understanding of their illness (72.7% n = 64/88) and an increased 
understanding of how to take medicines (84.1% n = 74/88). Similarly, respondents agreed 
that an HMR would increase the understanding of potential medication side-effects (71.2% 
n=62/88), improve medication adherence (69.3% n=61/88), improve pharmacist-patient 
relationships (77.7% n=66/88) and encourage patients to ask more questions about their 
medicines (68.2% 60/88). 
Perceived barriers: Lack of GP referrals (74.7% n=121/164), lack of pharmacist time (40.5% 
n=66/164) and low financial viability (16.6% n=27/164) were seen as barriers to delivery of 
HMRs to all population groups. 
Barriers to delivery of HMRs to Aboriginal patients also included difficulties in organising 
HMR interviews (57.4% n=51/88) and lack of understanding of cultural issues (49.4% 
n=43/88). Over half the respondents (52.8% n=47/88) also had a perception that Aboriginal 
patients may not want “a stranger in their home”, and 53.4% (n=47/88) expressed some 
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concern that the lack of an existing patient‒pharmacist relationship could cause a barrier 
to the delivery of HMR services to Aboriginal patients. By far the biggest perceived barrier 
(79.5% n=70/88) was lack of awareness of the HMR program by GPs and AHS staff. Barriers 
to the provision of HMRs for Aboriginal patients are summarised in Table 6.2. 
Table 6.2: Respondents’ perceptions of barriers to the provision of HMRs to Aboriginal 
and Torres Strait Islander patients 
Respondent Perceptions Percentage of Respondents 
n=164 Not at all 
Small to moderate 
degree 
High to very high 
degree 
Lack of awareness of HMRs 
by GPs/AHSs  
6.8% 
 
38.6% 
 
54.5% 
 
Organising an HMR referral  15.9% 39.8% 44.3% 
Lack of patient interest  14.8% 57.9% 27.3% 
Patient not wanting a 
stranger in their home  
20.5% 53.4% 26.1% 
Difficulties in organising 
appointments  
13.6% 62.5% 23.8% 
Liaising with AHW/AHS  31.0% 49.4% 19.5% 
Understanding cultural issues  19.5% 60.9% 19.5% 
Liaising with patient’s doctor  30.7% 47.7% 19.3% 
Effectively communicating 
with patients 
28.7% 54.0% 17.2% 
Providing feedback to 
patients  
28.7% 63.2% 8% 
Key: AHS=Aboriginal Health Service; AHW=Aboriginal Health Worker; GP=General 
practitioner; HMR=Home Medicines Review  
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Respondents who had conducted an HMR with an Aboriginal patient identified that the GP 
was responsible for organising the majority of the referrals (77.5% n=69/88) whilst the 
pharmacist was responsible for organising the majority of the interviews (74.2% n=66/88). 
Difficulty organising an HMR referral was rated by the majority of respondents to have a 
high or very high impact on the provision of HMRs. A few respondents’ comments indicated 
that they felt some GPs did not highly rate HMRs. 
“Prescribers do not see the benefit in a HMR and may not feel a pharmacist can add 
any more insight than themselves.” 
Just over half of the respondents (56.1% n=92/164) identified lack of professional 
relationships with their local AHS as the greatest barrier to providing professional pharmacy 
services to Indigenous communities. The pharmacy-AHS relationship was identified by 
39.0% (n=64/164) of the respondents to highly or very highly impact on their ability to 
provide services to the AHS. 
Other barriers to HMR delivery to Aboriginal patients were also suggested by respondents 
in their answers to the open-ended qualitative questions. These included difficulty 
allocating time for HMRs due to current work commitments, difficulty co-ordinating 
pharmacy opening times and visits to the AHS, excessive amounts of paper work, restrictive 
program rules and inconsistent HMR demand. 
Whilst some respondents indicated that they felt visiting Aboriginal patients’ homes was 
not always culturally appropriate, most of the HMRs (83% n=73/88) that had been 
conducted by respondents had been performed in the homes of the patients, and were by 
appointment (88.6% n=78/88), as per the HMR program regulations. However, a few 
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respondents indicated that as regulations make it very difficult to conduct HMRs in a venue 
other than the home that many patients were opting not to use the service. 
“By far the main barrier to doing HMRs in this area is the unwillingness of Aboriginal 
people to have visitors in their homes. The only viable method of doing HMRs for 
Aboriginal people in this community is on an opportunistic basis in the pharmacy. 
But this is not allowed.” 
The majority of respondents (69.5% n=114/164) indicated that they had never received any 
form of cultural awareness training or training relating to Aboriginal health or engagement 
with Aboriginal patients. Approximately half (49.4% n=43/88) of respondents felt that their 
lack of understanding of cultural issues impacted to a moderate to high degree on their 
ability to conduct HMRs for Aboriginal patients. 
Facilitators to HMR 
Greater involvement of AHS staff in the HMR process was seen as a facilitator for HMR 
delivery to Aboriginal patients. Although AHWs played no role in close to half of the HMRs 
(46.6% n=41/88) which had been conducted with Aboriginal patients, study participants 
expressed their desire for greater AHW or AHS nurse involvement, stating: 
“It would be great to have the nurse and a health worker present during interview 
and involved in follow-up discussions, especially regarding disease management 
and continuity of care.” 
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When AHWs were involved in HMRs it was to liaise with pharmacists and patients (38.6% 
n=34/88), to help organise HMRs (22.7% n=20/88), to help in the follow-up process (17% 
n=15/88) or to act as an interpreter (10.2% n=9/88). 
The majority of respondents (90.8% n=79/88) believed that allowing an AHW or AHS nurse 
to write HMR referrals would facilitate more HMRs being performed for Aboriginal patients, 
especially when GPs were time-poor and where there was high reliance on locum GPs. 
Participants commented: 
“The GPs want more HMRs done but don't want to have to do all the paperwork. It 
would be great if AHWs and nurses could write the referrals as they know which 
patients would benefit and usually have more time than the GPs.” 
Most respondents felt that it was appropriate for AHS nurses and AHWs to be involved in 
the referral process as “the nurses and AHWs are closer to the patient and are more likely 
to identify medicine issues”. 
A small number of respondents reflected the opinion, “Working at the AHS would be a 
great job. I could make a real difference. It is a pity that there is no funding to support this”. 
6.3.5 Discussion  
Although the respondents in this study were HMR-accredited pharmacists who conducted 
regular HMRs, over 70% of respondents had conducted fewer than 5 HMRs for Aboriginal 
people in the last 3 years. These findings endorsed those in earlier government reports 
which identified that very few HMRs have been performed for Aboriginal and Torres Strait 
Islander people (16,17). In 2013 approximately 107,000 HMRs were conducted across 
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Australia (18). However, there are no available statistics on how many of these were 
conducted for Aboriginal and Torres Strait Islander people. 
More than half of the respondents had no contact with their AHSs and very few had been 
involved in Aboriginal patient interaction; yet many of the pharmacists who participated in 
this study wanted to interact with their local AHSs and staff. This reflects similar studies 
which indicate that pharmacists are keen to work more closely with mainstream GP 
practices and deliver inter-professional healthcare, but are unsure as to how to facilitate 
the process (19-20). Studies have found that pharmacists are not confident in clinical 
decision-making, largely due to personality type and professional training (21-23). More 
investigation is needed to explore whether these factors influence pharmacists’ ability to 
engage with other health professionals and build relationships with other primary 
healthcare organisations. 
The respondents expressed an interest in delivering clinical services to the AHS if they could 
make the services financially viable. Respondents expressed the need for a suite of services 
for which they could be remunerated or the need for a salaried position within an AHS or 
GP practice to enable viability, sustainability and relationship building. Currently, the HMR 
program is the only clinical service in Australia for which a pharmacist can claim financial 
reimbursement from the Government. 
Pharmacists received $194.07 (AU) remuneration for an HMR service (in 2014) (1) but have 
suggested in this study and in other evaluations that HMRs are not financially viable due to 
the large amount of time required for HMR administrative costs (16,17) This lack of financial 
viability is exacerbated when the pharmacist has to travel large distances to patients’ 
homes, especially in rural areas; when a pharmacist has to apply for a prior approval so that 
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they can conduct an HMR outside a patient’s home; and when a patient has multiple co-
morbidities, multiple healthcare providers and complex medication regimens (24). 
Discussions between the Pharmacy Guild of Australia and the Australian Department of 
Health have commenced in preparation for negotiation of the Sixth Community Pharmacy 
Agreement (6CPA) by July 2015. These five-year Community Pharmacy Agreements provide 
remuneration and guidelines to around 5000 community pharmacies for the dispensing of 
Pharmaceutical Benefit Scheme subsidised medicines and the provision of pharmacy 
programs and services. Revised remuneration levels and program rules for HMR will be 
stipulated in 6CPA, and it is hoped that this study may persuade policy-makers that current 
remuneration levels for clinical services are inadequate and unsustainable. Pharmacy 
educators, organisations and policy-makers also need to be working with the Australian 
Government to develop service delivery models where pharmacists are remunerated for 
working in inter-professional primary healthcare settings, such as AHSs. 
The majority of respondents found the main barrier to delivery of clinical services, such as 
HMR to Aboriginal patients, was their lack of relationship with the AHS, despite dispensing 
and supplying DAAs, to the AHS and its patients. This lack of relationship with the AHS may 
reflect the lack of training of pharmacists in Aboriginal health and cultural awareness. The 
National Australian Pharmacy Student Association conducted a survey of students in 2012 
which showed that students felt it was important to be taught about Aboriginal and Torres 
Strait Islander health issues, but many pharmacy school curricula include very little or no 
content on Aboriginal health or cultural awareness (25). Respondents in this study indicated 
that they would like more education on issues of Aboriginal health and cultural awareness. 
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This study will be used to inform pharmacy schools of the need for increased cultural 
awareness training and Aboriginal Health education for pharmacy students. As a result of 
this study the main author is commencing work with the Pharmaceutical Society of Australia 
to develop a guide and a series of workshops for Australian pharmacists to assist them to 
be culturally responsive practitioners and assist them to engage with Aboriginal Health 
Services. 
The respondents in this study, similar to other HMR studies with non-Indigenous Australians 
(26, 27), indicated that two significant barriers to HMR program uptake were lack of 
awareness of the program by health professionals and lack of GP referrals. Studies have 
also found that some GPs often do not value the role of pharmacists in performing 
medication management review (16, 17). Research has also suggested that due to time 
constraints GPs often find it difficult to fulfil the administrative requirements of HMR 
referrals, as the current process is complex (16). An Urbis Keys Young evaluation (2005) of 
the HMR program found that incomplete or unclear referral forms from the GPs hindered 
the HMR process. This evaluation also found that the majority of accredited pharmacists 
believed GPs were unaware of HMRs and were reluctant to collaborate professionally with 
pharmacists (17). 
In February 2014 a lack of funding for the HMR program, under the Government - Pharmacy 
Guild agreement, resulted in the number of HMRs a pharmacist performed being capped 
at 20 HMRs per pharmacist per month (1). This capping of HMR program funding has 
negated the ability to promote HMRs to a wider audience despite the evidence that 
indicates the improved health outcomes and reduced preventable hospitalisations that 
result from medication reviews (2, 3, 28). Respondents in this study strongly indicated that 
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they believed that HMRs could greatly assist Aboriginal patients to better understand their 
medicines and health, and could improve medication adherence. 
The views of the pharmacists in this study reflected the views of Aboriginal patients in a 
recent study (13) which indicated that barriers to HMR for Aboriginal patients included the 
“home setting”, and the complex referral and interview arrangements. The pharmacist 
respondents noted the need for a closer relationship with the AHS and the AHS staff, to 
ensure successful implementation of the HMR process. This confirms previous studies 
which emphasise the important role the AHS plays in delivering primary care to Aboriginal 
people (29-31). 
Respondents acknowledged that GPs in AHSs are often overloaded or are transitory, and 
thus nurses and AHWs are often the primary contacts with patients. Respondents strongly 
endorsed greater involvement of AHS nurses and AHWs in the HMR process, from initial 
referral to follow-up post pharmacist intervention. The vast majority of pharmacists 
surveyed suggested allowing AHWs or AHS nurses to write HMR referrals and play a more 
key role in the HMR process to help facilitate good communication during the HMR 
interview and to aid in the administration procedures of the interviews and follow-ups (14-
18). 
The expanded role for AHS staff and the ability to conduct an HMR in a setting other than 
the home, were also identified as facilitators to increasing the number of HMRs for 
Aboriginal patient participants in a previous study (13). 
This study will be used to advise 6CPA negotiations of the need for changes to HMR 
program rules and suggest new and more appropriate medication review models for 
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Aboriginal and Torres Strait Islander people. The new models will suggest that medication 
reviews for Aboriginal and Torres Strait Islander people be uncapped in number, allow 
referrals from nurses, Aboriginal Health Workers and doctors, and allow flexibility of 
location. 
The issues of financial viability, lack of GP referrals and lack of program awareness were 
consistent with barriers identified by pharmacists in HMR studies with other population 
groups. The lack of ability to build relationships with Aboriginal health Services is a unique 
finding of this study and needs further investigation. 
6.3.6 Limitations 
Some of accredited pharmacists who were not regularly working with Indigenous patients 
were reluctant to participate in the survey. Several pharmacists contacted the authors to 
support the work but believed they could not contribute to the survey as they did not work 
with Aboriginal patients. Consequently, there was a limited sample, and the results of this 
study may under-estimate the barriers to performing HMRs for Aboriginal Australians. 
This study does not analyse the views of pharmacists working with AHSs who are not 
accredited to perform HMRs. Non-accredited pharmacists may be providing pharmacy 
services to AHSs. However, their views on the barriers and the facilitators to providing 
pharmacy services for Aboriginal Australians have not been captured in this study. 
6.3.7 Conclusion 
This study showed that HMR-accredited pharmacists are currently providing very limited 
clinical pharmacy services to Aboriginal Australians. Accredited pharmacists were very keen 
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to provide more services to AHSs. However, assistance and training to overcome the 
barriers which are inhibiting them from working more closely with AHSs and AHS staff are 
needed. Pathways and mechanisms to facilitate increased relationship building between 
pharmacists and other health professionals, and with primary care organisations, such as 
AHSs, need to be further investigated. 
 Increased promotion of the HMR program, GP education, increased and consistent 
financial remuneration to pharmacists, changes to the HMR referral process, improved 
relationships between pharmacists and AHS staff, and increased involvement of AHS staff 
in the HMR processes are needed to increase HMR delivery to Aboriginal and Torres Strait 
Islander people. 
Future government policies need to support and encourage pharmacists to conduct 
medication reviews for Aboriginal and Torres Strait Islander patients. 
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Chapter 7 
Discussion 
 
7.1 Introduction 
 
This chapter relates the main findings from all phases of this study to previous research and 
the available literature. Whilst this study explores medication management for Aboriginal 
and Torres Strait Islander people, most existing literature on medication management and 
medication review is based on studies with non-Indigenous people. In this chapter I draw 
conclusions and make recommendations based on the analysis and synthesis of the data 
generated in this study and use literature to position the findings. 
This aim of this study was to investigate how pharmacists, through the national HMR 
program (1), might better address the medication management needs of Aboriginal and 
Torres Strait Islander people. The barriers and facilitators to utilisation of the HMR program 
and medication review program modifications were investigated. To achieve this, three 
empirical studies were conducted. 
Aboriginal and Torres Strait Islander patients’ experiences with medicines were explored, 
as were their views of the HMR program. Aboriginal Health Service health professionals’ 
perceptions of the HMR program and their suggestions for an “improved” or more readily 
accessible model of medication review service were analysed. Pharmacists’ attitudes to 
provision of services to AHSs were examined. 
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Aboriginal Health Service staff assisted in facilitating focus groups with patients and 
interviews with health professionals. Aboriginal Health Services were used as sites for this 
research as they provide culturally safe places for Aboriginal and Torres Strait Islander 
people (2). The AHSs deliver holistic care and are often multi-disciplinary. However, most 
do not include a pharmacist in their multi-disciplinary teams. 
The views and perceptions of Aboriginal and Torres Strait Islander patients, AHS service 
providers and HMR-accredited pharmacists are amalgamated to inform the conclusions of 
this research. The importance of relationship, trust and culturally sensitive health 
professionals were recurrent themes. 
7.1.1 Research questions 
The goal of this study was to investigate how medication management programs, such as 
HMR, might address the needs of Aboriginal and Torres Strait Islander people. The following 
research questions were explored: 
1. What are the experiences and perceptions of Aboriginal and Torres Strait Islander 
people regarding taking medicines? 
2. What are the experiences and perceptions of Aboriginal and Torres Strait Islander 
people of the HMR program? 
3. What are the attitudes and perceptions of AHS service providers of the HMR 
program? 
4. What are the barriers and facilitators, from pharmacists’ perspectives, for the 
provision of pharmacy services, including HMR, to clients attending an AHS? 
211 
 
5. What strategies or program changes are needed to increase utilisation of the 
medication review programmes by Aboriginal and Torres Strait Islander people? 
7.2 Main findings 
7.2.1 Medication management 
Findings from this study confirmed previous research which reported that Aboriginal and 
Torres Strait people found medicines confusing and difficult to manage (3-5). The findings 
also reiterated that the level of Aboriginal and Torres Strait Islander people’s engagement 
in their health management often directly reflected the effectiveness of communication 
between patient and health professional, the level of patient empowerment and 
involvement in collaborative decision-making, and the cultural appropriateness of available 
health services (6-8). Prior experiences of individual or organisational racism and power 
imbalance influenced perceptions of health services by Indigenous patients (9-11). 
Australia’s mainstream medical model often focuses on compliance with medical advice 
and frequently ignores the complex historical and sociocultural influences that shape 
patients’ responses to their health and healthcare. Murray, an experienced remote medical 
practitioner and researcher, laments that non-compliance is an unhelpful construct used by 
health professionals with Aboriginal patients, and reflects that non-compliance is often 
used to defend poor standards of clinician practice (12). Murray feels that it is the clinician’s 
responsibility to ensure a patient’s understanding of the reasons for treatment, and that 
the prescriber should assess and discuss any barriers a patient may face (12). 
212 
 
Poor adherence to prescribed medication is documented and associated with adverse 
health outcomes in all population groups (5). Whilst accepting that compliance or 
adherence often has negative and judgemental connotations, it is appropriate to discuss 
medication adherence here in the context of how to improve health outcomes through 
improved clinician interactions and to examine the potential role of HMRs in improving 
medication adherence. 
The AHS health professionals in this study reported anecdotally that many of their patients 
were medication non-adherent (13). This may reflect the low levels of medication 
adherence for all population groups with chronic disease (14, 15) or may indicate even 
higher levels of medication non-adherence for Aboriginal and Torres Strait Islander people. 
Although the literature on health professionals working with Indigenous patients reports 
higher levels of non-adherence in Indigenous communities (16, 17), there are actually no 
conclusive comparative studies which measure medication adherence in Aboriginal and 
Torres Strait Islander people against other population groups. However, research does 
show that low patient self-efficacy, depression and stress, low education, low outcome 
expectations, fear of adverse effects and lack of knowledge of medication benefits, all 
negatively influence medication adherence (18-20). 
The majority of patients in this study reported they tried to be medication adherent. 
However, forgetfulness, financial pressures and other priorities, such as managing family, 
often reduced the likelihood of medication adherence (21). Lack of knowledge of medicines, 
polypharmacy and the fear of drug interactions and adverse effects were also mentioned 
as key factors contributing to poor medication adherence (21). Previous studies have shown 
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that pharmacist interventions and/or counselling can improve medication management 
and adherence in non-Indigenous populations (22-24). 
Previous studies have shown that communication failures between patients and health 
professionals and insufficient patient counselling about medicines, contribute to 
preventable hospital admissions (25). Patients in this study indicated that they received 
little or no medication counselling (21). Effective communication between health 
professional and patient is fundamental to optimal healthcare (26). This study, like previous 
studies, has identified significant concerns regarding communication between health 
professionals and Aboriginal and Torres Strait Islander patients (21, 27, 28). 
Very few of the patients in this study had asked their GP or pharmacist about their 
medicines, reflecting lack of relationship, power imbalance and sometimes lack of trust 
between some health professionals and patients. Many patients felt disempowered, too 
shy, ashamed or too ignorant to ask questions. For those who felt they could ask questions, 
it was usually to the GP or AHW rather than to the pharmacist, as they had a closer 
relationship with the GP and AHW than with the pharmacist and because they perceived 
that their community pharmacists were too busy or disinterested (21). The findings in the 
pharmacist survey section of this study confirmed that very few pharmacists had interacted 
with or counselled their Aboriginal clients (29). 
Most the GPs who participated in this study were unaware of their patients’ confusion 
about medicines. The majority of GPs in this study felt that their communications about 
medicines were effective and adequate. However, a few admitted that they did not 
prioritise medicine discussions with their patients (13). A quarter of the nurse and GP 
participant sample exhibited paternalistic attitudes, stating that Aboriginal and Torres Strait 
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Islander people were not interested in receiving medication information or reviews (13). 
This differs from what the Aboriginal and Torres Strait Islander patients in this study 
reported (21). The Aboriginal and Torres Strait Islander study participants stated that they 
received little or no medicines information, and that they wanted to know what medicines 
were for, how they worked and how to take them, as well as be informed of potential 
adverse effects or interactions (21). The gap between nurse-GP perceptions and patients’ 
perceptions indicates a real need for pharmacists to play an increased role in medication 
education. 
Many patient participants had little understanding of the role of a pharmacist and found 
community pharmacies uncomfortable environments for discussion of health, and some 
reported racist experiences in pharmacies (21). For some participants, confusion and poor 
explanations of the pharmacy program and dispensing rules, such as the 20-day rule, 
generic substitution and GP endorsement of “Closing the Gap” prescriptions (30), had 
reduced patient-pharmacist trust (21). Some participants commented that their only 
communications with pharmacists had been concerning these procedural issues rather than 
on matters concerning their health. Further studies need to be conducted into how complex 
and inflexible pharmacy program rules may damage pharmacist-client relationships and 
how this may impact medication management. 
The majority of AHSs participating in this study, although recognising that medication non-
adherence was negatively influencing the health of their clients, had not implemented any 
comprehensive medication management services. A few AHSs had organised for Dose 
Administration Aids for their clients to be financially subsidised (via QUMAX or Care 
Coordination and Supplementary Services (CCSS) funding (31)) but recognised that this only 
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assisted those clients who were non-adherent due to forgetfulness, without addressing the 
many other barriers to medication adherence and safe use of medicines (3, 5, 32, 33). Some 
of the participating AHS staff expressed concerns that pharmacists were too busy or not 
culturally competent to manage their clients (13). Most of the pharmacists who participated 
in this study did not work closely with their local AHS staff or clients to improve medication 
management (29). Many of the pharmacists expressed a desire to work more closely with 
AHSs but were uncertain as to how to broker a relationship which would facilitate a more 
collaborative approach to patient management (29). 
The Aboriginal and Torres Strait Islander participants in this study expressed a desire to 
better understand their medicines, to be provided with more medication information and 
to be given resources and tools to assist them with managing their medicines (34). 
Specifically, they requested written information in simple, plain English, and a medication 
history list. Very few, including those who had participated in HMRs, had received any 
written information. The majority of patients and AHS staff in this study supported a 
medication review process which might assist better medication management and 
adherence (34). 
The majority of nurses and AHWs in this study reported that they would benefit from more 
medication education training (13). The GPs in this study also commented that assistance 
with therapeutic decision-making and learning more about medicines were valued 
outcomes from their HMR interactions with pharmacists (13). 
This study found that many Aboriginal and Torres Strait Islander people in urban and rural 
settings had little or no relationship with community pharmacists and received little or no 
medication counselling, even though they had access to pharmacies (21). In some remote 
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areas there are no community pharmacies, often little or no pharmacy services, and no 
pharmacist-patient interactions (35). 
More interaction between pharmacists and Aboriginal and Torres Strait Islander people in 
all settings is needed to assist chronic disease management, safe and effective medication 
use and improved health outcomes. The pharmacist participants in this study indicated that 
they would like to provide HMRs, medication education and health promotion assistance 
but were hindered from doing so due to lack of remuneration models and lack of 
relationship with the AHS and its staff and patients (29). 
Similar to other GP settings, co-locating a pharmacist within an AHS may enable the 
pharmacist to address the medication education needs of health service staff, develop 
relationships with staff and patients, develop resources and protocols, conduct effective 
medication counselling with patients and perform a liaison role with the community 
pharmacy (36-38). 
7.2.2 Medication review 
Medication reviews are useful 
Despite the high burden of chronic disease and the resultant multiple medicines prescribed, 
very few Aboriginal and Torres Strait Islander people are referred for HMR (39, 40). Previous 
studies indicate that medication review may reduce hospital readmissions, improve 
medication knowledge, improve medication adherence, reduce inappropriate prescribing 
and improve health outcomes (41-45). 
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An evaluation of HMR eligibility criteria in 2014 recommended patients’ eligibility for an 
HMR be based on needs categorisation (46). This needs categorisation and refined eligibility 
were designed to reduce over-usage or injudicious usage, and subsequent cost blow-outs, 
of the HMR program. The evaluation identified patients who had chronic disease and/or 
complex management requirements, in addition to instability of health status and 
likelihood of compromised adherence, as being at high risk of medication misadventure. 
This high risk of medication misadventure, together with the poor health status of many 
Aboriginal and Torres Strait Islander patients, should result in unquestioned eligibility and 
prioritisation of Aboriginal and Torres Strait Islander people for medication review. 
Investment in medication review for Aboriginal and Torres Strait Islander people could 
significantly improve health outcomes (e.g. reduced renal dialysis from poorly controlled 
hypertension and/or diabetes) and reduce hospitalisations, and should result in a significant 
net saving to the state and national health budgets. Significant investment to increase 
awareness and implementation of medication review programs in AHSs is needed. 
Awareness of the existence of the HMR program was low among many of the patients, AHS 
nurses and AHWs who participated in this study. Similarly, low HMR awareness and lack of 
understanding of HMR were found by other studies in other demographic groups (47-49). 
As in previous studies, the awareness by GPs of the mechanics of how and when to refer a 
patient for an HMR was also found to be low in this study (13, 50). The 2015 evaluation of 
Fifth Community Pharmacy Agreement programs (5CPA) found that consumers had 
difficulty accessing programs due to low awareness and low GP engagement, and that this 
was especially the case for Aboriginal and Torres Strait Islander people and other CALD 
people (51). 
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Some patients involved in this study expressed frustration that they had not been informed 
of this “useful” HMR program previously. This study has not recorded the number of HMRs 
due to difficulty in obtaining accurate data. Aboriginal identity of HMR participants is not 
confirmed or recorded as part of the HMR process, and so there are no accurate data about 
the number of HMRs being conducted with Aboriginal and Torres Strait Islander people. 
Even within each AHS site the number of HMR referrals may show great variability over a 
period of time, reflecting fluctuations in AHS staffing and awareness, and the availability 
and prioritisation of the HMR program by individual staff members. 
Most of the health professionals in this study were supportive of the HMR program 
benefits, and stated that potential drug interaction and adverse-effect advice from the 
pharmacist were important HMR outcomes (13). Both patients and health professionals 
viewed a culturally appropriate medication review as a very useful tool and stated that 
because medication review engaged patients in discussions about their medications and 
empowered patients with knowledge and medication choices, they would be likely to 
improve medication adherence (34). 
In line with previous reports (40, 51, 52) in which practitioners and patients saw clear 
benefits of improved health outcomes resulting from medication review programs, the 
majority of Aboriginal and Torres Strait Islander patients, and the AHS staff who 
participated in this study, perceived that HMRs would be useful for increasing medication 
knowledge and improved health outcomes. In this study, however, it was clarified that the 
program would only be beneficial if the design and processes were more culturally 
appropriate (13). 
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Culturally appropriate medication review 
Providing patient-centred, culturally safe healthcare requires the provision of services that 
meet patient needs in an individualised, holistic, respectful and empowering way which 
facilitates the development of professional and patient relationships (53). Effective, 
patient-centred care for Aboriginal and Torres Strait Islander people also requires a 
culturally safe environment (8). 
This study confirmed that most Aboriginal and Torres Strait Islander people do not consider 
community pharmacies to be culturally safe environments (21). To improve pharmacist 
engagement with Aboriginal and Torres Strait Islander patients, pharmacy environments 
needed to be made welcoming, with private counselling areas. Aboriginal health training 
needs to be imbedded in university curricula, and cultural competency needs to be 
imbedded into the profession’s competency standards, as has been done in New Zealand 
(54). 
The Australian government funds a number of pharmacy programs, including HMR, which 
have been designed and implemented without consultation with Aboriginal and Torres 
Strait Islander people. Consequently, there are many aspects of the HMR program rules 
which are culturally inappropriate and contribute to low utilisation of the HMR program by 
Aboriginal and Torres Strait Islander people (40, 52). For Aboriginal-specific programs, such 
as QUMAX, RAAHS (S100) and Closing the Gap PBS Co-payment measure, there has been 
consultation with NACCHO, a peak Aboriginal representative body. However, there is still 
limited consideration of Aboriginal cultural safety and little or no Aboriginal representation 
on committees, when designing mainstream pharmacy programs. 
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The findings of this study concord with program evaluations which found that greater 
flexibility of administration and rules is needed to allow for cultural difference (51). To 
improve HMR cultural safety the following changes need to occur. 
1. The HMR processes need to be explained to patients (34). 
2. The interviews should to be organised by a trusted, familiar party, such as the AHS. 
3.  Patients should be given a choice of location for the interviews (13, 34). 
4. The AHWs should be integrated throughout the HMR process, writing referrals, 
attending the interviews and providing follow-up (13, 34). 
5. A remuneration model which acknowledges AHS and AHW input is needed to 
ensure sustainability and viability (13). 
6. Family members and significant community members need to be included in the 
HMR interviews (34). 
7. Group or shared medication reviews should be an option for patients (34). 
8. The pharmacist must be a culturally responsive health professional who builds 
relationships, is trusted and communicates appropriately and effectively (13, 34). 
Most pharmacists receive little or no cultural training (55). The majority of pharmacist 
respondents (69.5%) in this study indicated that they had never received any form of 
cultural or Aboriginal health training. Almost half of the pharmacists in this study (49.4%) 
admitted that they had a lack of understanding of cultural issues (29). The lack of 
understanding of cultural issues by pharmacists was identified, by both patients and health 
professionals in this study, as a major barrier to patients’ engagement with pharmacists and 
as a barrier for referral of a patient to a pharmacist by a GP (13, 29). 
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Cultural training is an important first step to achieving cultural awareness and 
understanding, but alone may not be enough to achieve cultural competency (2). A number 
of studies have shown that health professionals need to be working closely with Aboriginal 
people before developing true understanding and attitudinal shift (2, 56). An evaluation of 
a pharmacist-led medicines education programme for AHWs reported that the pharmacists’ 
changes in attitude and improved cultural competency were more significant after the 
pharmacists worked closely with local AHWs, than directly after they received some cultural 
training (57). 
Co-locating a pharmacist within an AHS would enable the pharmacist to work closely with 
Aboriginal colleagues and patients, acquiring local cultural knowledge, trust, strong 
relationships and a higher level of cultural competency. This AHS pharmacist, even if only 
employed part-time, would facilitate closer relationships between the AHS and the 
dispensing, community pharmacists. Pharmacist respondents in this study were unsure 
how to facilitate and build relationships with their local AHS and its staff, and this inhibited 
their engagement and service delivery to the health service (29). An AHS pharmacist would 
assist with brokering these relationships and thus increase Aboriginal patient engagement 
with pharmacists both within and external to the AHS. 
Integrating medication review into Aboriginal Health Service systems 
As in other HMR studies, some GPs in this study, although aware of the HMR program, did 
not regularly refer patients and were at times the “bottleneck” to the process (48, 52). As 
in previous research in non-Indigenous populations, barriers to GPs’ referring patients for 
HMR included the time needed to undertake the administrative tasks of HMR referral, 
complex HMR program rules, lack of conviction of HMR outcome benefits, and poor GP-
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pharmacist relationships (58, 59). The 5CPA evaluation stated that whilst GP engagement 
with pharmacists in the provision of programs and services appeared to have improved, 
that collaboration remained sub-optimal (51). 
Additional barriers to GPs’ referring Aboriginal and Torres Strait Islander patients for HMRs 
were identified in this study. The complexity and co-morbidities of Aboriginal patients 
resulted in increased workloads, greater time pressures and lower prioritisation of 
medicine discussions for AHS GPs (13). Also evident were a heightened protection by GPs 
of their patient relationships, paternalistic attitudes to patients, perceptions that 
pharmacists were not culturally sensitive, and a lack of available AHS staff to support HMR 
processes (13). This study reinforced the 2008 Campbell report findings from mainstream 
population groups that GPs needed assistance with administration of HMRs and that HMRs 
were very dependent on the relationship between GP and pharmacist (52). 
The research undertaken for this thesis found that in addition to low levels of GP referral, 
other barriers included the lack of relationship between pharmacists and AHSs, and that 
pharmacists found HMR interviews for Aboriginal patients difficult to organise (29). The 
patients participating in this study were adamant that they would only agree to an HMR if 
it was organised by someone they trusted (34). Thus, HMR referral, implementation and 
follow-up of medication reviews should be organised by AHS staff who are known to and 
trusted by their patients. 
As a previous evaluation has shown, changes to the medication regimen by the GP 
subsequent to the HMR interview were not often seen by the patient as resulting from the 
HMR (52). Many patients in this study viewed the HMR interview as a stand-alone 
information session and stated that more regular follow-up would be useful (34). Some AHS 
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staff commented that often patients did not return to the AHS within a timely period after 
the HMR, and thus medication management plans were not necessarily revised in 
accordance with the HMR report (13). It is suggested that systems be implemented in AHSs 
to recall patients after an HMR, and that medication reviews be conducted regularly rather 
than infrequently. A previous study has shown that a pharmacist’s recommendations are 
much more likely to be accepted and implemented by the GP when the HM-accredited 
pharmacist is co-located in a GP practice (60). 
Evaluators of the QUMAX program found that QUMAX progressed most successfully where 
a person was appointed to champion program implementation (55). Similarly, all the AHS 
health professionals interviewed in this study agreed that for medication reviews to 
become a regular occurrence within the AHS, a dedicated organiser/driver of the program 
within the AHS was needed (13). Many suggested that there should be health workers 
specifically employed, trained and reimbursed as AHW medication specialists to drive and 
assist such medication systems and processes. Whilst many AHWs in this study stated that 
they required more medication training and that a dedicated medication specialist role 
would be optimal, many were sceptical that such a role would occur due to the many 
competing priorities for AHWs. 
A number of both patient and health professional participants in this investigation 
suggested that medication review should be integrated into existing health assessment and 
chronic disease management processes (13, 34). This was also identified in the Campbell 
evaluation report in 2008 (52). Previous research has shown that integration of patient care 
plans and HMRs provide positive health outcomes for patients (61). 
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The Medicare Benefits Schedule (MBS) has Chronic Disease Management items which 
enable GPs to co-ordinate the care of patients with chronic disease and adopt multi-
disciplinary team-based care. Under this schedule, GPs, assisted by practice nurses, 
Aboriginal and Torres Strait Islander health practitioners, and AHWs, can refer patients to 
eligible allied health clinicians for a maximum of five allied health services in a calendar year 
(62). There are currently 13 allied health professions listed as eligible providers, but 
pharmacists are not included. General practices can also claim on MBS for Indigenous 
Health Assessments (63). This health assessment allows another five allied health services, 
but once again pharmacists are not included in the list of eligible providers. Revision of the 
MBS to imbed pharmacist services such as medication review programs within current 
Indigenous health plans would enable engagement of a pharmacist, prioritise medication 
management and streamline processes for AHS health professionals. 
This study reinforced the Campbell report findings that the HMR program exists in isolation 
rather than in parallel with other Medicare items (52). The 2015 evaluation of the suite of 
Fifth Community Pharmacy Agreement (5CPA) programs (2010-2015) also stated that HMRs 
were undertaken in isolation from other primary care initiatives, and that there was little 
integration and unclear linkages between pharmacy programs (51) Only one AHS 
participating in this study had established internal systems which triggered an HMR referral 
as part of an Indigenous health assessment or a Chronic Disease management care plan. 
Arguably, referral for medication review should be an essential component of chronic 
disease management in primary care. 
This research clearly identified the lack of relationship between pharmacist and AHS, and 
between GP and pharmacist. Professional collaboration and co-management of chronic 
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disease have been found to improve patient outcomes and reduce the risk of medication 
misadventure (64, 65). The 5CPA evaluation report calls for incentivised professional 
collaboration using a model based on pay-for-performance patient outcomes, similar to the 
United Kingdom Quality Outcomes Framework (51, 66). Integrating a pharmacist into a GP 
practice is known to increase rapport between health professionals, enhance information 
exchange and facilitate communication (38, 67, 68). In this research health professionals 
and patients alike called for a pharmacist to be co-located within AHSs (13, 34). Pharmacists 
working in primary care need to have the right personality attributes and may need 
communication training (69). A number of studies have found that many pharmacists 
deliver information in an instructional way rather than as a two-way discussion (70, 71). Co-
located AHS pharmacists may need motivational interviewing and communication training, 
as well as cultural training. 
A previous evaluation has reported that HMRs had not resulted in much improvement in 
cooperation within the healthcare team (52). Co-location of pharmacists in GP practices has 
been shown to have enabled greater communication, collaboration and relationship 
building among the co-located health professionals (72, 73). Thus for effective collaboration 
and integration of medication reviews into health assessment or chronic disease 
management plans, pharmacists need to be co-located with GPs, nurses and/or AHWs 
conducting health assessments and implementing chronic disease care plans in AHSs. 
Pharmacists, when imbedded within GP services, both overseas and in Australia, are 
providing advanced clinical services resulting in significant reductions in medication-related 
problems and improvements in medication adherence (74, 75). This co-location of 
pharmacists in AHSs could result in interventions which significantly improved blood 
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pressure, glycosylated haemoglobin (diabetes), cholesterol, osteoporosis management and 
cardiovascular risk, as has occurred in general practice clinics (76). 
Co-location of a pharmacist with an AHS could result in the pharmacist, with AHW 
collaboration, being the driver of the medication review processes. The AHS pharmacist 
would develop relationships with the referring GPs and potentially reduce some barriers 
associated with GPs’ protective or paternalistic patient relationships. The AHS pharmacist 
would liaise closely with community pharmacies and enhance the valuable contribution of 
community pharmacies to the AHS and its patients. 
Tiered, flexible and regular medication review 
This study, like previous research, found that HMRs provided medication information and 
benefits on a number of levels. For patients, in this study as well as in previous studies, the 
HMR interview provided increased medication knowledge and health literacy, validation, 
affirmation, emotional reassurance and empowerment (77). Comprehensive HMR reports 
have been found to assist GPs to rationalise prescribing, use evidence-based medicine, 
identify drug interactions and adverse effects, understand patient medication adherence 
and reconcile medications across a variety of settings and prescribers (50). The GPs in this 
study similarly valued the HMR reports (13). 
The 2005 Urbis evaluation of the HMR program recommended a tiered payment structure 
reflecting levels of complexity of medication reviews from case to case (40). The recent 
5CPA evaluation suggested delivery of services and programs according to complexity of 
patient need, with appropriate funding allocated across the continuum of service (51). Most 
Aboriginal and Torres Strait Islander patients have multiple co-morbidities and thus high 
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complexity. These, together with higher rates of death at a younger age than the non-
Indigenous population, suggest that a greater proportion of the medication review funding 
should be allocated to Aboriginal and Torres Strait Islander people. 
A type of tiered medication review structure was introduced in 2012 with the 
commencement of the MedsCheck program. MedsCheck was introduced to provide 
patients with medication information from non-accredited pharmacists, without referral by 
or need for GP collaboration. MedsCheck and Diabetes MedsCheck services focus on 
education and medicines literacy and are offered opportunistically by community 
pharmacists within their pharmacies to patients taking multiple medicines. There is no 
integration of these services with GP management plans, team care arrangements or 
medication management plans (78). 
This study showed that patients highly valued the education component of the HMR 
interview (34). This medicines information could be similarly received in a MedsCheck-style 
process. There are no recorded numbers of Aboriginal and Torres Strait Islander people who 
have had a MedsCheck. Anecdotally, it is believed that very few Aboriginal and Torres Strait 
Islander people have participated in MedsCheck (78). This may be a result of Aboriginal and 
Torres Strait Islander people’s unease in discussing their health in community pharmacies, 
which are viewed as culturally unsafe environments. It may also be a result of their lack of 
relationship with community pharmacists (21, 51). The more concise MedsCheck-style 
consultation (Medication Usage Review) (78), which focuses on medication reconciliation 
and providing medicines information to the patient without collaboration with the GP, may 
be a useful adjunct to HMR for Aboriginal and Torres Strait Islander people, if conducted in 
a setting other than a community pharmacy. 
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Currently, there is limited evidence about whether multiple interventions and/or a 
combination of medication review programs is the most effective strategy to improve 
behavioural and health outcomes (51). Participants in this study called for regular 
engagement with pharmacists regarding medication issues, rather than annual or every two 
year engagements (34). Regular health coaching has been proven to be more effective than 
once-only advice (79, 80). Haynes et al’s systematic review found that regular 
communication, follow-up and family engagement led to improvements in health outcomes 
(81). In this study, participants were disappointed that there were no follow-up visits or 
engagements with the pharmacist after the HMR interview (34). Participants in this 
research called for regular follow-up to discuss their medicines, aligning with findings from 
the Campbell report, which recommended that Aboriginal and Torres Strait Islander 
patients have multiple visits with a pharmacist (52). In the NZ Medicines Use Review model, 
the pharmacist provides at least two follow-up consultations (82). The current HMR 
program rules, which only allow one HMR per patient every 24 months, conflict with 
previous recommendations (39) and the findings in this study. To maximise medication 
management, multiple interactions with patients are needed. 
A blended program of full medication reviews, like HMRs and MedsCheck style medication 
information programs, is needed to resolve medication issues, reduce medication 
misadventure and improve medication adherence. A program consisting of a medication 
information session, followed by a full medication review, and then one or two follow-up 
sessions within a 12-month period, appears optimal, based on the available evidence. 
Co-location of a pharmacist within an AHS would allow the pharmacist to regularly engage 
with patients and to deliver appropriate levels of service, be that stand-alone medication 
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counselling, medication reconciliation, a full medication review, a group medication 
education session, a tailored interaction to address a patient’s individual needs or a 
combination of all of the above. 
7.2.3 Pharmacists in primary care 
A non-dispensing pharmacist co-located within an AHS would be able to address many of 
the issues identified in this research and in the literature. The literature outlined that for a 
health professional working with Aboriginal patients to be effective, they needed to commit 
time to building rapport, take time to develop effective communication and decision aids, 
be culturally competent, provide services in a culturally safe environment, deliver holistic 
care, work closely with AHWs, integrate services and work in team care arrangements. This 
model can best be delivered by a pharmacist working within the AHS. 
 The AHS pharmacist would be the “driver” of the medication review processes and 
integrate medication review into AHS systems and chronic disease management programs. 
Close working relationships between the pharmacist and AHS GPs and AHWs would 
facilitate inter-professional healthcare. The AHS pharmacist would develop the trust, 
relationships and cultural competency needed to enable effective, appropriate 
communication with Aboriginal and Torres Strait Islander patients and AHS staff. The AHS 
pharmacist would be able to source or create appropriate written medication resources for 
his/her patients. Access to medical software and complete patient histories would enable 
the AHS pharmacist to make meaningful, informed clinical interventions (83, 84). 
The pharmacist role within the AHS needs to be more than just one that facilitates and 
implements medication review. High levels of prescribing errors and hospitalisations due to 
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medication interactions, adverse effects, and under- or over-dosing may indicate that GPs 
would benefit from prescribing assistance and a review system, such as medication review 
by a pharmacist (59, 85). This is especially true in settings where GPs have a heavy patient 
load or complex patients, such as in AHSs, and do not have time to reconcile patient 
histories and review patients’ medications (86). Consultations undertaken by pharmacists 
located within primary healthcare clinics have been proven to be effective in identifying 
and resolving medication-related problems and improving medication adherence. (74) 
Aboriginal Health Service pharmacists would have a role to play in providing daily advice 
about prescribing to GPs, as well as regular medication education and prescribing protocols 
for AHS nurses, AHWs and GPs (83). Pharmacists have a role to play in monitoring chronic 
disease and medication outcomes, and in coaching patients for better medication 
adherence. Also, they should be involved in community health promotion, immunisation, 
and health assessments when appropriate. Pharmacists are well-qualified to facilitate 
shared medical appointments and group education sessions. An AHS pharmacist would 
assist patients to navigate our complex health and dispensing systems, overcome any 
medication access barriers and liaise closely with community pharmacies on such services 
as DAAs, prescriptions and medication supply. He/she could also assist with administration 
of programs such as QUMAX, and in remote AHSs where medicines are received in bulk and 
usually dispensed by nurses, GPs or AHWs, the pharmacist would also oversee the 
dispensing and supply processes. 
The Pharmaceutical Society of Australia, with support from the Australian Medical 
Association, have lobbied government to fund salaried positions for pharmacists in GP 
practices and AHSs in line with current funding arrangements for practice nurses (87). This 
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research endorses the funding of salaried positions which will imbed pharmacists within 
AHSs. To date no funding has been made available for salaried pharmacist positions. 
The few pharmacists who are employed by AHSs are mostly funded through chronic disease 
programs and sometimes funding from the Medical Specialist Outreach Assistance program 
for Indigenous Chronic Disease. It is complicated and time-consuming to achieve this 
funding, and often AHSs have to choose between pharmacy and nursing staff. Whilst AHSs 
have little understanding of a non-dispensing pharmacist’s role, and there is no 
remuneration specifically allocated for pharmacists, they will continue to prioritise 
employment of nurses. 
Revision of the MBS to remunerate pharmacists for provision of services, other than just 
medication review, would allow for more service delivery from pharmacists to AHSs. 
Pharmacists need to be included in the list of MBS eligible allied health service providers. 
Income from HMRs may provide some pharmacist time to an AHS but restricts pharmacists 
to medication review services only. In rural and remote areas, travel time and cost 
contribute to lack of viability and sustainability of HMRs (78). 
If pharmacists were employed in salaried positions within AHSs they would not need to 
claim for HMRs through the MBS program and this would “free up” some of this capped 
funding pool for HMRs. The salaried AHS pharmacists could tailor their service delivery to 
their client and AHS needs. By my rough calculations, for a modest annual investment of 
$10 million the government could employ 100 pharmacists in approximately 100 AHSs 
across the country, making a significant difference to Aboriginal health outcomes. Follow-
up research which evaluates alternative medication review models and multiple 
interventions is needed. 
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If pharmacists were funded for salaried positions in AHSs, the government could abolish 
the current S100 support allowance to pharmacists, and some of the components of the 
QUMAX programme, as these services would be delivered by the AHS pharmacist. The 
abolition of the S100 support allowance and half of QUMAX funding would save 
approximately $5 million (according to expenditure allocated in 6CPA). This saving, together 
with improved health outcomes (e.g. reduced renal dialysis from poorly controlled 
hypertension and/or diabetes) and reduced hospitalisations due to medication 
misadventure, should result in a significant net saving to the national health budget. Proper 
economic analysis is needed of this proposal. 
Having a pharmacist co-located within an AHS allows a sustainable systems-based approach 
to implementing medication management processes. 
7.3 Congruence of perspectives across participants and settings 
Although Phase 1 of this research was conducted with patients in different AHS sites across 
urban, regional, rural and remote settings, recurrent themes emerged at all sites. These 
included difficulty in managing medicines, the need for more medication information, the 
lack of effective engagement between patients and GPs, and between patients and 
pharmacists. Other recurrent themes included lack of awareness of the HMR program and 
support for a more culturally appropriate medication review program. 
Phase 2 of this research was conducted with health professionals in AHSs, including AHWs, 
GPs and nurses. Across these professions there were recurrent themes. These included 
difficulty in managing medicines, the need for more medication information, lack of 
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awareness of the HMR program, support for a more culturally appropriate medication 
review program, a need for less bureaucratic HMR processes, and poor relationships with 
pharmacists. 
Findings from the pharmacist survey in Phase 3 also found a perceived lack of awareness of 
the HMR program by consumers and health professionals, support for a more culturally 
appropriate medication review program, a need for less bureaucratic HMR processes, and 
pharmacists’ poor relationships with GPs and staff at AHSs. 
Although this study had limitations, recurrent themes emerged across all three phases of 
research. Significant congruence exists between patients and their service providers on 
how to improve medication management and HMR services for Aboriginal and Torres Strait 
Islander people. Patients, AHS service providers and pharmacists agreed that HMRs should 
be organised by the AHS, that referrals should be written by AHS nurses and AHWs, as well 
as GPs, and that success of the program depends on having a “driver”. 
This congruence of perspectives related to medication knowledge, awareness, relationships 
and culturally appropriate HMR, across the three phases of the research and across all sites, 
adds validity to this research. 
7.4 Study limitations 
The limitations of this study included small sample sizes of AHS sites, Aboriginal and Torres 
Strait Islander participants, AHS health professionals and pharmacists. 
All AHS sites used in this study were located within reasonable proximity to pharmacies, 
and thus the views of patients who cannot access pharmacy services have not been 
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investigated. Only Aboriginal and Torres Strait Islander patients who could speak English 
and who attended an AHS were recruited to participate in focus groups. Thus the views of 
non-English-speaking Aboriginal and Torres Strait Islander people have not been explored. 
The views of Aboriginal and Torres Strait Islander people who do not attend AHSs have also 
not been captured. Therefore, it is difficult to extrapolate findings to all Aboriginal and 
Torres Strait Islander people. 
Most of the Aboriginal and Torres Strait Islander people who participated in focus groups 
had no experience or knowledge of HMRs. Their perceptions of the HMR program are based 
on the HMR program description presented by the researcher. 
The researcher was a non-Indigenous woman with no relationship with study participants. 
Although the researcher worked hard to establish trust, the lack of relationship may have 
inhibited participants from sharing some thoughts. 
Despite the limitations described here and in Chapters 3-6, the findings endorse conclusions 
from previous literature. The triangulation of findings across the three phases of the study 
adds validity to this research. 
7.5 New findings and recommendations 
Previously, there has been very little research which has explored medication management 
challenges and potential solutions for Aboriginal and Torres Strait Islander people. 
235 
 
7.5.1 Culturally appropriate medication reviews are useful for Aboriginal and 
Torres Strait Islander people 
As well as endorsing previous research, which found that HMRs provided medication 
information and benefits for the general population, this study found that culturally 
appropriate medication review could also build pharmacists’ relationships with their 
Aboriginal and Torres Strait Islander patients, and empower Aboriginal patients to ask 
questions and make medication choices. This would potentially increase medication 
adherence and improve medication management for Aboriginal and Torres Strait Islander 
people. 
During this research, participants suggested strategies to improve medication management 
and the HMR program for Aboriginal and Torres Strait Islander people and AHS staff. To 
increase HMR or alternative medication review programs uptake by Aboriginal and Torres 
Strait Islander people, strategies are required to increase awareness, prioritise medication 
management, streamline processes, reduce administrative burden and increase medication 
review referrals. 
To increase the accessibility and effectiveness of medication review for Aboriginal and 
Torres Strait Islander people, the following strategies, as identified by this research, are 
recommended. 
 Rename the HMR program, removing the word, “Home”, so that there is no 
implication that the HMR has to occur in a “home” 
 Develop culturally appropriate HMR promotional resources, including leaflets and 
posters for the AHS, that describe the purpose and processes of HMR  
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 Encourage AHS management to prioritise medication management programs such 
as medication review, and appoint staff to implement medication management 
programs 
 Broaden referral options. The AHW staff, as well as GPs, need approval to write HMR 
referrals for their patients 
 Facilitate HMR processes through the AHS. The AHS staff need to refer patients, 
conduct all administrative processes, organise HMR interviews, and call back 
patients after interviews to revise medications with GPs 
 Remunerate the AHS for its participation in facilitating an HMR and for attendance 
of an AHW at an HMR interview 
 Increase options for the AHS patient regarding the HMR interview 
o a single or group HMR 
o location of HMR at home, clinic or other suitable place 
o choice of AHW to attend the interview 
o option to invite family or other significant community members to attend 
 The HMR pharmacist to be chosen and trained by the AHS 
 Culturally appropriate clinical resources to be sourced by the pharmacist and made 
available to patients 
 Make an HMR report/Action plan available to the patient 
 Remunerate for regular follow-up visits and medication education by the HMR 
pharmacist, using a tiered payment scale 
 Provide community pharmacists and accredited pharmacists with cultural training 
 Encourage pharmacists to make their community pharmacies culturally safe 
environments. 
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7.5.2 Better relationships and cultural training needed 
One of the most significant findings of this research was the poor relationships between 
community pharmacists and AHS patients, GPs, nurses and AHWs. Even pharmacists 
working in close proximity to an AHS had little or no engagement with the AHS service 
providers or clients, other than to facilitate medication supply (29). The GPs hesitated to 
refer patients for HMRs as they felt pharmacists were too busy, unavailable, not culturally 
trained and/or not suitable to clinically engage with their patients (13). The AHWs 
commented on pharmacists’ lack of cultural sensitivity and their lack of relationship with 
their Aboriginal and Torres Strait Islander clients (13). 
Over half the pharmacist participants identified the lack of relationship with their local AHS 
as the greatest barrier to providing professional services to Aboriginal and Torres Strait 
Islander people (29). Pharmacist participants were keen to deliver more education and 
clinical services to AHSs if their services were remunerated appropriately and if 
relationships could be brokered. Pharmacists were unsure how to facilitate these 
relationships. 
 Many pharmacists felt they would be more confident in engaging with Aboriginal and 
Torres Strait Islander people and organisations if they received some cultural awareness 
training. Currently, there is little or no cultural training imbedded in many pharmacy school 
curricula or pharmacists’ continuing education. 
Aboriginal pharmacists could better facilitate relationships with Aboriginal people, but to 
date there are very few Aboriginal pharmacists. In line with medicine and other allied health 
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disciplines, more pathways and scholarships for Aboriginal students to enter university and 
study pharmacy need to be created (88). 
7.6 Conclusion 
The aim of this thesis was to identify strategies for improving medication management for 
Aboriginal and Torres Strait Islander people who attend AHSs. Whilst the original focus was 
to identify strategies to increase utilisation of the HMR program, major organisational and 
cultural issues were identified which could affect the delivery of all pharmacy programs. 
Thus, the conclusion presented here extends beyond the original aim. 
Data from this study did inform and answer the research questions. Participants from 
patient, service provider and pharmacist groups confirmed that little or no medication 
education occurs with Aboriginal and Torres Strait Islander clients, and that Aboriginal and 
Torres Strait Islander people are low users of the HMR program, despite their high burden 
of chronic disease. All groups agreed that medication review could be a useful tool to 
increase medication knowledge and adherence. However, most found the current HMR 
program rules and processes inappropriate, from both cultural and AHS systems 
perspectives. 
A specific medication management program addressing the needs of Aboriginal and Torres 
Strait Islander people needs to be designed in collaboration with Aboriginal and Torres 
Strait Islander people and their key organisations. Such a medication management program 
needs to deliver culturally appropriate medication education on a regular basis to clients 
and their families/communities, to increase health and medication understanding, address 
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low health literacy, support clients in their medication choices, liaise with dispensing 
pharmacies, and build trust and rapport. 
The multiple co-morbidities of many Aboriginal and Torres Strait Islander people often 
result in polypharmacy, complex medication regimens and potential medication 
misadventure. Therefore, comprehensive medication reviews which enable medication 
reconciliation, assist rational prescribing, identify potential adverse effects and drug 
interactions, and recommend dosing and monitoring regimens and optimisation of 
medicines, are essential. Many GPs highly value the checking and safety support that HMRs 
provide to their prescribing. Most GPs find the HMR reports informative and educational. 
Some AHSs have part-time/locum/fly-in fly-out GPs, and a high staff turnover. Often, rural 
and remote AHSs have difficulty recruiting GPs and employ overseas trained doctors. In 
these settings, HMRs are especially important as they assist GPs and nursing staff to provide 
safe and appropriate prescribing of medicines and continuity of care. 
Medication programs need to be integrated into the myriad AHS programs and funding 
sources. Medication programs need to provide income to AHSs and so have equal status 
and value as other chronic disease management programs. Medication management 
programs need to be facilitated by the AHS, an organisation which is trusted and culturally 
sensitive to community needs. This research showed that most patients would only 
participate in medication reviews if they were organised by the AHS. 
The cultural divide between many community pharmacists and their Aboriginal and Torres 
Strait clients, and the lack of a culturally safe space within many community pharmacies in 
which to discuss health issues, are large and real barriers to effective communication 
between pharmacists and their Aboriginal clients. Community pharmacists need to receive 
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comprehensive cultural training. A program needs to be developed which connects 
community pharmacists with their local AHSs, local AHWs and local Aboriginal 
communities. A pharmacist who is co-located within an AHS could work with Aboriginal 
colleagues to help facilitate the building of these relationships with community 
pharmacists. It takes time to build relationships. Not until trust, respect and rapport are 
developed can effective two-way communication with Aboriginal and Torres Strait Islander 
clients occur. 
There are currently very few Aboriginal pharmacists in Australia. To increase the number of 
Aboriginal pharmacists, more pathways for Aboriginal students into university pharmacy 
schools and more scholarships for Aboriginal students are needed. 
The role of a pharmacist in an AHS should be more comprehensive than just being a 
provider of one-off medication reviews. Previous studies indicate that medication 
management programs are most effective if they include multiple interactions between a 
pharmacist and the patient, and close collaboration between pharmacists and the patients’ 
other healthcare providers (45, 89). An Aboriginal medication management health 
assessment should include individual or group patient education on disease, lifestyle 
modifications and medicines, as well as a full medication review and action plan, and at 
least two follow-up medication adherence/monitoring reviews. The suite of medication 
management programs needs to be integrated into AHS systems. 
Without appropriate medication management and improved medication adherence, 
chronic diseases will continue to be poorly managed and there will be high incidences of 
complications and increased hospitalisations. Co-location or integration of culturally 
responsive pharmacists in AHSs to implement medication management services and 
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engage patients and service providers in discussions about medications is crucial to 
improving health outcomes and “Closing the Gap” for Aboriginal and Torres Strait Islander 
people. 
7.7 Translation of research into Practice 
This research has already contributed significantly to discussions regarding the need for 
revised medication programs for Aboriginal and Torres Strait Islander people. Translation 
of this research into practice is outlined in the Epilogue. 
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Epilogue 
Since commencing my PhD research in 2008 I have led a number of projects driving 
improvements to provision of pharmacy services to Aboriginal and Torres Strait Islander 
people. I have also been advocating for change and have contributed to government 
submissions and education programs. 
My learnings from my PhD study have enabled me to bring skills and expertise to these 
projects. My increased cultural understanding and development of relationships with 
Aboriginal and Torres Strait Islander people have assisted further research. Research skills, 
such as focus group facilitation with Aboriginal and Torres Strait Islander people and 
Aboriginal Health Service staff, have been used. The key principles of respect and 
reciprocity needed in Aboriginal research have been applied and taught to other 
researchers. I frequently work with an Aboriginal colleague who has helped me and 
provided more cultural credibility, wisdom and learning. 
The projects listed below address the findings of my research and thus are examples of 
translation of research into practice. They respond to the need for more Aboriginal people 
working in pharmacies, improved written medication information for Aboriginal people, 
much-needed cultural training and guidelines for pharmacists, changed medication review 
models and co-location of pharmacists in Aboriginal Health Services. 
Although it is difficult to prove, I believe that many of these projects have been initiated 
due to my advocacy for equity and improvements to pharmacy services for Aboriginal and 
Torres Strait Islander people. They have been initiated as a result of this doctoral work and 
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informed by it. I have sent all my publications to the appropriate representatives at the 
NACCHO, the Department of Health and the Pharmacy Guild of Australia. 
2010-2016: Aboriginal Pharmacy Assistant School Based 
Traineeships – Northern Rivers Career Link Pharmacy program 
This program won the National Medicines Symposium (NMS) National MedicineWise Award 
2012 for Building a MedicineWise community through consumer programs. 
My role: I designed the program and brokered the collaboration between Connect, TAFE 
and the Department of Education and Training. Connect now runs this program, but each 
year I work with local pharmacists to obtain employment sites for trainees. 
Project overview 
Pharmacists have had little or no training in Indigenous health or cultural issues and 
consequently may fail to convey the correct messages about medication usage in terms 
understood by their Indigenous patients. Aboriginal Pharmacy Assistants could play a vital 
role in bridging the gap between pharmacists, pharmacy assistants and Indigenous patients. 
The CareerLink Pharmacy project in NSW's Northern Rivers has implemented Aboriginal 
school student pharmacy assistant traineeships, and supported these trainees to complete 
a Pharmacy Assistant Certificate II at TAFE, complete high school and attain employment in 
local pharmacies. This program has given Aboriginal school students employment pathway 
opportunities and helped them play an important role in assisting the medication 
management and healthcare of Aboriginal patients. 
This program works with community members to select and mentor students identified as 
potential advocates for Aboriginal health, and offers Aboriginal youth employment 
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opportunities and support. A number of the trainees have now been employed full-time in 
pharmacies as the pharmacists have found them invaluable employees who can play an 
important role in assisting the medication management and healthcare of Aboriginal 
patients. This program still continues today and has graduated over 25 Aboriginal pharmacy 
assistants with Certificate II Pharmacy Assistant. 
2010: Development of the Living Everyday with My Heart Failure 
resource for the National Heart Foundation 
This resource won the NMS National MedicineWise Award 2014 for Excellence in Consumer 
Information. 
My role: As one of the lead researchers I was involved in project tender, study design, 
establishment of participant sites through relationships, facilitation of focus groups and 
interviews with Aboriginal clients and AHS health professionals in needs assessment and 
audience-testing phases, expert input into content and language, and thematic analysis. 
Project overview 
Chronic heart failure (CHF) is a major course of illness and death among Aboriginal and 
Torres Strait Islander communities. Whilst self-management resources have been 
developed to support heart failure patients, standard health resources were not culturally 
or linguistically useful for many Indigenous people. This project produced an evidence-
based resource for supporting CHF self-management in Aboriginal and Torres Strait Islander 
Australians. 
Consultation, collaboration and partnership underpinned this project. It was critical that 
the resource met the needs of the clients and health professionals who would be using it, 
256 
 
and input from all stakeholders guided each step of the resource development. A 
partnership between the Heart Foundation’s Aboriginal and Torres Strait Islander Chronic 
Heart Failure Working Group and a multi-disciplinary research team comprising 
researchers, pharmacists, health promotion educator and specialist cardiovascular nurse 
was established. Both the working group and the research team included Indigenous and 
non-Indigenous members. Consultation and collaboration was a key focus of the project, 
with an initial national needs analysis providing input from 54 stakeholders across the 
country. During development of the resource, extensive consumer consultation saw input 
from 33 Indigenous community members throughout Australia and from an additional 15 
health professionals. 
Phase 1 comprised an extensive needs analysis, whilst Phase 2 was the development and 
audience-testing Phase. Key findings from the needs analysis guided the resource 
development. The aim of the audience-testing phase was to allow input from the 
community into the final resource and to determine if the layout, content and design of the 
resource met the needs of clients with CHF and their health professionals. A combination 
of individual semi-structured interviews and focus groups was used in both Phase 1 and 
Phase 2, with AHWs and members of the CHF working group acting as cultural brokers 
between the research team and their local communities. 
The resource, published by the Heart Foundation, is used extensively throughout Australia. 
Whilst the resource was developed for the Indigenous community, feedback has indicated 
a high uptake of use among non-Indigenous clients with CHF, showing that an attractive, 
easily understood resource meets the needs of many CHF clients. The Living Everyday with 
My Heart Failure resource is available from the Heart Foundation: 
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 https://heartfoundation.org.au/your-heart/heart-conditions/chronic-heart-failure-the-
facts. 
2014: Guide to Providing Pharmacy Services to Aboriginal and 
Torres Strait Islander People 
This guideline was developed by the Pharmaceutical Society of Australia (PSA), with funding 
from the Department of Health, to assist pharmacists to become more culturally competent 
and better able to address the needs of their Aboriginal and Torres Strait Islander clients. 
My Role: I was the consultant and author for this guideline. Content was guided by a 
working group which consisted of Indigenous people and pharmacists who work with 
Indigenous people. 
The guide includes information on understanding culture, building relationships, 
communication, Aboriginal and Torres Strait Islander pharmacy programs, improving 
cultural safety in the pharmacy, and considerations for provision of pharmacy services to 
Aboriginal and Torres Strait Islander people. 
This guide was launched at the PSA national pharmacy conference in 2014. Printed copies 
were distributed to pharmacists. It is also available online at http://www.psa.org.au/wp-
content/uploads/Guide-to-providing-pharmacy-services-to-Aboriginal-and-Torres-Strait-
Islander-people-2014.pdf. 
After the guideline launch I conducted a PSA online educational webinar on Providing 
Pharmacy Services to Aboriginal and Torres Strait Islander People. The webinar was 
attended by approximately 140 pharmacists. 
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2014–2015: North Coast Cultural Competency Workshops 
In 2014-2015, in conjunction with an Aboriginal colleague from the North Coast Medicare 
Local/Primary Health Network, I conducted a series of workshops for pharmacists and 
pharmacy staff on Better Provision of Pharmacy Services to Aboriginal and Torres Strait 
Islander People. Workshops were conducted in Ballina, Lismore, Grafton, Coffs Harbour and 
Kempsey. A total of 61 pharmacists and 40 pharmacy staff attended. 
2014–2016: Pharmacy student education 
Together with an Aboriginal colleague, I annually deliver lectures and workshops to 
pharmacy students (n≈70 each year) at the University of Technology Sydney (UTS) on 
Provision of Medicines to Aboriginal and Torres Strait Islander People. In 2016 for the first 
time I was invited to provide workshops at UTS on Medication Reviews for Aboriginal and 
Torres Strait Islander People. 
I organise cultural awareness training provided by local Bundjalung people for all pharmacy 
and allied health students attending clinical placements facilitated by the University Centre 
for Rural Health in the NSW Northern Rivers region. 
2011‒2016: Government submissions 
From 2011 to early 2016 I was employed part-time as the Director, Rural and Indigenous 
Policy, for the Pharmaceutical Society of Australia. During my time in this role I wrote 
submissions to: 
 The Senate Community Affairs References Committee Inquiry into the effectiveness 
of Section 100 supply of PBS medicines to the remote area Aboriginal Health 
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Services program. This submission advocated for the Commonwealth to fund clinical 
pharmacists in remote Aboriginal Health Services. 
 The Federal Budget (2012-2013, 2014-2015, 2015-2016, 2016-2017). These budget 
submissions advocated for funding for clinical pharmacists in Aboriginal Health 
Services. 
2016: Pharmacy Competency Standards 
In 2016 I assisted Indigenous Allied Health Australia (IAHA) with their submission to the 
consultation on National Competency Standards Framework for Pharmacists. The IAHA 
submission suggested that cultural competency needed to be imbedded in all pharmacy 
training and practices. The original standards had no mention of Aboriginal and Torres Strait 
Islander people. I believe the new standards, soon to be released, have specifically 
incorporated attention to the special needs of Aboriginal and Torres Strait Islander people 
and the need for culturally competent pharmacists. 
2010–current: Pharmacists in Aboriginal Health Services on NSW 
North Coast 
In 2009 I assisted Dharah Gibinj AHS, Casino to recruit a pharmacist to conduct HMR 
monthly. This service, with the same pharmacist, still runs in 2016. 
In 2010 I assisted Galambila AHS, Coffs Harbour to recruit a pharmacist to conduct HMR 
weekly. Galambila found the services of the pharmacist so useful that they now employ her 
as a full-time staff member. She runs diabetes and respiratory clinics, and medication 
education days, and conducts medication reviews. 
260 
 
From 2014-2015 I established a clinical pharmacist role at Bullinah Aboriginal Medical 
Service for one day per week. I provided medication education to elders’ groups, 
medication review, GP advice and facilitation of shared medical appointments. In 2015 I 
trained another pharmacist to take over this role from me, and she is still providing these 
services to Aboriginal clients in Ballina. 
2016‒2020: Medicines Management Review Trial for Aboriginal and 
Torres Strait Islander people 
In March 2016 Health Minister Ley announced that an Aboriginal medication management 
program would be a priority of the 6CPA Pharmacy Trials Program (PTP). I have been asked 
to join the successful team and be a researcher and consultant for this project. This project 
will evaluate medication review models for Aboriginal and Torres Strait Islander people in 
Queensland and is a direct translation of my PhD research into a trials phase. I am also a 
member of a team which is applying in the Second Tranche of the PTP for a program piloting 
Pharmacists in Aboriginal Health Services.   
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